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One in six people will ever in their life suffer a stroke and over 35,000 stroke patients are 
annually admitted to a hospital in the Netherlands.1,2 The effect of stroke is devastating: it 
is a significant cause of long-term disability and the second leading cause of death 
worldwide.3,4
Stroke is caused by a sudden interruption in the blood supply to the brain due to a thrombus 
that occludes an artery (ischemic stroke) or by a ruptured artery that leads to a bleeding in 
the brain tissue (hemorrhagic stroke). The vast majority of strokes are ischemic (87%), with 
atherosclerosis and cardio-embolism as main underlying causes.3 In ischemic stroke, the 
impaired blood flow results in a lack of oxygen and glucose in the underlying brain tissue. 
Neurons will be damaged and, due to their high energy demand, die quickly. The loss of 
neurological function depends on the size and location of the brain tissue that is affected, 
and may include paralysis of one side of the body, sensory disturbances, impaired vision, 
and speech and language difficulties. 
Acute treatment of ischemic stroke
During the acute phase of ischemic stroke, on average 1.9 million neurons are destroyed 
each minute that the artery is blocked.5 Since neurological function loss can be reversible 
if the blood flow is restored in time, treatment has to be started as soon as possible. 
Intravenous treatment with alteplase (IVT) to dissolve the blood clot is standard of care for 
ischemic stroke patients presenting within 4.5 hours after stroke onset.6-8 However, IVT is 
less effective in the subgroup of patients with a large vessel occlusion (LVO), a thrombus in 
one of the proximal intracranial arteries in the anterior circulation, which account for 
approximately 24% to 46% of all ischemic strokes.9-11 These patients are often severely 
affected and have a poor prognosis despite treatment with IVT.12,13
Endovascular treatment
A more effective treatment option for patients with LVO is endovascular treatment (EVT), 
which consists of mechanical clot removal (thrombectomy, Figure 1.1), and originally of 
delivery of a thrombolytic agent at the site of the occlusion. From 1998, multiple trials 
demonstrated that this treatment is effective in reopening the occluded vessel and restoring 
the blood flow, but these studies were not able to show an effect on functional outcome of 
patients.14-19 The breakthrough came in 2015, when The Multicenter Randomized Clinical 
Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) 
was the first to prove the safety and clinical effectiveness of EVT in patients presenting within 
6 hours after onset of stroke.20 Four other randomized controlled trials (RCTs) were stopped 
early after publication of the MR CLEAN results and showed similar effectiveness.21-24 EVT 
soon became standard of care in developed countries.25 
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Treatment benefit
Endovascular treatment aims to improve functional outcome of ischemic stroke patients. 
Therefore, the primary outcome in most EVT trials was the modified Rankin Scale (mRS), an 
ordinal scale that measures the degree of disability during daily life activities.26 This scale 
ranges from 0 (no symptoms) to 5 (severe disability), with an extra category of 6 to account 
for death (Table 1.1). 
Table 1.1 Modified Rankin Scale.
Grade Description
0 No remaining symptoms
1 No significant disability despite symptoms; able to perform all usual activities
2 Slight disability; unable to perform all previous activities, but independent
3 Moderate disability; requiring some help, but able to walk without assistance
4 Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
5 Severe disability; bedridden, requiring constant nursing care and attention
6 Dead
Figure 1.1 Illustration of mechanical thrombectomy, reprinted with permission of MayfieldClinic.com. 
All rights reserved. No reuse permitted.
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In a patient-level pooled meta-analysis of five RCTs, the chance of achieving a good functional 
outcome, defined as an mRS score of 0–2, increased with EVT from 26.5% to 46%. The 
analysis revealed an astonishingly low number needed to treat of 2.6 to reduce disability 
by at least one level on the mRS.27 However, this is the average treatment effect for the 
overall group of patients included in the trials, while the effect will likely vary between 
individual patients. Some patients will benefit more from EVT than other patients due to 
heterogeneity of baseline risk and relative treatment effect.28-31 The baseline risk of good 
outcome without treatment, or in other words, the natural history of disease, can be affected 
by prognostic factors such as age or severity of symptoms. Changes in baseline risk will 
affect the absolute benefit of a certain treatment, ie, the difference between outcome with 
and without treatment (Figure 1.2A). The relative treatment effect can be modified by 
predictive factors, for example when the treatment has a larger effect if started earlier after 
onset of symptoms (Figure 1.2B). Relative effects appear to be more stable across 
populations with different baseline risks, and are therefore useful when comparing two 
treatments or when combining the results of different trials in a meta-analysis. However, 
the absolute treatment benefit is what matters for a patient and is therefore more relevant 
for clinical decision-making.32 As an extreme example, a relative risk of 5 might increase the 
probability of the outcome with only 0.04% if that outcome is very rare (baseline risk = 
0.01%).
Subgroup analysis are often performed to compare the relative treatment effect between 
different subgroups of patients within a trial population.33-35 However, these analyses are 
mostly underpowered, assess only one variable at a time, without taking into account a 
patient’s full baseline risk, and are prone to false-negative and false-positive results.36,37 
When multiple patient characteristics are evaluated simultaneously, more clinically relevant 
heterogeneity in treatment effect between individual patients will be found.28,29,38
Treatment delay and workflow
Early initiation of EVT is associated with better clinical outcomes as the treatment effect 
strongly declines over time. Every hour of delay between symptom onset and start of EVT 
results in a 3-5% decreased probability of achieving functional independence.39,40 It is 
estimated that every 20 minutes decrease in time to treatment may lead to an average 
benefit equivalent to 3 months of disability-free life.41 Reducing delay will also increase the 
number of stroke patients that can be treated within the recommended 6 hour time-window. 
Although recent trials have shown that EVT can also be beneficial 6-24 hours after onset of 
symptoms, this applies to a selected group of patients with sufficient viable brain tissue on 
additional imaging only.42,43 Efficient workflow processes that decrease the time from onset 
to treatment are therefore important to increase the number of patients eligible for EVT 
and improve the overall outcome of treated patients. 
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Previously, several quality improvement initiatives resulted in significantly shorter door-to-
needle times and a higher percentage of patients treated with IVT.44-46 These studies showed 
that in-hospital workflow processes can be streamlined using pre-notification of hospitals 
by the emergency medical services, rapid stroke team activation, readily available imaging 
facilities, and frequent feedback to the stroke team on time performance measures. Efficient 
workflow processes for EVT will also require interdisciplinary teamwork and communication 
between the emergency department and the neuro-interventional team. In the prehospital 
setting, potential EVT candidates should be recognized by the emergency medical services 
and transported to a hospital without any further delay. Potential workflow improvements 
include direct transportation to an intervention center with facilities for EVT instead of 
transportation to the closest hospital, and the use of air transportation or mobile stroke 
units. However, it is unknown how these interventions affect the delivery of EVT.
 
Figure 1.2 Example to illustrate the hypothetical effect of (A) decreasing baseline risk with older age, assuming 
the same relative treatment effect (relative risk (RR) = 3) for all age categories; and (B) smaller relative treatment 
effect with increasing time to treatment, assuming a constant baseline risk. 
Chapter 1
14
Prehospital triage
In current clinical practice, most suspected stroke patients are transported to the nearest 
primary stroke center for rapid IVT and further evaluation. When eligible for EVT, patients 
have to be transferred to an intervention center. Due to the importance of early treatment, 
it has been suggested that patients with ischemic stroke due to LVO would benefit from 
direct transportation to a center capable of performing EVT.47 LVO can only be assessed 
with computed tomography (CT) imaging in the hospital, but several prehospital stroke 
scales have been developed to estimate the likelihood of LVO in patients presenting with 
stroke symptoms in the ambulance, based on the neurological examination and severity of 
symptoms.48,49 Although potentially beneficial for LVO patients, bypassing the nearest 
primary stroke center might be harmful for the majority of stroke patients because of the 
time-depending effect of IVT.6,50 Prehospital triage of suspected stroke patients therefore 
requires a trade-off between the harm of delaying IVT versus the potential benefit of rapid 
EVT.
Methods used in this thesis
Prediction modeling
A clinical prediction model estimates the probability of an individual to have a certain disease 
(diagnosis) or develop a certain clinical outcome (prognosis) based on the combination of 
a number of characteristics.51 Such models enable researchers or clinicians to make 
predictions for individual patients based on the effect of multiple factors combined. It can 
be used to inform individuals about their expected outcome and to select the right patients 
for a certain treatment or study.52 In contrast to etiological studies, a prediction model is 
not used to suggest a causal relationship between predictors and outcome. Also, it does 
not provide relative risk estimates such as an odds ratio or risk ratio, but it provides the 
absolute probability of a certain disease or outcome for an individual patient.  
The development of a prediction model consists of several important steps, including careful 
predictor selection and model specification.52-54 The validity of the model should be evaluated 
at least in the derivation cohort (internal validation), and preferably also with external 
validation to assess generalizability of the model in other populations or settings.55-57 
Performance measures often used in validation studies are discrimination and calibration. 
Discrimination assesses whether models are able to distinguish between patient with low 
risk and high risk of the outcome, while calibration describes the agreement between 
observed and predicted values.53 
Decision analyses
Decision analyses are designed to compare strategies in situations with decisional 
uncertainty. It provides a framework to combine all available evidence and uncertainties, 
to balance the harms and benefits of each alternative, and to make informed decisions.58-61 
A decision tree is a visual representation of all these alternatives and the consequence of 
General introduction
15
1
each choice. The expected outcome per strategy is calculated by multiplying the outcome 
values with the probability that the outcome will occur. According to the basic principles of 
decision analyses, the strategy with the highest outcome value would be preferred. 
Uncertainty concerning estimated model parameters and assumptions can be explored 
using sensitivity analyses in which parameters are varied over a range of estimates to assess 
its effect on the decision.62  
Data sources
The analyses in this thesis were performed using clinical data from multiple sources (Table 1.2).
-  The MR CLEAN trial randomized patients with ischemic stroke due to a proximal LVO 
between EVT (within 6 hours after stroke onset) plus usual care, versus usual care 
alone.20,63  
-  The MR CLEAN Registry included all consecutive patients treated in the Netherlands 
after the final MR CLEAN inclusion, to monitor the implementation, outcome and safety 
of EVT in routine clinical practice.64 
-  The IMS III trial (Interventional Management of Stroke) randomized ischemic stroke 
patients to EVT after IVT versus IVT alone. Patient inclusion was not restricted to patients 
with a proven LVO on non-invasive vessel imaging and the trial was stopped early 
because of futility.17,65 
Table 1.2 Overview of the data sources used in this thesis.
Study Design Location of    
participating 
centers
Time frame  
of patient 
inclusion
Number of patients 
used for the analyses 
in this thesis
MR CLEAN Phase III, multicenter 
RCT with open-label 
treatment and blinded 
outcome evaluation
The Netherlands December 2010 
– March 2014
500 (Chapters 3 and 6)
MR CLEAN 
Registry
Nationwide, prospective, 
observational study
The Netherlands March 2014 – 
November 2017
3156 (Chapter 4)
3260 (Chapter 5)
1526 (Chapter 7)
IMS III Phase III, multicenter 
RCT with open-label 
treatment and blinded 
outcome evaluation
The United States, 
Canada, Australia, 
and several 
countries in Europe 
August 2006 
– April 2012
260 (Chapter 3)
HERMES Individual patient data 
from seven RCTs
The United States, 
Canada, Australia, 
New Zealand, Korea, 
and several 
countries in Europe
2010 – 2015 1242 (Chapter 4)
781 (Chapter 5)
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-  The HERMES collaboration (Highly Effective Reperfusion Using Multiple Endovascular 
Devices) combined data from seven international randomized controlled trials (RCTs), 
including MR CLEAN.20-24,66,67 Patient enrollment was performed according to the specific 
inclusion and exclusion criteria of each trial. 
Aim and outline of this thesis 
The overall aim of this thesis is to increase the benefit of endovascular treatment for 
ischemic stroke by optimizing prediction of outcome and treatment effect, reducing 
treatment delay, and improving prehospital triage strategies. 
This translates into the following research questions:
1. Which are the right patients to treat?
 a.  Can we reliably and accurately predict outcome and treatment benefit of EVT for 
individual patients?
2. How can we treat patients at the right time?
 a.  What are the main causes of prehospital and in-hospital delay of EVT?
 b. How do workflow improvements effect treatment delay and outcome?
3. How to direct patients to the right place?
 a.  Which factors should influence the decision to transport individual patients directly 
to an intervention center?
 b.  What is the optimal prehospital triage strategy for suspected stroke patients?
The first part of this thesis covers the development and validation of prediction models for 
outcome and treatment benefit of EVT (“treat the right patient”). Chapters 2 and 3 describe 
the development and first external validation of a clinical decision tool to predict outcome 
with and without EVT (MR PREDICTS). In Chapter 4, this model is externally validated and 
updated with data from the HERMES collaboration and the MR CLEAN Registry. Chapter 5 
contains the development and validation of MR PREDICTS@24H, a post-procedural tool to 
predict functional outcome at 3 months more accurate with clinical data available within 24 
hours after EVT. 
The second part of this thesis is focused on rapid initiation of EVT (“treat at the right time”). 
Chapter 6 aims to identify treatment delay in the MR CLEAN trial and factors associated 
with such delay. In Chapter 7, the effect of inter-hospital transfer on time to treatment and 
functional outcome is assessed by comparing patients transferred from a primary stroke 
center with patients directly admitted to an intervention center in the MR CLEAN Registry. 
Chapter 8 reports the results of a systematic review and meta-analysis on the effectiveness 
of workflow improvements on time to treatment and outcome.
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The third part of this thesis evaluates prehospital triage strategies for suspected stroke 
patients to reduce treatment delay and further improve effectiveness of EVT (“treat in the 
right place”). Chapter 9 describes a decision-analytic model to determine the optimal 
prehospital transportation strategy for individual patients and to assess the factors that 
should influence this decision. In Chapter 10, this model is applied to the United States to 
evaluate the effect of several policies on outcomes of the ischemic stroke population. 
Chapter 11 contains the study protocol of PRESTO, a multicenter observational cohort study 
to prospectively validate prehospital stroke scales for the prediction of LVO in the prehospital 
setting.
The main results of this thesis are summarized and discussed in Chapter 12, providing 
recommendations for future research and current clinical practice.
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Abstract
Introduction
Endovascular treatment (EVT) proved to be overall beneficial in patients with ischemic stroke 
due to a proximal occlusion in the anterior circulation. However, heterogeneity in treatment 
benefit may be relevant for personalized clinical decision making. Our aim is to improve 
selection of patients for EVT by predicting individual treatment benefit or harm.
Methods and analysis
We will use data collected in the Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial to analyze the 
effect of baseline characteristics on outcome and treatment effect. A multivariable 
proportional odds model with interaction terms will be developed to predict outcome for 
each individual patient, both with and without EVT. Model performance will be expressed 
as discrimination and calibration, after bootstrap resampling and shrinkage of regression 
coefficients to correct for optimism. External validation will be conducted on data of patients 
in the Interventional Management of Stroke III trial (IMS III). Primary outcome will be the 
modified Rankin Scale (mRS) at 90 days after stroke.
Ethics and dissemination
The proposed study will provide an internationally applicable clinical decision aid for EVT. 
Findings will be disseminated widely through peer-reviewed publications, conference 
presentations and in an online web-application tool. Formal ethical approval was not 
required as primary data were already collected. 
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Introduction
In 2015, five consecutive randomized controlled trials (RCTs) showed that endovascular 
treatment (EVT) within 6 hours after stroke onset, improves functional outcome of patients 
with a proximal occlusion in the anterior circulation.1-6 This was a major breakthrough in 
the field, and EVT is now implemented in updated guidelines on ischemic stroke 
management.7
Ideally, EVT will be targeted at patients who are expected to have optimal benefit: 
personalized treatment. In this study protocol we present seven steps for development and 
validation of a clinical decision aid to predict which individual patients with ischemic stroke 
will benefit most from EVT.8,9
Methods and analysis
Step 1: Problem definition and data inspection
Problem definition
RCTs provide estimates of treatment effects for average patients. However, it is important 
to take potential heterogeneity of treatment effects into account. Clinically relevant 
differences in the absolute effect of a treatment can be caused by 1) differences in the relative 
treatment effect (predictive effects) and 2) differences in baseline risk on the outcome of 
interest (prognostic effects).10,11 For example, in the Multicenter Randomized Clinical Trial of 
Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial, there 
is no predictive effect of age; the relative treatment effect is constant across age subgroups.1 
This is demonstrated by a non-significant test for interaction between age and treatment 
(Figure 2.1A). However, variation in baseline risk on favorable outcome according to age 
results in a larger absolute treatment benefit in younger patients (Figure 2.1B).
Strengths and limitations of this study
• Multiple characteristics will be evaluated simultaneously to show clinically relevant
heterogeneity in treatment benefit between patients.
• Multivariable prediction modelling substantially increases statistical power compared
to other approaches and is more robust, especially in small datasets.
• We will use a relatively small cohort for the development of a prediction model.
• Using a proportional odds model requires the assumption that the odds ratio are the
same for each cut-off of the modified Rankin Scale.
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Conventional subgroup analyses are focused mainly on predictive effects and asses the 
effect of only one variable at a time. If predictive and prognostic effects of multiple 
characteristics are evaluated simultaneously in multivariable prediction modelling, it is likely 
that larger heterogeneity in treatment benefit between individual patients will be found. 
Our aim is to improve selection of patients for EVT by predicting treatment benefit or harm 
for individual stroke patients.
Development data
We will use data of the MR CLEAN trial (n=500), which was a phase 3, multicenter clinical 
trial with randomized treatment group assignment, open-label treatment, and blinded end-
point evaluation. EVT plus usual care (which could include intravenous administration of 
alteplase) was compared with usual care alone. EVT consisted of arterial catheterization 
with a microcatheter to the level of occlusion and delivery of a thrombolytic agent, 
mechanical thrombectomy, or both.1
Figure 2.1. Relative risk (A) and absolute risk difference (B) for functional independence (mRS 0-2) in MR 
CLEAN sort by age. MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands; mRS, modified Rankin Scale
MR PREDICTS study protocol
29
2
Severity of stroke was assessed at baseline with the National Institutes of Health Stroke 
Scale (NIHSS; range 0–42). Baseline Computed tomography (CT) was evaluated with the 
Alberta Stroke Program Early Computed Tomography Score (ASPECTS; range 0–10).  Baseline 
imaging (CT angiography) was used to determine the location of occlusion and to grade the 
quality of collateral flow to the ischemic area with a 4-point scale. Detailed information 
about the MR CLEAN trial can be found in the study protocol and the publication of the main 
results.1,12
Endpoints of interest
Primary outcome will be the modified Rankin Scale (mRS), a 7-point scale ranging from 0 
(no symptoms) to 6 (death) at 90 days after stroke.13 We will provide estimates of treatment 
benefit as the absolute increase in probability on functional independence (defined as mRS 
0–2) and survival (defined as mRS 0–5).
Step 2: Coding of variables
As variables, we will use patient characteristics that are expected to predict outcome, or 
that are expected to interact with treatment, based on expert opinion and the recent 
literature (Table 2.1). Non-linearity of continuous variables will be tested by comparing the 
2 log likelihood of models with linear and restricted cubic spline (RCS) functions.14 
Timing of treatment is an essential predictor of outcome. Since time to randomization was 
not a reliable indicator for time to treatment in the MR CLEAN trial and will not be applicable 
in clinical practice, we will use time from stroke onset to groin puncture. Since time to groin 
puncture is not observable in the control group, we will explore imputation approaches 
based on the correlation with time to randomization. All other baseline variable values are 
more than 98% complete in the MR CLEAN data, so we choose simple imputation by the 
mean for continuous variables and simple imputation by the mode for categorical variables. 
Step 3 and 4: Model specification and estimation 
We will test the effect of variables on functional outcome and treatment effect with 
proportional odds regression modelling. All variables from Table 2.1 will be tested for effect 
on outcome and interaction with treatment effect. Prognostic variables (main effects) and 
predictive variables (interaction effects) with a p-value of 0.15 in univariable and multivariable 
analyses will be included in our final model. A p-value of 0.15 was chosen to make the 
predictor selection less data driven and prevent overfitting.14,15  We will perform shrinkage 
of all regression coefficients with ridge regression to prevent overfitting of the model.14 
Predicted probabilities for each of the mRS categories, with and without treatment, will be 
derived from the ordinal model. All statistical analyses will be performed within the 
computing environment R version 3.2.2 (The R Foundation).
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Step 5: Model performance
Model performance will be expressed in discrimination and calibration. Discrimination will 
be quantified with the c-statistic. The c-statistic is similar to the area under the curve (AUC) 
for binary outcomes and estimates the probability that out of two randomly chosen patients, 
the patient with the higher predicted probability of a good outcome will indeed have a better 
outcome. Calibration refers to the agreement between predicted and observed risks and 
will be assessed graphically with calibration plots, and expressed as calibration slope and 
intercept. The calibration slope describes the relative overall effect of the variables in the 
validation sample, and is ideally equal to 1. 
The intercept indicates whether predictions are systematically too high or too low, and 
should ideally be zero.16 We will calculate a general c-statistic to express the performance 
of our ordinal model and additional calibration plots with specific c-statistics for the 
predictions of favorable functional outcome (mRS 0-2) and survival (mRS 0-5).
Table 2.1. Patient characteristics that are expected to predict outcome (prognostic), or that are expected to 
interact with treatment (predictive).
% of data 
complete in 
MR CLEAN
Prognostic Predictive
Clinical
Age6,24 100% X
Baseline NIHSS25,26 100% X
History of diabetes mellitus27 100% X
History of previous stroke28 100% X
History of atrial fibrillation29 100% X
Pre-stroke mRS score28 100% X
Systolic blood pressure30 100% X
IV treatment with alteplase31-33 100% X
Time from stroke onset to groin puncture34,35 100%* X X
Radiological
ASPECTS6,36 99.2% X
Location of intracranial occlusion on non-invasive vessel 
imaging37,38  
99.8% X
Collateral score on CTA38,39 98.4% X X
*Of patients undergoing endovascular treatment. 
ASPECTS, Alberta Stroke Program Early CT score; CTA, computed tomography angiography; IV, intravenous; MR 
CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
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Step 6: Model validity
The c-statistic will be internally validated with a bootstrap procedure (500 samples with 
replacement) to estimate the degree of optimism in parameter estimates.8 After penalization 
of the regression coefficients we will externally validate the model on data of patients in 
the Interventional Management of Stroke III trial (IMS III) with an occlusion in the anterior 
circulation on non-invasive vessel imaging.17 Coefficients of the final model will be fitted on 
the combined development and validation datasets.
After validation, we will assess whether the model can be used to discriminate between 
patients with low and high expected benefit by making individual predictions of outcome 
for all patients included in the development and validation data. 
Step 7: Model presentation 
The final model will be online available to be used in clinical practice, both for mobile devices 
and as a web-application. It will provide predictions of all mRS categories for each individual 
patient, both with and without EVT. 
Ethics and dissemination
Findings will be disseminated widely through peer-reviewed publications, conference 
presentations and in an online web-application tool. Formal ethical approval was not 
required for this study as primary data were already collected.
Discussion
Compared to the current subgroup analyzes on the effect of EVT, our modelling approach 
has multiple advantages. First, it accounts for the fact that patients have multiple 
characteristics that simultaneously affect the likelihood of treatment benefit.18 Thus, our 
model will show more clinically relevant heterogeneity in treatment benefit between 
patients. Second, a multivariable prediction model substantially increases statistical power 
to identify heterogeneity in treatment effects compared to other approaches.19 These include 
neural network and decision trees. We use regression modelling since it is considered more 
robust, especially in relatively small datasets.20,21  
There are some differences between patients included in MR CLEAN and IMS III that may 
influence the external validity of our model. IMS III had different inclusion criteria, used 
older devices and used older treatment paradigms than MR CLEAN. In order to overcome 
these limitations, we will use only those patients in IMS III with an occlusion in the intracranial 
anterior circulation on noninvasive vessel imaging. We will compare the baseline 
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characteristics of the derivation and validation cohort and describe relevant differences 
that might lead to an under- or overestimation of the model performance. Interestingly, a 
substantial treatment effect in the IMS III patients with proven intracranial large vessel 
occlusion has been reported.22
Furthermore, even though the MR CLEAN trial has included most patients of the recent 
RCTs, the cohort remains relatively small for the development of a prediction model, 
especially for the selection of both main effect and interaction effects. We will reduce 
regression coefficients to prevent overfitting and we will perform external validation. In the 
future, we will further validate and update our model in the pooled individual patient data 
of the Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) 
collaboration, harboring data of all patients from recent randomized trials regarding EVT 
(over 1700 patients in total). Moreover, we aim to investigate the validity of our model 
predicting outcome after treatment in clinical practice. Our model will therefore be tested 
by applying it to recently treated patients in all Dutch neurovascular centers participating 
in the MR CLEAN Registry. 
We will use a proportional odds model to analyze the full mRS score as outcome. Formally 
this model requires the assumption that the odds ratio are the same for each cut-off of the 
mRS. However, previous studies have shown that even if the proportionality assumption is 
violated, proportional odds analysis is still more efficient than dichotomization.23 In addition, 
all recent RCTs on the effect of EVT used the full mRS and analyzed their results with 
proportional odds regression.
Conclusion
The proposed study will provide an internationally applicable clinical decision aid for the 
selection of patients for EVT. We consider this study an important next step towards 
personalized treatment of ischemic stroke patients. 
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Abstract
Objective 
To improve the selection of patients with acute ischemic stroke for endovascular treatment 
(EVT) using a clinical decision tool to predict individual treatment benefit.
Design 
Multivariable regression modeling with data from two randomized controlled clinical trials. 
Setting 
Sixteen hospitals in the Netherlands (derivation cohort) and 58 hospitals in the United States, 
Canada, Australia and Europe (validation cohort).
Participants 
500 patients from the Multicenter Randomized Clinical Trial of Endovascular Treatment for 
Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial (derivation cohort) and 260 
patients with proven intracranial occlusion from the Interventional Management of Stroke 
III (IMS III) trial (validation cohort).
Main outcome measures 
The primary outcome was the modified Rankin Scale (mRS) at 90 days after stroke. We 
constructed an ordinal logistic regression model to predict outcome and treatment benefit, 
defined as the difference between the predicted probability of good functional outcome 
(mRS 0–2) with and without EVT.
Results 
Eleven baseline clinical and radiological characteristics were included in the model. The 
externally validated c-statistic was 0.68 (95% confidence interval (CI) 0.64 to 0.73) for the 
ordinal model and 0.73 (95% CI 0.67 to 0.79) for the prediction of good functional outcome, 
indicating moderate discriminative ability. The mean predicted treatment benefit varied 
between patients in the combined derivation and validation cohort from -2.3% to 24.3%. 
There was benefit of EVT predicted for some individual patients from groups in which no 
treatment effect was found in previous subgroup analyses, such as those with no or poor 
collaterals.
Conclusion
The proposed clinical decision tool combines multiple baseline clinical and radiological 
characteristics and shows large variations in treatment benefit between patients. The tool 
is clinically useful as it aids in distinguishing between individual patients who may experience 
benefit from EVT and those who will not.
Development and validation of MR PREDICTS
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Trial registration 
clinicaltrials.gov NCT00359424 (IMS III) and isrctn.com ISRCTN10888758 (MR CLEAN).
What is already known on this topic
• Endovascular treatment  improves functional outcome in patients with acute ischemic
stroke caused by a proximal occlusion.
• There is large variation in the selection of candidates for endovascular treatment in
current practice because of the uncertainty of treatment benefit in specific subgroups.
What this study adds
• A newly developed clinical decision tool combines multiple baseline clinical and
radiological characteristics and shows large variations in treatment benefit between
patients.
• Selection of individual patients for endovascular treatment should therefore not be
based on single patient characteristics.
• This model is the first step towards individualized selection of patients for endovascular
treatment of ischemic stroke and may be used as a tool for assisting clinical decision
making.
ASPECTS
A quantitative grading system to assess early ischemic changes on a non-contrast CT scan. 
Scores ranges from 0 to 10, with 10 points for a normal CT scan and 1 point subtracted 
for every defined region with evidence of early ischemic changes.16
Collateral score
A 4 point scale to grade the collateral flow of the occluded territory on vessel imaging, 
with 0 representing absent collateral flow, 1 representing poor collateral flow (<50% 
filling), 2 representing moderate collateral flow (between 50% and 100% filling), and 3 
representing good collateral flow (100% filling).17
Box 3.1 Research in context.
Box 3.2 Descriptions of ASPECTS and collateral score.
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Background
Stroke is the second most common cause of mortality world-wide and of disability in high-
income countries.1 In Western countries, 80% of strokes are ischemic.2 Ischemic strokes 
caused by a proximal occlusion in the intracranial cerebral arteries result in poor outcome.3,4 
Endovascular treatment (EVT) improves functional outcome in patients with acute ischemic 
stroke caused by such a proximal occlusion,5-11 with a number needed to treat of 5 (odds 
ratio 2.35, 95% confidence interval (CI) 1.85 to 2.98).12 However, this is an average treatment 
effect and it is likely that treatment benefit will vary between individual patients.13,14 In 
current practice there is debate on the selection of candidates for EVT because of uncertainty 
of treatment benefit in specific subgroups and patients not included in the trials.12,15 
Clinicians combine multiple clinical features in their clinical decision making on how to treat 
an individual patient. For example, consider a 70-year old man who is admitted 40 minutes 
after onset of symptoms, with a severe left hemisphere ischemic stroke and a National 
Institutes of Health Stroke Scale (NIHSS) score of 22, an Alberta Stroke Program Early 
Computed Tomography Score (ASPECTS) of 7 and a M1 occlusion but no collaterals on 
computed tomography angiography (CTA). A previous subgroup analysis using data of the 
MR CLEAN trial suggested no treatment effect for patients with no or poor collaterals.15 But 
if this man can be treated very early after onset of stroke, will he benefit from EVT? Or 
consider a diabetic woman with high systolic blood pressure, aged 80, who arrived in a 
primary stroke center too late for treatment with intravenous (IV) alteplase, with a NIHSS 
score of 22, ASPECTS of 9, and a carotid-T occlusion with good collaterals on CTA. Should 
she be transferred to an intervention center 40 miles away if EVT just within the 6-hour time 
window is possible? 
We developed and validated a clinical decision tool to provide individualized predictions of 
the effect of EVT based on multiple characteristics. Such a tool may be helpful to support 
clinical judgement when making complicated treatment decisions. 
Methods
In short, we developed a multivariable prediction model in patients included in the MR 
CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands, n=500) and validated this model in a subgroup of 
patients with an occlusion on CTA in the IMS III trial (Interventional Management of Stroke 
III, n=260). The primary outcome was the modified Rankin Scale (mRS) at 90 days after stroke. 
We constructed an ordinal logistic regression model to predict outcome and treatment 
benefit. This benefit was defined as the difference between the predicted probability of 
good functional outcome (mRS 0–2) with and without EVT. Variables were selected using 
univariable and multivariable selection steps (P<0.15).
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Derivation cohort
We used data from all 500 patients of MR CLEAN (derivation cohort) for the development 
of our model.5 MR CLEAN was a phase III multicenter clinical trial with randomized treatment-
group assignment, open-label treatment and blinded outcome evaluation. EVT plus usual 
care was compared with usual care alone (control group). Usual care could include treatment 
with IV alteplase if eligible. Enrolled patients were 18 years or older (no upper age limit), 
had a score of 2 or higher on the NIHSS (range 0 to 42), an occlusion of the proximal 
intracranial carotid artery, middle cerebral artery (M1 or M2), or anterior cerebral artery (A1 
or A2), established with CTA. The start of EVT had to be possible within six hours after stroke 
onset. The imaging committee evaluated the findings on baseline non-contrast computed 
tomography (NCCT) for the ASPECTS and non-invasive baseline vessel imaging (CTA, 
magnetic resonance angiography, or digital subtraction angiography) for the location of the 
occlusion and collateral score.16,17 
More detailed information about MR CLEAN can be found in the study protocol and the 
publication of the main results.5,18 
Model development
Patient characteristics obtained before treatment that are expected to predict outcome or 
to interact with treatment, based on expert opinion or recent literature, were specified in 
our statistical analysis plan.19 We used ordinal logistic regression modeling, which assumes 
proportional odds, to test the effect of age, baseline NIHSS score, systolic blood pressure, 
treatment with IV alteplase, history of ischemic stroke, atrial fibrillation, diabetes mellitus, 
prestroke mRS, ASPECTS, location of occlusion, collateral score and time to treatment, as 
well as the corresponding interactions with treatment. Primary outcome was the mRS score, 
a 7-point scale ranging from 0 (no symptoms) to 6 (death), at 90 days after stroke.20 For 
additional analyses, we derived the probabilities for good functional outcome (mRS 0–2) 
from the ordinal model. Treatment benefit was defined as the difference between the 
predicted probability of good functional outcome with and without EVT.
In our final multivariable model we selected the main effects or interaction terms with a P 
value of <0.15 in univariable and multivariable analyses. Location of occlusion was analyzed 
categorically and ASPECTS and collateral score were analyzed continuously. Continuous 
variables were not dichotomized. Non-linearity of continuous variables was tested with 
restricted cubic spline functions.21 In the final model we used restricted cubic spline functions 
for age and systolic blood pressure. As a measure for time to treatment we used the time 
from stroke onset to groin puncture. Since groin puncture was not performed in control 
subjects, time to groin puncture was not observable in the control arm. Single imputation 
based on regression using age, NIHSS score, inter-hospital transfer, hospital of first 
presentation and time to randomization, was used to assign time to expected groin puncture 
(R2=0.89). Since all other variables were more than 98% complete within the derivation 
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cohort, we used simple imputation by the mean for continuous variables and simple 
imputation by the mode for categorical variables. 
Internal validation with bootstrapping was used to estimate the degree of optimism in the 
final model. Regression coefficients were reduced with penalized regression to correct for 
this optimism.21,22 Coefficients of non-linear terms and interaction terms were reduced with 
a larger penalty than the main effects.22 
External validation 
External validation of our model was performed in the Interventional Management of Stroke 
III (IMS III) trial.23 The IMS III trial (n=656) was a phase III multicenter clinical trial with 
randomized treatment group assignment, open label treatment, and blinded outcome 
evaluation. The trial tested the approach of IV alteplase followed by EVT, as compared with 
standard IV alteplase. Further details on the methods used in the trial have been reported 
extensively.23,24 
We included patients with proven occlusion in the anterior circulation on non-invasive vessel 
imaging, and an available mRS score at 90 days in the validation cohort (n=260). Missing 
collateral scores because of insufficient CTA imaging (n=68) were replaced by single 
imputation with regression using age, history of diabetes mellitus and presence of internal 
carotid T occlusion. Single imputation for time to groin puncture (n=102; primarily control 
patients) was performed using age, NIHSS, time to randomization and inter-hospital transfer. 
All other variables were more than 98% complete and missing values of these variables 
were imputed with the mean (continuous variables) or mode (categorical variables).
Model performance in the validation cohort was expressed by discrimination and calibration. 
Discrimination was quantified with the concordance or c-statistic, which varies between 0.5 
for a non-informative model and 1 for a perfectly discriminating model.25 We calculated the 
general c-statistic of our ordinal model and an additional c-statistic for the predictions of 
good functional outcome (mRS 0–2). 
Calibration refers to the level of agreement between predicted risks and observed outcome; 
this was assessed graphically with a validation plot for the prediction of good functional 
outcome (mRS 0–2) expressed as calibration slope and intercept. The calibration slope 
describes the effect of the predictors in the validation sample versus the derivation sample, 
and is ideally equal to 1. The intercept indicates whether predictions are systematically too 
high or too low, and should ideally be zero.26 
After external validation, the regression coefficients were fitted on a dataset combining all 
patients in the derivation and validation cohort. To assess if our model could be used to 
select individual patients for EVT, we estimated the individual predictions for all 760 patients 
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included in this combined dataset. We created a scatterplot with the predicted probabilities 
of good functional outcome (mRS 0–2) for these patients without EVT on the x-axis and the 
predicted probabilities with EVT on the y-axis. We made additional plots for the predictions 
of patients with no or poor collaterals and patients with low ASPECTS scores, since pre-
specified subgroup analyses showed that these groups had no or very limited benefit of 
treatment.
All statistical analyses were performed with R statistical software (version 3.2.2) and the rms 
library (version 4.4-0). The web-application was developed with the R Shiny package (shiny 
version 0.13.0).
Patient involvement
No patients were involved in setting the research question or the outcome measures, nor 
were they involved in the design and implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. There are plans to disseminate the results 
of the research to the relevant patient community.
Results
Table 3.1 shows that baseline patient characteristics and important characteristics of 
workflow and outcome were similar between the derivation cohort (n=500) and validation 
cohort (n=260). The validation cohort was somewhat more homogeneous, by not including 
patients with baseline disability (premorbid mRS ≥3) or patients not treated with IV alteplase.
Most variables were predictors of outcome (Table 3.2). The strongest predictors in 
multivariable analysis were age (P<0.001), baseline NIHSS (P<0.001), systolic blood pressure 
(P<0.001), history of ischemic stroke (P=0.03), diabetes mellitus (P=0.02), prestroke mRS 
(P=0.003), ASPECTS (P=0.001), location of occlusion (P=0.03) and collateral score (P<0.001). 
Interactions with relative treatment effect were found in univariable analysis for history of 
ischemic stroke, atrial fibrillation, collateral score and time to groin puncture (all P≤0.10, 
Figure 3.1). In the multivariable model, the effects of EVT were similar as in univariable 
analysis, with larger effects in patients without previous ischemic stroke (P=0.07), in patients 
with better collateral scores (P=0.07), and in patients with shorter times to groin puncture 
(P=0.13). Atrial fibrillation was not significant in multivariable analysis as either a main effect 
(P=0.67) or interaction effect (P=0.27), and was therefore excluded from the model.
The final multivariable model included age, baseline NIHSS score, systolic blood pressure, 
IV treatment with alteplase, history of ischemic stroke, diabetes mellitus, pre-stroke mRS, 
ASPECTS, location of occlusion, collateral score and time from onset to groin puncture. We 
added terms representing the interaction between treatment and each of previous stroke, 
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Table 3.1. Overview of the derivation and validation cohort.
Derivation cohort
(n=500)
Validation cohort
(n=260)
Age, years – mean (SD) 65 (14) 67 (12)
Male sex 292 (58%) 135 (52%)
Baseline NIHSS – median (IQR) 18 (14–22) 17 (14–21)
Systolic blood pressure, mmHg – mean (SD) 145 (25) 149 (26)
Treatment with IV alteplase 445 (89%) 260 (100%)
Allocation to EVT 233 (47%) 174 (67%)
Medical history
Ischemic stroke 54 (11%) 28 (11%)
Atrial fibrillation 135 (27%) 89 (35%)
Diabetes mellitus 68 (14%) 49 (19%)
Pre-stroke mRS 
        0 404 (81%) 231 (89%)
        1 50 (10%) 22 (8%)
        2 25 (5%) 7 (3%)
        ≥3 21 (4%) 0
Imaging
ASPECTS on NCCT – median (IQR) 9 (8–10) 8 (6–9)
Location of occlusion on non-invasive vessel imaging
        ICA-(T) 138 (28%) 66 (25%)
        M1 319 (64%) 144 (55%)
        M2 39 (8%) 50 (19%)
        A1 3 (1%) 0
Workflow
Onset to randomization, min – median (IQR) 200 (150–261) 143 (120–170)
Onset to groin puncture, min – median (IQR) 260 (210–311) 205 (168–235)
Onset to reperfusion, min – median (IQR) 340 (274–395) 275 (238–319)
Outcome 
Recanalization (mTICI 2B/3) 116 (59%) 69 (45%)
mRS at 90 days 
      0 7 (1%) 27 (10%)
      1 36 (7%) 46 (18%)
      2 84 (17%) 39 (15%)
      3 87 (17%) 36 (14%)
      4 133 (27%) 44 (17%)
      5 45 (9%) 18 (7%)
      6  (mortality) 108 (22%) 50 (19%)
Values are numbers (percentages) unless stated otherwise.
ASPECTS, Alberta Stroke Program Early CT score; EVT, endovascular treatment; ICA-(T), internal carotid artery 
(with terminal segment); IQR, interquartile range; IV, intravenous; mRS, modified Rankin Scale; mTICI, modified 
thrombolysis in cerebral infarction scale; NCCT, non-contrast computed tomography; NIHSS, National Institutes 
of Health Stroke Scale.
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collateral score and time to groin puncture. The internally validated c-statistic for ordinal 
outcome was 0.74 without interaction terms and this increased to 0.75 by adding interaction 
with treatment. The c-statistic for good functional outcome was 0.79. 
External validation 
Similar effects were found for most variables in the validation cohort except for systolic 
blood pressure, diabetes mellitus and the interaction between history of ischemic stroke 
and treatment effect. The externally validated c-statistic was 0.69 (95% CI 0.64 to 0.73) for 
the ordinal model and 0.73 (0.67 to 0.79) for the prediction of good functional outcome 
(Figure 3.2). 
Table 3.2. Main effects in derivation cohort (n=500). 
Univariable model Multivariable model
Common odds 
ratio (95% CI)
p-value Common odds 
ratio (95% CI)
p-value
Intra-arterial treatment 1.66 (1.21 to 2.28) 0.002 1.86 (1.34 to 2.59) <0.001
Age (per year) <0.001 <0.001
     <65 years 0.97 (0.95 to 0.99) 1.00 (0.97 to 1.02)
     >=65 years 0.92 (0.89 to 0.94) 0.92 (0.89 to 0.95)
Baseline NIHSS (per point) 0.91 (0.88 to 0.94) <0.001 0.93 (0.90 to 0.96) <0.001
Systolic blood pressure (per 10 mmHg) <0.001 <0.001
     <130 mmHg 1.12 (0.88 to 1.41) 1.24 (0.97 to 1.59)
     >=130 mmHg 0.76 (0.70 to 0.83) 0.77 (0.70 to 0.85)
Treatment with IV alteplase 1.85 (1.12 to 3.08) 0.02 1.62 (0.94 to 2.79) 0.08
History of ischemic stroke 0.48 (0.29 to 0.80) 0.005 0.53 (0.31 to 0.92) 0.03
Atrial fibrillation 0.52 (0.36 to 0.73) <0.001 0.92 (0.62 to 1.36) 0.67
Diabetes mellitus 0.37 (0.23 to 0.59) <0.001 0.54 (0.33 to 0.90) 0.02  
Prestroke mRS 0.63 (0.52 to 0.77) <0.001 0.72 (0.58 to 0.90) 0.003
ASPECTS (per point) 1.16 (1.07 to 1.26) <0.001 1.16 (1.06 to 1.28) 0.001
Level of occlusion on non-invasive imaging 0.02 0.03
     ICA-(T) 1.0 (reference) 1.0 (reference)
     M1 1.53 (1.08 to 2.17) 1.43 (0.98 to 2.07)
     M2 2.11 (1.15 to 3.88) 2.35 (1.20 to 4.60)
Collateral score 1.95 (1.62 to 2.36) <0.001 1.61 (1.31 to 1.96) <0.001
Time from onset stroke to groin puncture 
(per 30 minutes)
0.94 (0.88 to 1.00) 0.07 0.93 (0.86 to 1.00) 0.04
Presented common odds ratios reflect the effect on the reversed modified Rankin Scale (odds ratio >1 
corresponds with better functional outcome).
ASPECTS, Alberta Stroke Program Early CT score; CI, confidence interval; CTA, computed tomography 
angiography; EVT, endovascular treatment; ICA-(T), internal carotid artery (with terminal segment); IQR, 
interquartile range; IV, intravenous; mRS, modified Rankin Scale; NCCT, non-contrast computed tomography; 
NIHSS, National Institutes of Health Stroke Scale.
Part I  |  Chapter 3
46
The expected benefit of EVT varied largely between patients in the combined derivation and 
validation cohort (Figure 3.3A). Mean predicted absolute treatment benefit was an 11.8% 
higher probability of mRS 0–2 compared to the probability without EVT, and varied from 
-2.3% to 24.3% between individual patients in the combined derivation and validation cohort. 
The individual predictions for patients with no or poor collaterals (score 0–1) or low ASPECTS 
(score 0–5) illustrate the substantial variation in outcome and treatment benefit in these 
groups (Figures 3.3B and 3.3C). For some patients, who have multiple characteristics that 
negatively affect treatment benefit, the model predicts no benefit or even harm.
We calculated the predicted probabilities of good functional outcome with and without EVT 
for the two patients described in the introduction (Figure 3.4). The first patient is expected 
to benefit from EVT despite absent collaterals and moderate ASPECTS. The probability of 
achieving good functional outcome increases by 11 percentage points, from 16% without 
EVT to 27% with EVT. The predictions for the second patient illustrate that a good collateral 
score does not guarantee a large treatment benefit. The 80-year old patient has a low 
probability of achieving good functional outcome (3% without EVT and 5% with EVT), with 
some shift on the total mRS scale.
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Figure 3.1. Univariable interaction effects in the derivation cohort (n=500). Interaction with treatment 
is expressed as the log odds for good functional outcome (modified Rankin Scale 0–2) with and without 
endovascular treatment on the y-axis. Variables on the x-axis are expressed continuously (time to groin 
puncture) or categorically (previous stroke, atrial fibrillation and collateral score).  
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We implemented our model in a web-application that provides predictions of outcome for 
individual patients based on baseline clinical and radiological characteristics for use in clinical 
practice. It shows bar charts with the expected distribution of mRS categories with and 
without EVT, the predicted probabilities of good functional outcome and the predicted 
absolute treatment benefit (Figure 3.4). This web-application was made accessible online 
at www.mrpredicts.com.
Predicted probability according to model
O
bs
er
ve
d 
pr
op
or
ti
on
 in
 v
al
id
at
io
n 
co
ho
rt
0 0.2
1
0
0.4 0.6 0.8 1.0
0
0.2
0.4
0.6
0.8
1.0
Flexible calibration (Loess)
Calibration
  Intercept: 0.81 (0.53 to 1.09)
  Slope: 0.75 (0.50 to 0.99)
Discrimination
C-statistic: 0.73 (0.67 to 0.79)
Ideal
Figure 3.2. Calibration plot for predicted good functional outcome, defined as modified Rankin Scale (mRS) 0-–
2, in the validation cohort (n=260). The calibration slope reflects the strength of the predictors. The calibration 
intercept reflects the calibration-in-the-large, indicating whether predicted probabilities are systematically too 
low or too high. The overall observed proportion of patients with mRS 0–2 in the validation cohort was higher 
as to be expected using our model. The linear bar chart shows the distribution of patients with (=1) or without 
(=0) an observed outcome of mRS 0–2. Discrimination between low and high likelihood of good functional 
outcome was moderate (c-statistic 0.73, 95% CI 0.67 to 0.79).
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Figure 3.3. (A) Predicted probabilities of good 
functional outcome (modified Rankin Scale (mRS) 
score 0–2) for all individual patients in combined 
derivation and validation cohort (n=760). Each 
dot represents one individual patient, with the 
probability of good functional outcome (mRS 
score 0–2) without endovascular treatment (EVT) 
expressed on x-axis, and probability for good 
functional outcome with EVT on y-axis. Above the 
diagonal line the predicted probability of good 
functional outcome with EVT is higher than that 
without EVT. The farther above this line, the larger 
the predicted effect of treatment. (B) Patients 
highlighted with no or poor collaterals (score 0–1). 
(C) Patients highlighted with low Alberta Stroke 
Program Early CT Score (ASPECTS, score 0–5).
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Patient 1 MR PREDICTS
Clinical decision tool for endovascular treatment in acute ischemic stroke
Patient characteristics
Predicted modied Rankin Scale (mRS) scores at 90 days
Modied Rankin Scale
Age (years) ASPECT score
Location of occlusion
Intracranial ICA (with
or without M1)
70 0 107
NIHSS
22
Prestroke mRS
0
Previous stroke
No
Diabetes mellitus
No
Systolic blood
pressure (mmHg)
140 Estimated time from
onset to groin (minutes)
100
IV alteplase
Yes
M1 only
M2 only
CTA collateral score
0 - absent collaterals
1 - poor (<50% lling)
2 - moderate (>50% lling)
3 - good collaterals
With EVT
Percentage
Predicted probability of good functional outcome (mRS 0-2) 
With endovascular treatment = 27.2%
Without endovascular treatment = 15.7%
Absolute treatment benefit = 11.5%
Without EVT
0 20 40 60 80 100
0 1 2 3 4 5 6
DeathNo symptoms
Patient 2 MR PREDICTS
Clinical decision tool for endovascular treatment in acute ischemic stroke
Patient characteristics
Predicted modied Rankin Scale (mRS) scores at 90 days
Modied Rankin Scale
Age (years) ASPECT score
Location of occlusion
Intracranial ICA (with
or without M1)
80 0 109
NIHSS
22
Prestroke mRS
0
Previous stroke
No
Diabetes mellitus
Yes
Systolic blood
pressure (mmHg)
180 Estimated time from
onset to groin (minutes)
350
IV alteplase
No
M1 only
M2 only
CTA collateral score
0 - absent collaterals
1 - poor (<50% lling)
2 - moderate (>50% lling)
3 - good collaterals
Percentage
Predicted probability of good functional outcome (mRS 0-2) 
With endovascular treatment = 5%
Without endovascular treatment = 2.7%
Absolute treatment benefit = 2.3%
0 20 40 60 80 100
0 1 2 3 4 5 6
DeathNo symptoms
With EVT
Without EVT
Figure 3.4. A stylized representation of the clinical decision tool. Baseline characteristics and predicted 
probabilities of good functional outcome (modified Rankin Scale (mRS) score 0–2) for two examples (see 
introduction). ASPECT, Alberta Stroke Program Early Computed Tomography Score; EVT, endovascular 
treatment; NIHSS, National Institutes of Health Stroke Scale; ICA, internal carotid artery; CTA, computed 
tomography angiography.
Part I  |  Chapter 3
50
Discussion
We developed and externally validated a clinical decision tool to predict the benefit of EVT 
for individual patients with ischemic stroke, based on multiple patient characteristics. The 
predicted treatment benefit varied substantially between individual patients with different 
risk profiles.
Strengths and weaknesses in relation to other studies
Two risk scores have been described previously for the prediction of functional outcome 
after EVT.27,28 These scores are of limited value because they were developed on older 
cohorts of patients who were treated before the introduction of stent-retrievers and contain 
only a small number of clinical variables. Furthermore, they do not provide individual 
predictions and most of the variables and outcome measures in these studies had been 
dichotomized, which is considered to be statistically inefficient and biologically implausible.29 
Our model combines eleven baseline clinical and radiological characteristics simultaneously 
to provide individualized predictions of the effect of EVT. In contrast, conventional subgroup 
analyses focus mainly on predictive effects and assess the effect of only one variable at a 
time. Previous subgroup analyses of EVT trials have tested whether there are differences 
in effect of EVT based on for example: time to treatment,30-34 stroke severity,12,35 and collateral 
score.15 Analyzing one variable at a time may provide mechanistic insights to inform future 
studies and shape clinical considerations. However, they are of limited value in individual 
patient care, because treatment benefit is influenced by multiple individual factors 
simultaneously.13,14 Furthermore, even with similar relative treatment effect, individual 
patients may have different absolute treatment effects due to different baseline risks. More 
targeted individual treatment decisions can be obtained by using a more complex 
multivariable modeling approach to identify individual patients with large or small expected 
treatment benefit.13 
We found modest interaction with treatment for history of ischemic stroke, collateral score 
and time from stroke onset to groin puncture. For collateral score and time to groin 
puncture, interaction with effect of EVT was already shown in previous subgroup analyses.15,30 
Both variables are clinically likely to cause interaction with EVT. However, previous stroke 
has not been studied for interaction with treatment before, and was an unexpected finding 
in our study. It may be a chance finding, since it was not reproduced in the validation cohort 
and we have no clinical explanation. When the regression coefficients were fitted on data 
of the combined derivation and validation cohort and the coefficients of interaction terms 
were reduced to prevent overfitting, the interaction effect for previous stroke in the final 
model was small. Further validation should reveal whether the relative effect of EVT is 
modified by experience of a previous stroke. 
Our study has several limitations. The discriminative ability of the model in the external 
validation was modest. It should be emphasized however, that the c-statistic for the ordinal 
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outcome is a conservative measure. It assesses discrimination between exact categories of 
the mRS, instead of discrimination between 2 groups with different outcome (for example 
mRS 0–2 versus mRS 3–6). Externally validated c-statistics of all cut-offs were better than 
the ordinal c-statistic (eg, 0.73 for good functional outcome and 0.75 for mortality). 
Nevertheless, the relatively small sample size and inclusion of interaction terms in the model 
may have resulted in some optimism and overfitting, despite shrinkage of the regression 
coefficients. The calibration was also suboptimal; despite the fact that most patients were 
treated with first generation thrombectomy devices, patients in the IMS III trial had a better 
outcome than predicted by our model. This could be explained by the patient selection in 
IMS III (eg, premorbid mRS 0–2, age <82 years, treatment with IV alteplase),36 which resulted 
in a better prognosis overall. Patients in the IMS III control group had better outcomes than 
patients in the control group in MR CLEAN (mRS 0–2 = 39% (IMS III with occlusion on CTA) 
versus 19% (MR CLEAN)), leading to inadequate calibration of our model.5,36
Implications for clinicians
Despite its limitations, the currently developed model is the first to predict the effect of EVT 
for individual patients upon arrival at the emergency department. When compared to other 
models used in neurovascular practice, HAS-BLED (c-statistic = 0.65) and CHA2DS2-VASc 
(c-statistic = 0.61), it performs accurately.37,38 The predictions made by our decision tool often 
agree with clinical intuition, which should not be surprising. However, estimates derived 
from large datasets are preferable to the subjective opinion of a physician, whose experience, 
no matter how vast, can never match the information contained in large datasets.39
Currently, some centers withhold EVT in specific subgroups of patients (eg, low ASPECTS, 
no collaterals, age >80 years, or M2 occlusion). Indeed, our model predicts no benefit of EVT 
for some individual patients, especially when a patient has more than one characteristic 
that negatively affects the effect of EVT. The decision not to treat may be particularly relevant 
in patients who have to be transferred to an intervention center. The model may help to 
identify patients without expected benefit of EVT and topple the balance in favor of no 
treatment. But, perhaps more importantly, our study shows that treatment should not be 
withhold based on a single characteristic. Some patients belonging to one of the subgroups 
that are considered as having no benefit of EVT, such as poor collaterals or low ASPECTS, 
may still benefit from EVT substantially if other characteristics are favorable. This emphasizes 
the importance of making personalized treatment decisions, instead of using average 
treatment effects, and shows the need for combining multiple clinical and radiological 
baseline characteristics instead of withholding treatment based on a single characteristic.40
This is the first model for EVT decision making. The predictions of our model should be 
considered as a starting point for clinical decision making, and not as a final recommendation. 
Our model was developed using the MR CLEAN database, consisting of an unselected 
population with few selection criteria. Therefore, our model is likely applicable in centers 
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that use few clinical and radiological selection criteria. Future analyses within larger studies 
may refine the current recommendations and improve the validity of the model. 
Conclusion
The proposed clinical decision tool combines multiple baseline clinical and radiological 
characteristics and shows large variations in treatment benefit between patients. The model 
is clinically useful as it aids in distinguishing between individual patients who may experience 
benefit from endovascular treatment for acute ischemic stroke and those who will not.
Development and validation of MR PREDICTS
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Abstract
Objective
The effect of endovascular treatment (EVT) for acute ischemic stroke is highly time-
dependent. We investigated delay of EVT and factors associated with such delay.
Methods 
MR CLEAN was a randomized trial of EVT plus usual care versus usual care alone (n=500). 
With multivariable linear regression, we analyzed the effect of intravenous treatment, 
general anesthesia, off-hours and inter-hospital transfer on time to admission at the 
emergency department (ED) of the intervention center and time to treatment. Furthermore, 
we assessed compliance with a target of 75 minutes for time from ED to treatment, and 
calculated the potential absolute increase of patients with a good outcome (modified Rankin 
Scale score ≤2), if this target had been achieved in all treated patients.
Results
Inter-hospital transfer prolonged time to ED with 140 minutes (95% confidence interval 129 
to 150), but reduced time from ED to treatment with 77 minutes (64 to 91). Time from ED 
to treatment was increased with 19 minutes by general anesthesia (5 to 33) and total time 
was increased with 23 minutes during off-hours (6 to 40). The in-hospital target was achieved 
in 11.5% (22/191) of patients. Full compliance with the target time of 75 minutes from ED 
to treatment would have increased the proportion of patients with good outcome with 7.6% 
(6.7% to 8.5%). 
Conclusion 
Inter-hospital transfer is an important cause of delay in the delivery of EVT and every effort 
should be made to avoid transfers and reduce transfer-related delay. Furthermore, in-
hospital workflow should be optimized to improve functional outcome after EVT.
Workflow and treatment delay 
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Introduction
Endovascular treatment (EVT) with the use of stent retrievers has been proven safe and 
effective for patients with acute ischemic stroke due to a proximal intracranial arterial 
occlusion in the anterior circulation.1 The effect of treatment is highly time-dependent and 
increased time from stroke onset to reperfusion is associated with a decreased likelihood 
of good functional outcome.2-7 The Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) showed a decrease in 
the effect of EVT on good outcome (risk difference between intervention and control) of 
6.4% per hour delay in time to expected reperfusion.3 It seems likely that reducing treatment 
delay will further increase the effect of EVT.
The timeline from stroke onset to reperfusion consists of several steps, and each step is 
prone to factors causing delay. An important potential cause of delay in the prehospital 
stage is referral to a community hospital without facilities for EVT (a primary stroke center), 
which necessitates inter-hospital transportation of patients to an intervention center. Other 
factors that may increase time to reperfusion are intravenous treatment with alteplase (IVT), 
the use of general anesthesia during the endovascular procedure, and inefficiency of in-
hospital workflow, specifically outside working hours.8-10 In-hospital workflow consists of all 
protocols and procedures in the emergency department (ED) of the primary stroke center, 
the ED of the intervention center, and the interventional suite.
In addition to the previously defined benchmark time of 60 minutes for IVT, various lenient 
or strict target times for EVT are now being suggested to improve in-hospital workflow.11-13 
The Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials (HERMES) 
collaborators reported the 25th percentile of ED admission to groin puncture, which 
amounted to 75 minutes, and could very well serve as a benchmark time.7
Our aim was to investigate prehospital and in-hospital delay in the delivery of EVT in the 
MR CLEAN trial and to assess the impact of inter-hospital transfer and other factors on such 
delay. 
Methods
Study design
MR CLEAN was a multicenter randomized clinical trial in the Netherlands comparing EVT 
plus usual care (intervention group) with usual care alone (control group).14,15  MR CLEAN is 
registered with the ISRCTN registry (ISRCTN10888758). 
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Study setting and population
Patients of 18 years or older with a clinical diagnosis of acute stroke, a deficit on the National 
Institute of Health Severity of Stroke (NIHSS) scale of 2 points or more, and a proximal 
occlusion in the anterior circulation on vessel imaging were included. Detailed inclusion and 
exclusion criteria can be found in the study protocol.14 Usual care could include IVT if 
indicated. The endovascular procedure had to be initiated within 6 hours after onset of 
stroke symptoms and could include intra-arterial delivery of a thrombolytic agent at the 
level of occlusion, mechanical thrombectomy, or both. In total 500 patients were enrolled 
from December 2010 to March 2014. Of these patients, 233 were allocated to the intervention 
arm and 267 were allocated to the control arm. EVT consisted of stent thrombectomy in the 
majority of cases (195/233, 84%).14,15 
Study protocol
Inclusion in the study could occur in three settings: (1) patients arrived directly at an 
intervention center after onset of stroke symptoms; (2) patients were presented at a primary 
stroke center first before being transferred to an intervention center for study participation; 
or (3) patients suffering a stroke while already hospitalized. In the hospital of first 
presentation, a non-contrast CT (NCCT) was performed to exclude intracerebral hemorrhage. 
This was followed by standard medical treatment which could include IVT. Vessel imaging 
with computed tomographic angiography (CTA), magnetic resonance angiography (MRA), 
or digital-subtraction angiography (DSA), had to be performed before inclusion in the study 
in the intervention center, to assess the presence of an intracranial arterial occlusion.
Time points of various events were prospectively collected in the trial, including time of 
stroke onset, start of IVT, admission to the ED of the intervention center and time of 
randomization. In patients receiving EVT, timing of treatment was documented by the local 
interventionist. Time of imaging (ie, NCCT and CTA, MRA or DSA) was prospectively recorded 
in the intervention centers, but had to be collected retrospectively if performed in a primary 
stroke center.
Definitions and outcome measures
Stroke onset was defined as the time point when stroke symptoms were first noticed by 
the patient or an observer. In case the time of first symptoms was unknown, stroke onset 
was defined as the moment the patient was last seen well. We defined off-hours as weekend 
days or working days between 17:00 hours and 08:00 hours. Groin puncture was defined 
as the moment of placing a sheet in the groin, indicating the start of the endovascular 
procedure. Reperfusion was measured with the modified Thrombolysis in Cerebral Infarction 
(mTICI) score, which can range from grade 0 for no reperfusion, to grade 3 for full 
reperfusion.16 We defined time of reperfusion as the first moment a mTICI score of 2b or 3 
was reached. When reperfusion was not achieved, we used the timepoint when the last 
angiography run was done, which indicated the end of the endovascular procedure. 
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Time intervals of primary interest were: (1) time from stroke onset to admission at the ED 
of the intervention center as a measure for prehospital delay; (2) time from admission at 
the ED of the intervention center to groin puncture as a measure for in-hospital delay; and 
(3) time from stroke onset to groin puncture. Additionally, we compared the following time 
intervals between transfer patients and direct patients: (4) time from stroke onset IVT; (5) 
time from admission at ED to vessel imaging; (6) time from vessel imaging to randomization; 
and (7) time from groin puncture to reperfusion. If all vessel imaging was performed in the 
primary stroke center, the patient was excluded from analyses (5) and (6). Time of 
transportation from the primary stroke center to the intervention center was estimated for 
all transfer patients with the TomTom MyDrive application (version 4.1.4.3089, available at 
mydrive.tomtom.com). 
Statistical analysis
For descriptive purposes, time intervals were reported as medians with interquartile range 
(IQR). To assess transfer-related treatment delay, we compared baseline characteristics and 
median time intervals of patients transferred from a primary stroke center versus patients 
directly arrived at the intervention center.
Using multivariable linear regression analyses we evaluated the effect of patient and 
workflow-related characteristics on time to treatment. Factors assessed were administration 
of IVT, use of general anesthesia during the endovascular procedure, admission during 
off-hours and inter-hospital transfer. We included the following potential confounders in 
these analyses: age, gender, baseline NIHSS score, history of ischemic stroke and prestroke 
modified Rankin Scale (mRS). Missing baseline characteristics were imputed with the mean 
(continue variables) or mode (categorical variables). Missing time variables were not imputed.
To assess the impact of in-hospital delay, we compared the time from admission at ED to 
groin puncture with the target time of 75 minutes. For each individual patient we estimated 
the excess delay by subtracting target time from the actual time. The mean excess delay of 
all treated patients was multiplied by an increase in treatment benefit (defined as the risk 
difference for good outcome (mRS score 0–2)) of 6.4% per hour, based on previous results 
of the MR CLEAN trial.3 This provides an estimate of the potential increase in treatment 
benefit if the target time would have been achieved in all treated patients.
All statistical analyses were performed with R software (version 3.2.1, R Foundation).
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Results
Of the 500 patients included in MR CLEAN, 281 (56.2%) arrived directly at an intervention 
center and 219 (43.8%) were transferred from a primary stroke center. Transfer patients 
were significantly younger than those arriving directly at an intervention center (62.2 versus 
67.0 years) and were admitted more frequently during off-hours (63.4 versus 51.6%). Other 
baseline characteristics are shown in Table 6.1. 
Table 6.1. Baseline characteristics of patients in the MR CLEAN trial, according to mode of arrival at the 
emergency department of the intervention center.
 Direct
(n=281)
Transfer 
(n=219)
p-value
Age, years – mean (SD) 67.0 (13.6) 62.2 (13.6) <0.01
Male sex – n (%) 156 (55.5) 136 (62.1) 0.16
Medical history – n (%)
     Atrial fibrillation 77 (27.4) 58 (26.5) 0.90
     Hypertension 135 (48.0) 92 (42.0) 0.21
     Hyperlipidemia 71 (25.3) 58 (26.5) 0.84
     Diabetes mellitus 41 (14.6) 27 (12.3) 0.55
     Previous ischemic stroke 33 (11.7) 21 (9.6) 0.53
Prestroke mRS – n (%) 0.09
     0 220 (78.3) 184 (84.0)
     1 27 (9.6) 23 (10.5)
     2 19 (6.8) 6 (2.7)
     >2 15 (5.3) 6 (2.7)
NIHSS score – median (IQR) 17 (14–22) 18 (15–22) 0.13
Location of occlusion – n (%)* 0.24
     Internal carotid artery 72 (25.7) 66 (30.1)
     M1 middle cerebral artery segment 180 (64.3) 139 (63.5)
     M2 middle cerebral artery segment 27 (9.6) 12 (5.5)
     A1 or A2 anterior cerebral artery 
segment
1 (0.4) 2 (0.9)
IVT – n (%) 249 (88.6) 196 (89.5) 0.87
Admission during off hours – n (%)† 141 (51.6) 128 (63.4) 0.01
Allocation to EVT – n (%) 132 (47.0) 101 (46.1) 0.92
Use of general anesthesia – n (%)‡ 39 (32.5) 41 (42.3) 0.18
*One missing value. †25 missing values. ‡Only endovascular treated patients.
EVT, endovascular treatment; IVT, intravenous treatment; mRS, modified Rankin Scale; NIHSS, National Institutes 
of Health Stroke Scale.
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Median time from stroke onset to groin puncture was 233 minutes (IQR 202–287) in direct 
arrival patients, and 315 minutes (260–346) in transfer patients (Table 6.2). The median time 
of inter-hospital transportation was 30 minutes (23–41), but total time from onset to 
admission at the ED of the intervention center was 148 minutes longer in transfer patients 
than in direct arrival patients. In-hospital workflow was improved in transfer patients, with 
a decrease in median time from arrival to vessel imaging of 15 minutes and a decrease in 
time from vessel imaging to randomization of 32 minutes. Duration of the endovascular 
procedure from groin puncture to reperfusion was comparable (56 minutes in direct arrival 
patients versus 61 minutes in transfer patients). Overall, we observed an association 
between increasing time from onset of stroke to admission at ED and decreasing time from 
admission to groin puncture (Supplementary Figure 6.1). However, the average prehospital 
delay caused by inter-hospital transfer was only partially compensated by improved in-
hospital workflow (Figure 6.1).
In multivariable analysis, the total time to treatment (groin puncture) was increased by 23 
minutes during off-hours (95% confidence interval (CI) 6 to 40) and by 65 minutes due to 
inter-hospital transfer (95% CI 48 to 82) (Figure 6.2). Transfer prolonged time to admission 
to the ED by 140 minutes (129 to 150), but was associated with a shorter time to groin 
puncture (77 minutes, 95% CI 64 to 91). Time from ED to groin puncture was increased by 
an additional 19 minutes by the use of general anesthesia during the endovascular 
procedure (95% CI 5 to 33).
Table 6.2. Time intervals in the MR CLEAN trial according to mode of arrival at the emergency department of 
the intervention center, expressed as median (IQR).
All patients Direct
(n=281)
Transfer 
(n=219)
Stroke onset to IVT (n=444) 85
(65–110)
85
 (66–110)
Stroke onset to admission to ED (n=471) 52
(34–75)
200
(166–245)
Admission to ED to vessel imaging (n=439) 39
(25–67)
24
(17–32)
Vessel imaging to randomization (n=460) 53
(34–80)
21
(15–33)
Endovascular treated patients Direct 
(n=132)
Transfer 
(n=101)
Stroke onset to groin puncture (n=205) 233
(202–287)
315
(260–346)
Admission to ED to groin puncture (n=192) 170
(142–205)
96
(75–120)
Groin puncture to reperfusion (n=194) 56
(42–86)
61
(37–90)
ED, emergency department; IVT, intravenous treatment.
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Figure 6.1. Mean time intervals in MR CLEAN (n=500) according to mode of arrival at the emergency 
department of the intervention center. CTA, computed tomography angiography; ED, emergency department; 
IVT, intravenous treatment.
Figure 6.2. Effect of clinical factors on time intervals in MR CLEAN (n=500). ED, emergency department (of the 
intervention center).
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In patients receiving EVT, time from admission to the ED to groin puncture was on average 
145±61 minutes. The defined target time of 75 minutes was reached in only 11.5% (22/191) 
of the treated patients. However, if this target time had been achieved in all patients, mean 
time from onset to groin puncture would have been 71 minutes (95% CI 63 to 80) shorter. 
Because the risk difference of good functional outcome decreases with 6.4% per hour, the 
absolute treatment benefit (proportion of patients with mRS 0–2) in MR CLEAN could have 
been 7.6% (6.7% to 8.5%) higher. 
Discussion
This study shows that inter-hospital transfer was the most important factor associated with 
treatment delay in MR CLEAN. Time from onset to treatment increases with more than one 
hour in patients transferred from a primary stroke center, despite improved in-hospital 
workflow times. Furthermore, only a few patients received EVT within the proposed target 
time of 75 minutes for time from admission to the ED to groin puncture, and enhancing this 
compliance by improving in-hospital workflow might further increase functional outcome 
after EVT.
Overall, the time intervals in MR CLEAN are longer than in several other trials on EVT, such 
as The Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke 
(ESCAPE), EXtending the time for Thrombolysis in Emergency Neurological Deficits with 
Intra-Arterial therapy (EXTEND-IA) and Solitaire With the Intention for Thrombectomy as 
Primary Endovascular Treatment (SWIFT PRIME).17-19 For example, median time to reperfusion 
was 340 minutes in MR CLEAN versus 241 minutes in ESCAPE. This can be explained by the 
strong focus on improving workflow and reducing time delays in ESCAPE, while MR CLEAN 
did not require the participating investigators to be trained in delivery of fast care and 
logistics. Furthermore, the study design of these trials allowed verbal or deferred informed 
consent, while in MR CLEAN a written informed consent was required before 
randomization.15,18 Trials with a shorter median time to groin puncture had a significant 
larger treatment effect (Supplementary Figure 6.2).
Total time to treatment was increased most by inter-hospital transfer, confirming the results 
of previous studies.4,5,9,10 Transfer patients arrived 148 minutes later at the ED, while the 
median transportation time in our study was only 30 minutes. This suggests that that most 
delay was caused during work-up in the primary hospital. However, increased time to arrival 
at the ED was clearly associated with a decrease in the following time to groin puncture. 
This paradoxical effect was likely caused by the fact that this group consisted mainly of 
transfer patients who had already undergone part of the workup, the intervention center 
was pre-notified and clinical information was available before arrival at the ED, which made 
it possible for the staff to mobilize the neuro-interventional team and for the angiosuite to 
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be prepared in advance. This finding suggests that improvement of in-hospital workflow 
might lead to a shorter time from ED to treatment for patients who are directly admitted 
to an intervention center. 
Our study has a number of limitations. Our analysis was restricted to data that was collected 
during the trial. We had no information available on the time of arrival in the primary stroke 
center and the time of departure to the intervention center to estimate door-in to door-out 
times, while this might have provided more insight into the various elements of delay. Also, 
the reported workflow times from this randomized study might not be representative for 
daily clinical practice, since the process of obtaining written informed consent and 
randomization can increase treatment delay substantially. Furthermore, the vessel imaging 
in MR CLEAN was often performed or repeated in the intervention center, while in daily 
routine transfer patients can be directly transferred to the interventional suite without any 
delay of additional imaging. Since the distances between hospitals in the Netherlands are 
very short and the median transportation time in this study was only 30 minutes, our results 
cannot be easily extrapolated to other countries. Transportation times in larger countries 
are usually longer, and the effect of inter-hospital transfer on treatment delay might 
therefore be much stronger in those countries. Last, inter-hospital transfer has not only a 
disadvantageous effect on time to treatment, but also on the number of patients that might 
be eligible for treatment.20 We had no data on the patients in primary stroke centers who 
were not included in the trial because of the need for a transfer and the associated delay. 
Therefore, we were not able to quantify the impact of transfer delay on the likelihood of 
receiving EVT.
Overall, it remains clear that inter-hospital transfer causes significant pre-hospital delays 
in EVT, and that adequate measures have to be taken to shorten transfer times and, if 
possible, to reduce the number of transferred patients. This could be achieved by 
transporting ischemic stroke patients directly to an intervention center using prehospital 
triaging scales to select patients with a high risk of a large vessel occlusion.21-23 These scales 
have to be implemented in regional care systems and protocols for prehospital triage to 
minimize transfer delays depending on the characteristics of the area.24-26 In regions with 
very large distances, the additional use of air ambulance services for the transportation of 
EVT candidates might be beneficial. Another possibility would be to bypass the primary 
stroke center by using a mobile stroke unit; an ambulance with a CT scanner and a specialized 
team on board, allowing in-ambulance initiation and administration of IVT and direct 
transportation to the intervention center.27-29 
The other important step in reducing treatment delay in EVT is improving in-hospital 
workflow. The reduced time from ED to groin puncture in transfer patients suggests that it 
should be possible to shorten the time delay in the ED. Previous studies have already shown 
that optimizing workflow and protocols can decrease time to treatment.30,31 Pre-notification 
Workflow and treatment delay 
111
6
of the interventional team as soon as a patient with a suspected large vessel occlusion is 
announced, direct transport from door to scanner, a parallel nature of care processes and 
optimizing the processes around IVT administration and initiation of EVT are all potential 
factors to reduce ED delay.10,32,33 Providing reasonable time targets might also improve this 
process, as was shown with the introduction of door-to-balloon target times for percutaneous 
coronary intervention.34 
In summary, inter-hospital transfer is an important cause of delay in the delivery of EVT and 
every effort should be made to avoid transfer and reduce transfer-related delay. 
Furthermore, in-hospital workflow can and should be optimized to improve functional 
outcome after EVT.
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Supplementary material
Supplementary Figure 6.1. The relationship between time from stroke onset to admission to the emergency 
department (ED) of the intervention center and the following time to groin puncture. Each dot represents one 
patient, the blue line is the fitted regression line with 95% confidence bands.
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Supplementary Figure 6.2. The relationship between the median time from stroke onset to groin puncture 
and the treatment effect on functional outcome (adjusted common odds ratio) of different trials. Each dot 
represents one trial, the dashed line is the fitted regression line with 95% confidence bands.
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Abstract
Background and purpose
To assess the effect of inter-hospital transfer on time to treatment and functional outcome 
after endovascular treatment (EVT) for ischemic stroke, we compared patients transferred 
from a primary stroke center to patients directly admitted to an intervention center in a 
large nationwide registry.
Methods 
The MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in the Netherlands) Registry is an ongoing, prospective, observational study 
in all centers that perform EVT in the Netherlands. We included adult patients with an acute 
anterior circulation stroke who received EVT between March 2014 to June 2016. Primary 
outcome was time from arrival at the first hospital to arterial groin puncture. Secondary 
outcomes included the 90-day modified Rankin Scale (mRS) and functional independence 
(mRS 0–2). 
Results
In total, 821/1526 patients (54%) were transferred from a primary stroke center. Transferred 
patients less often had pre-stroke disability (227/800 (28%) versus 255/699 (36%), P=0.02) 
and more often received intravenous treatment with alteplase (659/819 (81%) versus 
511/704 (73%), P<0.01). Time from first presentation to groin puncture was longer for 
transferred patients (164 versus 104 minutes, P<0.01, adjusted delay 57 minutes (95% CI 
51 to 62)). Transferred patients had worse functional outcome (adjusted common odds ratio 
0.75 (95% CI 0.62 to 0.90)) and less often achieved functional independence (244/720 (34%) 
versus 289/681 (42%), absolute risk difference -8.5% (95% CI -8.7 to -8.3)).
Conclusions
Inter-hospital transfer of patients with acute ischemic stroke is associated with delay of EVT 
and worse outcomes in routine clinical practice, even in a country where between-center 
distances are short. Direct transportation of patients potentially eligible for endovascular 
treatment to an intervention center may improve functional outcome. 
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Introduction
Endovascular treatment (EVT) has been proven effective in patients with ischemic stroke 
due to an intracranial large vessel occlusion (LVO) of the anterior circulation.1 The effect of 
EVT is highly time-dependent and a reduction in onset-to-treatment time increases the 
chance of good functional outcome for the patient.2,3
Studies focusing on workflow characteristics identified inter-hospital transfer as one of the 
main causes of treatment delay in the recent randomized controlled trials.4,5 Patients with 
ischemic stroke are often first presented at the nearest primary stroke center to provide 
rapid treatment with intravenous thrombolytics (IVT). If the diagnostic work-up indicates 
eligibility for EVT, the patient is then transferred to an intervention center with facilities for 
EVT (‘drip-and-ship’). Analysis of data from a US registry suggested that this drip-and-ship 
method increases time to treatment and decreases the odds of good functional outcome 
in daily clinical practice.6 However, the effect of inter-hospital transfer might be different in 
a more densely populated region with short between-center distances and a well-organized 
acute stroke care system. 
We investigated the frequency of inter-hospital transfer and the characteristics of transferred 
patients in a large nationwide cohort in the Netherlands: the MR CLEAN (Multicenter 
Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the 
Netherlands) Registry. We aimed to assess the effect of inter-hospital transfer on time to 
treatment and functional outcome in routine clinical practice.
Material and methods
Study design
Detailed methods of the MR CLEAN Registry have been reported previously.7 The MR CLEAN 
Registry is an ongoing, prospective, observational study in all centers that perform EVT in 
the Netherlands. Registration started in March 2014, directly after the final inclusion in MR 
CLEAN. All eighteen intervention centers in the Netherlands, of which sixteen centers 
participated in the MR CLEAN trial, registered their patients. All data were centrally collected 
and checked for completeness and consistency. The imaging assessment committee 
assessed imaging and the adverse event committee scored the safety parameters. 
The central medical ethics committee of the Erasmus MC University Medical Center, 
Rotterdam, The Netherlands, evaluated the study protocol and granted permission to carry 
out the study as a registry. Data will not be made available to other researchers as no patient 
approval has been obtained for sharing coded data. However, syntax and output files of 
statistical analyses are available from the corresponding author on reasonable request.
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Study population
All consecutive patients with ischemic stroke in the anterior and posterior circulation who 
received arterial groin puncture in the angiosuite have been registered. For the current 
analysis, we used data of patients treated between March 2014-June 2016. We included 
patients adhering to the following criteria: age ≥ 18 years; treatment in a center that 
participated in the MR CLEAN trial; and presence of an intracranial proximal arterial occlusion 
in the anterior circulation (intracranial carotid artery (ICA/ICA-T), middle cerebral artery (M1/
M2) or anterior cerebral artery (A1/A2)), demonstrated by computed tomography (CT) 
angiography. EVT could consist of arterial catheterization followed by mechanical 
thrombectomy and/or thrombus aspiration, with or without delivery of a thrombolytic agent. 
Patients arrived either directly at the intervention center or were transferred from one of 
the primary stroke centers (Figure 7.1). Emergency medical services in the Netherlands 
identify potential stroke patients using the Face, Arm, Speech Test (FAST) and transport 
patients with an onset time of less than 6 hours to the closest stroke center with IVT or EVT 
facilities.
Definitions and outcome measures
Time of stroke onset was defined as the moment of witnessed onset of stroke symptoms 
or, when exact onset was unknown, the moment that the patient was last seen well. 
Admission outside office hours was defined as time of arrival at the intervention center on 
working days between 17:00 hours and 8:00 hours, during weekend days or national festive 
days. All transfer patients received a non-contrast CT in the primary stroke center and most 
transfer patients received a CT angiography before transfer to an intervention center. 
Imaging was not routinely repeated upon arrival at the intervention center, but only in case 
of a clinical indication (e.g. deterioration or substantial improvement). Imaging characteristics 
were assessed based on the first scan made (for transferred patients in the primary stroke 
center, for direct patients in the intervention center). Transfer-related travel time between 
each primary stroke center and the receiving intervention center was estimated using the 
TomTom MyDrive application (version 4.2.1.3495, available on mydrive.tomtom.com). 
A ratio of 0.85 was subsequently applied on each calculated time to approach the transfer-
related travel time that an ambulance would actually need. This ratio is based upon 
measured travel times of ambulances in a previous study in the Netherlands.8 The door-in-
door-out time in the primary stroke center was then estimated by subtracting the transfer-
related travel time from the reported time from door of the primary stroke center to door 
of the intervention center.
Primary outcome was the time from first presentation to start of treatment, defined as the 
interval between arrival at the first hospital to arterial groin puncture. Secondary outcomes 
included: time from arrival at intervention center to groin puncture; time from stroke onset 
to groin puncture; the modified Rankin Scale (mRS) at 90 days after stroke; functional 
independence, defined as mRS score 0–2; mortality at 90 days; successful reperfusion at 
Inter-hospital transfers
121
7
the end of EVT, defined as an extended Thrombolysis in Cerebral Infarction (eTICI) score 
≥2B;9 and occurrence of symptomatic intracerebral hemorrhage. Intracerebral hemorrhage 
was defined as symptomatic if patients died or deteriorated neurologically (an increase of 
≥4 points on the National Institutes of Health Stroke Scale (NIHSS) score compared with the 
NIHSS before worsening), and the hemorrhage was related to the clinical deterioration 
(according to the Heidelberg Bleeding Classification).10
Statistical analysis
We compared patients transferred from a primary stroke center with patients who were 
directly admitted to an intervention center. Baseline characteristics were compared using 
Chi-square test for categorical variables, independent samples T-test for normally distributed 
Figure 7.1. Map of the Netherlands including primary stroke centers, intervention centers and population 
density.
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continuous variables, and Mann-Whitney U test for non-normal distributed continuous 
variables. Time intervals were expressed as medians with interquartile range (IQR). For 
regression analyses, missing data were imputed using multiple imputations by chained 
equations (MICE) based on relevant covariates and outcome.
Linear regression analyses were used to assess the effect of transfer on time intervals. 
Prespecified adjustments were made for age, baseline NIHSS score, prestroke mRS score, 
treatment with IVT, hypertension (baseline systolic blood pressure >185 mmHg and/or 
diastolic blood pressure >110 mmHg), location of occlusion, Alberta Stroke Program Early 
Computed Tomography Score (ASPECTS) on non-contrast CT, collateral score on CT 
angiograpy, the use of general anesthesia, and admission outside office hours. The effect 
of transfer on functional outcome was assessed using an ordinal logistic regression analysis 
for the shift in mRS score at 90 days. Binary logistic regression analyses were used for 
functional independence, mortality, successful reperfusion, and occurrence of symptomatic 
intracerebral hemorrhage. These analyses were adjusted for the following prespecified 
variables: age, baseline NIHSS score, prestroke mRS score, history of ischemic stroke or 
transient ischemic attack, treatment with IVT, location of occlusion, ASPECTS, collateral score, 
and time from onset to first hospital.
All analyses were performed using R software (Version 3.4.4, R Foundation) with the rms 
package (version 5.1-2).
Results
In total, 1627 consecutive patients treated with EVT for ischemic stroke were included in the 
MR CLEAN Registry between March 2014 and June 2016. We excluded 101 patients for the 
following reasons: age below 18 years (n=2); EVT performed in a non MR CLEAN center (n=20), 
and occlusion of the posterior circulation (n=79). The remaining 1526 patients were included 
in the analyses (Figure 7.2). Of these patients, 821 (53.8%) were transferred from a primary 
stroke center and 705 (46.2%) were presented directly to an intervention center. The 
percentage of transferred patients ranged between 3.4% and 77% per intervention center.
Baseline characteristics
Demographics and baseline stroke severity were similar in both groups: median age was 
71 years for transferred patients versus 70 years for directly admitted patients, 53% of all 
patients were men, and median NIHSS at baseline was 16 for both groups (Table 7.1). 
Transferred patients were more often treated with IVT (80.5% versus 72.6%, P<0.01) and 
had less often pre-stroke disability (mRS≥1, 28.4% versus 36.5%, P=0.02). Imaging 
characteristics were less favorable for transferred patients, with lower ASPECTS (median 8 
versus 9, P=0.01) and more often absent or poor collaterals (collateral score 0–1, 44.1% vs. 
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35.2%, P<0.01). Transferred patients less often had an occlusion of segment 2 of the middle 
cerebral artery (10.6% versus 14.4%, P=0.01). Imaging was repeated in 49/821 (6%) and 
39/821 transfer patients (4.8%) for non-contrast CT and CT angiography, respectively.
Treatment times
The median time from arrival at the first hospital to groin puncture was longer for transferred 
patients than for patients who were directly admitted to an intervention center (164 versus 
104 minutes, P<0.01, Table 7.2). The adjusted difference was 57 minutes (95% confidence 
interval (CI) 51 to 62 minutes), in favor of patients who were admitted directly (Table 7.3). 
After subtraction of the mean estimated transfer-related travel time (23 minutes), this time 
difference was 39 minutes. Transferred patients arrived slightly earlier after stroke onset 
at the first hospital (50 versus 55 minutes, P<0.01), but time from onset to arrival at the 
intervention center was much longer (174 versus 55 minutes, P<0.01). Median door-to-
needle times for patients that received IVT were slightly longer for transferred patients (26 
versus 24 minutes, P=0.02). Although the interval from arrival at the intervention center to 
start of treatment was shorter for transferred patients (47 versus 104 minutes, P<0.01, 
adjusted difference -58 minutes (95% CI -62 to -54)), the total time from onset to groin 
puncture was still substantially longer in these patients (230 versus 170 minutes, P<0.01, 
adjusted difference 40 minutes (95% CI 31 to 48)). The median duration of the endovascular 
procedure was similar in both groups (63 versus 62 minutes, P=0.79).
Clinical outcome
There was a significant shift towards worse functional outcome in transferred patients 
(adjusted common odds ratio (OR) 0.75, (95% CI 0.62 to 0.90); Figure 7.3). Transferred 
Figure 7.2. Flowchart of patient selection. EVT, endovascular treatment.
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Table 7.1. Baseline characteristics.
Direct presentation
n = 705
Transferred patients
n = 821
P-value
Age, median (IQR) 70 (59 – 79) 71 (60 – 80) 0.45
Male sex, n (%) 371/705 (52.6) 438/821 (53.3) 0.78
Baseline NIHSS*, median (IQR) 16 (11 – 20) 16 (12 – 20) 0.19
Systolic blood pressure†, mean+SD 149±25 150±25 0.41
Treatment with IVT, n (%) 511/704 (72.6) 659/819 (80.5) <0.01
Presentation outside office hours, n (%) 441/705 (62.6) 541/821 (65.9) 0.17
General anesthesia, n (%) 180/662 (27.2) 205/759 (27.0) 0.94
Medical history
Ischemic stroke, n (%) 118/703 (16.8) 135/814 (16.6) 0.92
Myocardial infarction, n (%) 113/697 (16.2) 120/798 (15.0) 0.53
Diabetes mellitus, n (%) 126/700 (18.0) 136/817 (16.6) 0.49
Atrial fibrillation, n (%) 147/697 (21.1) 188/807 (23.3) 0.31
Prestroke mRS, n (%) 0.02
    0 444/699 (63.5) 573/800 (71.6)
    1 97/699 (13.9) 98/800 (12.3)
    2 66/699 (9.4) 49/800 (6.1)
    ≥3 92/699 (13.2) 80/800 (10.0)
Imaging characteristics
ASPECTS on first NCCT‡, median (IQR) 9 (7 – 10) 8 (7 – 10) 0.01
Collateral score on first CTA, n (%) <0.01
    Grade 0 42/674 (6.2) 56/743 (7.5)
    Grade 1 195/674 (28.9) 272/743 (36.6)
    Grade 2 259/674 (38.4) 288/743 (38.8)
    Grade 3 178/674 (26.4) 127/743 (17.1)
Location of occlusion, n (%) 0.01
    ICA 39/693 (5.6) 46/765 (6.0)
    ICA-T 142/693 (20.5) 180/765 (23.5)
    Proximal M1 161/693 (23.2) 210/765 (27.5)
    Distal M1 231/693 (33.3) 240/765 (31.4)
    M2 100/693 (14.4) 81/765 (10.6)
    Other§ 20/693 (2.9) 8/765 (1.0)
Number of missing values: *30, †43, ‡67. 
§Occlusion in segment 1 or 2 of the anterior cerebral artery (A1: n=3; A2: n=3), segment 3 of the middle cerebral 
artery (M3: n=9), or no occlusion visible (n=13) on CTA after adjudication by the imaging assessment committee. 
ASPECTS, Alberta Stroke Program Early CT Score; CTA, computed tomography angiography; M1, segment 1 of 
the middle cerebral artery; M2, segment 2 of the middle cerebral artery; mRS, modified Rankin Scale; NCCT, 
non-contrast computed tomography; NIHSS, National Institutes of Health Stroke Scale; ICA, internal carotid 
artery; ICA-T, internal carotid artery tandem; IVT, intravenous thrombolytics.  
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patients less often achieved functional independence when compared to directly admitted 
patients (mRS 0-2, 33.9% versus 42.4%, absolute risk difference -8.5% (95% CI -8.7 to -8.3)), 
also after adjustment (adjusted OR 0.69 (95% CI 0.54 to 0.89); Table 7.4). Mortality rates 
were not significantly different between the two groups (adjusted OR 1.27 (95% CI 0.97 to 
1.66)). There were no significant differences in successful reperfusion rate (adjusted OR 1.13 
(95% CI 0.91 to 1.39)) and occurrence of symptomatic intracerebral hemorrhage (adjusted 
OR 0.87 (95% CI 0.56 to 1.36)).
Table 7.2. Treatment times, presented as medians with interquartile range.
Direct 
presentation
n = 705
Transferred 
patients
n = 821
P-value Missing values
n (%)
Onset to door first hospital 55 (37 – 105) 50 (35 – 80) <0.01 197/1526 (12.9)
Onset to door intervention center 55 (37 – 105) 174 (139 – 220) <0.01 30/1526 (2.0)
Onset to IVT 82 (63 – 125) 79 (60 – 115) <0.01 218/1173 (18.6)
Door to needle 24 (18 – 34) 26 (20 – 36) 0.02 215/1173 (18.3)
Door to door* NA 112 (91 – 140) N/A 196/822 (23.5)
Primary stroke center to 
intervention center (estimated)
NA 21 (15 – 31) NA 3/821 (0.4)
Door in door out† (estimated) NA 88 (68 – 117) NA 197/821 (24.0)
Door first hospital to groin 
puncture
104 (80 – 135) 164 (135 – 198) <0.01 197/1526 (12.9)
Door intervention center to groin 
puncture
104 (80 – 135) 47 (31 – 70) <0.01 30/1526 (2.0)
Onset to groin puncture 170 (135 – 246) 230 (190 – 277) <0.01 0
Duration of procedure 62 (40 – 90) 63 (40 – 87) 0.79 163/1526 (10.7)
Onset to reperfusion 238 (185 – 314) 288 (244 – 343) <0.01 91/1526 (6.0)
*Door primary stroke center to door intervention center. †Door primary stroke center to door intervention 
center, minus the estimated travel time from primary stroke center to intervention center.
IVT, intravenous thrombolytics; NA, not applicable.
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Discussion
In this large, nationwide cohort study, more than half of the patients treated with EVT were 
transferred from a primary stroke center. These patients had significant longer time intervals 
between first presentation and start of treatment, between symptom onset and start of 
treatment, and a lower chance of achieving good functional outcome. Even when we 
accounted for the travel time required to transfer a patient to an intervention center, start 
of treatment was still delayed by half an hour in transferred patients compared to patients 
who were directly admitted to an intervention center. 
Table 7.3. Outcome measures: time intervals (in minutes).
Direct 
presentation
n = 705
Transferred 
patients
n = 821
Unadjusted 
beta
(95% CI)
Adjusted 
beta*
(95% CI)
Door first hospital to groin 
puncture 
104 (80 – 135) 164 (135 – 198) 55 (50 to 61) 57 (51 to 62)
Door intervention center to groin 
puncture
104 (80 – 135) 47 (31 – 70) -59 (-63 to -55) -58 (-62 to -54)
Onset to groin puncture 170 (135 – 246) 230 (190 – 277) 36 (27 to 44) 40 (31 to 48)
*Adjusted for age, baseline National Institute of Health Stroke Severity score, prestroke modified Rankin Scale, 
treatment with intravenous thrombolytics, hypertension (baseline systolic blood pressure >185 mmHg and/or 
diastolic blood pressure >110 mmHg), location of occlusion, Alberta Stroke Program Early Computed 
Tomography Score, collateral score, use of general anesthesia and admission outside office hours. 
Table 7.4. Outcome measures: clinical outcome.
Direct 
presentation
n = 705
Transferred 
patients
n = 821
Unadjusted OR
(95% CI)
Adjusted OR*
(95% CI)
Functional independence  
at 90 days (mRS 0-2) 
289/681 (42.4) 244/720 (33.9) 0.71 (0.58 to 0.88) 0.69 (0.54 to 0.89)
Mortality at 90 days 180/681 (26.4) 227/720 (31.5) 1.24 (0.99 to 1.55) 1.27 (0.97 to 1.66)
Successful reperfusion 
(eTICI ≥2B) 
395/698 (56.6) 473/806 (58.7) 1.10 (0.90 to 1.35) 1.13 (0.91 to 1.39)
Symptomatic ICH 45/705 (6.4) 44/821 (5.4) 0.83 (0.54 to 1.27) 0.87 (0.56 to 1.36)
*Adjusted for age, baseline National Institute of Health Stroke Severity score, prestroke modified Rankin Scale, 
history of ischemic stroke, treatment with intravenous thrombolytics, location of occlusion, Alberta Stroke 
Program Early Computed Tomography Score, collateral score and time from onset to first hospital. 
eTICI, extended Thrombolysis In Cerebral Infarction scale; ICH, intracerebral hemorrhage; mRS, modified Rankin 
Scale.
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From earlier studies, we know that treatment delay translates to a decreased chance of 
achieving a favorable outcome.2 However, because of selection bias and time delay 
associated with informed consent procedures, data from randomized trials may not always 
reflect daily practice. The STRATIS (Systematic Evaluation of Patients Treated With 
Neurothrombectomy Devices for Acute Ischemic Stroke) Registry included 984 patients from 
a large region in the United States of America after the implementation of EVT as standard 
care.6 Similar to our study, the authors found that transferred patients had longer treatment 
times and worse functional outcomes when compared to direct admitted patients. However, 
their time analyses included only patients with successful reperfusion, which is not a fair 
representation of routine clinical practice. Also, distances between hospitals in rural areas 
of the USA are much larger than in our region, and time delays in primary hospitals – for 
instance because of initiation of IVT – are generally longer in the USA than in the 
Netherlands.8,11,12 Results from an earlier small study in a region with short distances, 
including only one primary stroke center and one intervention center, showed that treatment 
times were longer for transferred patients, and the difference between the two groups for 
functional outcome was similar to our study.13
The Netherlands is a small, densely populated country, with 82 hospitals that provide 24/7 
acute stroke care. Approximately 99.8% of the Dutch population has the ability to reach an 
emergency department within 45 minutes.14 Our country has short between-center 
distances. This is emphasized by the fact that the mean transfer time was only 23 minutes, 
indicating that these results probably reflect the acute stroke care logistics in other highly 
populated regions. Although the observed in-hospital workflow times in this study were 
almost an hour shorter than in the MR CLEAN trial in the Netherlands,15 there is still room 
Figure 7.3. Functional outcome measured with the modified Rankin Scale score at 90 days, for patients 
presented directly in intervention center versus transferred from a primary stroke center (125 missing values). 
Transferred patients had worse functional outcomes than directly presented patients (adjusted common odds 
ratio 0.75 (95% CI 0.62 to 0.90)).
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for improvement. It has been suggested that increased experience, reflected in higher 
volumes of patients treated with EVT, leads to shorter treatment times and, subsequently, 
improved functional outcomes.16 Workflow times in our cohort do gradually decrease over 
time from 2014 until 2016. A decline in the median door-to-groin time (with the door of the 
first hospital as start) was observed for both transfer patients (187 to 149 minutes) and 
direct patients (123 to 97 minutes). However, the times achieved in our cohort are still longer 
when compared to other studies reporting workflow times. Additional interventions to 
optimize patient transfer management (eg, holding the initial ambulance primary stroke 
center until the decision of EVT eligibility has been made, streamlining transfer protocols, 
improving cloud-based image sharing, and transporting transfer patients directly to the 
angio-suite) might be useful to further reduce transfer-related delay in the future.17-20
Pre-hospital transportation of stroke patients suspected of LVO directly to an intervention 
center decreases time to EVT, but the potential harm of delaying IVT should be taken into 
account as well. We know, however, that the chance of achieving recanalization with IVT 
prior to thrombectomy in patients with LVO is low.21 Therefore, we should focus on finding 
an algorithm to predict LVO early, so that emergency medical services can present these 
patients directly to the intervention center.22,23 Implementing such a triage protocol has 
already shown to be feasible and seems to improve treatment times.24 One ongoing 
randomized trial in Catalonia, Spain, is evaluating the effect of the mothership vs. the drip-
and-ship strategy on functional outcome, among patients with a high likelihood of having 
a LVO identified with the Rapid Arterial Occlusion Evaluation (RACE) scale (Direct Transfer 
to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute 
Stroke Patients With Suspected Large Vessel Occlusion (RACECAT), URL: www.clinicaltrials.
gov. Unique identifier: NCT02795962). While this trial will provide class I evidence on whether 
a mothership model improves functional outcome, it will be challenging to translate its 
results to regions with other geographical and demographical conditions. Modeling studies 
showed that differences in transportation times and treatment times affect the optimal 
transportation strategy and that triage protocols should therefore be based on regional 
characteristics and individual likelihood of LVO.25-28 
There were a number of baseline imbalances between the two groups. First, transferred 
patients more often received IVT. One of the reasons that could explain this observation is 
that patients who passed the time window for IVT are probably more often directly 
transported to an intervention center. Second, transferred patients more often had proximal 
occlusions (ie, ICA, ICA-T, and proximal M1) when compared to directly admitted patients. 
It could be that physicians hesitate to transport a patient with a more distal occlusion 
towards the intervention center, as earlier studies showed that these occlusions generally 
respond well to IVT.29 Another observation that might be explained by a selection mechanism 
in the intervention center is that transferred patients less often had prestroke disability. 
This suggests that patients with favorable characteristics are more likely to be transferred 
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to an intervention center. However, imaging characteristics, assessed at the hospital of first 
presentation, were slightly less favorable for transferred patients. After adjustment for these 
baseline imbalances, we still found an 8.5% decrease in the chance of achieving functional 
independence after inter-hospital transfer.
Strengths of our study include that the analyses were performed with data from one of the 
largest cohorts of consecutive patients treated with EVT, with individual patient data from 
all stroke intervention centers in the Netherlands. It strongly reflects daily clinical practice, 
including a relatively large number of transferred patients. A number of limitations also 
warrant comment. Despite the fact that the MR CLEAN Registry is a nationwide study with 
consecutive inclusion of patients, our study is not completely free from a risk of selection 
bias. Patients with an LVO who did not receive EVT, for example due to clinical improvement 
on arrival, were not included in the study. Some patients who were initially admitted to a 
primary stroke center may not have been transferred to an intervention center because the 
time window would have been passed by the moment they would arrive in the intervention 
center or because there was uncertainty about treatment eligibility in case of an M2 
occlusion. These patients could have been treated if they had been transported directly to 
the intervention center. Since the MR CLEAN Registry only contains data of patients who 
actually received EVT, we cannot estimate the size and impact of this patient population. 
The negative effect of a drip-and-ship strategy might therefore be larger in real life. Another 
limitation of our study is that we had no recorded door in door out times available to 
distinguish between in-hospital delay in the primary stroke center and delay due to the 
actual travel time between the primary stroke center and intervention center. We estimated 
the average inter-hospital travel times using the TomTom MyDrive application and then 
calculated the estimated door in door out times. Also, we used multiple imputation for time 
from first presentation to groin puncture, since time of arrival in the first hospital was 
missing for 13% of the patients. The difference between transferred patients and directly 
admitted patients in time from first presentation to groin puncture was comparable with 
the difference in time from onset to groin puncture, a variable that was available for all 
patients. We therefore believe that it has little impact on the validity of our results.  Last, 
even though we adjusted for differences in prognostic factors, residual confounding might 
still influence our results.
Conclusions
In conclusion, these results from a large national cohort show that inter-hospital transfer 
of ischemic stroke patients eligible for EVT is associated with longer treatment times and 
worse functional outcome in clinical practice, even in a country where between-center 
distances are short. Direct transportation of EVT candidates to an intervention center might 
reduce treatment delay and thereby may improve functional outcome. 
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In Response:
We read with interest the letter by Drs Seners and Baron regarding our recent publication 
about the effect of inter-hospital transfer on time to treatment and functional outcome of 
stroke patients undergoing endovascular treatment (EVT) in the MR CLEAN Registry.1 
We agree that our results apply only to those patients with a large vessel occlusion (LVO) 
who effectively received groin puncture in an intervention center. As we stated in our 
discussion, the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment 
for Acute Ischemic Stroke) Registry does not contain data of patients with an LVO who did 
not undergo EVT. Due to this limitation, it is impossible to fully estimate the effect of first 
presentation in a primary stroke center versus direct transportation to an intervention 
center for the total LVO stroke population. A subset of the patients presenting in a primary 
stroke center with an LVO might not receive EVT due to clinical improvement on arrival at 
the intervention center. Assuming that the thrombus has resolved due to prior IV treatment 
with alteplase, these patients are indeed likely to have a more favorable outcome, and 
excluding them will lead to an underestimation of good functional outcome in the total 
transfer population. Direct transportation to an intervention center could have a negative 
effect on functional outcome of these patients because it delays IV treatment. On the other 
hand, there might also be patients in the transfer group that did not receive EVT because 
the remaining time window did not allow for transportation to the intervention center or 
because there was uncertainty about treatment eligibility (eg, in case of an M2 occlusion). 
These patients could potentially have been treated with EVT if they had been transported 
directly to an intervention center. Excluding these patients will, therefore, lead to an 
overestimation of good functional outcome in the transfer population. In other words, due 
to the limitations inherent to our study population, our results could both overestimate and 
underestimate the true difference in clinical outcome of patients between the drip-and-ship 
and mothership models.
Drs Seners and Baron refer to a study of Gerschenfeld et al, 2 in which all patients that were 
transferred for EVT - including those who eventually did not receive EVT - were included. 
However, patients who received only IV alteplase and were not transferred to an intervention 
center, were not included in the analysis. The reasons for withholding EVT in these 144 
patients in the drip-and-ship paradigm and 122 patients in the mothership paradigm are 
not clearly described. Also, due to the small sample size, this study was likely underpowered 
to detect a difference in clinical outcome in the first place. 
In conclusion, our results suggest that, if treated with EVT, patients directly transported to 
an intervention center have a shorter time to treatment and better functional outcome 
compared to patients transferred from a primary stroke center. Caution is warranted when 
generalizing these results to the total LVO stroke population and, similar to our colleagues, 
we look forward to the results of ongoing randomized trials that directly compare the drip-
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and-ship versus mothership approach. Still, even the results of these trials cannot be directly 
translated to regions with other geographical and organizational characteristics, and 
modeling studies will therefore be required.3
This letter was written in response to:
Seners P, Baron JC. Letter by Seners and Baron Regarding Article, “Effect of Interhospital 
Transfer on Endovascular Treatment for Acute Ischemic Stroke”. Stroke 2019; 50(9) :e259.
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Abstract
Background and purpose
Rapid initiation of endovascular stroke treatment is associated with better clinical outcome. 
The effect of specific improvements is not well known. We performed a systematic review 
and meta-analysis on the effectiveness of specific workflow improvements on time to 
treatment and outcome.
Methods
A random effects meta-analysis was used to evaluate the difference in mean time to 
treatment between intervention group and control group. Secondary outcomes included 
good functional outcome at 90 days (modified Rankin Scale score 0–2).
Results
Fifty-one studies (3 randomized controlled trials, 13 pre-post intervention studies, and 35 
observational studies) with in total 8,467 patients were included. Most frequently reported 
workflow intervention types concerned anesthetic management (n=26), in-hospital patient 
transfer management (n=14), and prehospital management (n=11). Patients in the 
intervention group had shorter time to treatment intervals (weighted mean difference 26 
minutes; 95% CI 19 to 33; P<0.001) compared with controls. Subgroup meta-analysis of 
intervention types also showed a shorter time to treatment in the intervention group: a 
mean difference of 12 minutes (95% CI 6 to 17; P<0.001) for anesthetic management, 37 
minutes (95% CI 22 to 52; P<0.001) for prehospital management, 41 minutes (95% CI 27 to 
54; P<0.001) for in-hospital patient transfer management, 47 minutes (95% CI 28 to 67; 
P<0.001) for teamwork, and 64 minutes (95% CI 24 to 104; P=0.002) for feedback. The mean 
difference in time to treatment of studies with multiple interventions implemented 
simultaneously was 50 minutes (95% CI 31 to 69; P<0.001) in favor of the intervention group. 
Patients in the intervention group had increased likelihood of favorable outcome (risk ratio 
1.39; 95% CI 1.15 to 1.66; P<0.001).
Conclusions
Interventions in the workflow of endovascular stroke treatment lead to a significant 
reduction in time to treatment and results in an increased likelihood of favorable outcome. 
Acute stroke care should be reorganized by making use of the examples of workflow 
interventions described in this review to ensure the best medical care for stroke patients.
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Introduction 
Multiple trials have shown the benefit of endovascular recanalization therapy in selected 
stroke patients.1-3 Earlier treatment is associated with better functional outcome.4 The time 
from symptom onset to treatment is influenced by prehospital and in-hospital processes. 
Healthcare systems are being reorganized to offer stroke patients rapid and effective 
medical care. Stroke services had already changed their workflow since treatment with 
intravenous alteplase for selected stroke patients was proven effective.5 Implementation 
of new strategies to improve the workflow process for treatment with intravenous alteplase 
has led to a significant reduction of in-hospital delay.6 
Providing an optimal diagnostic process and rapid endovascular stroke treatment requires 
close collaboration of the emergency medical service, emergency department team, stroke 
team, neurointerventional team, and anesthesia team. Diagnostic imaging and endovascular 
treatment facilities should be available in very little time. Several strategies to reduce the 
time to endovascular stroke treatment have been proposed.7-9 However, the effect of 
individual and combined strategies on reducing time to treatment is unclear. We performed 
a systematic review and meta-analysis on the effectiveness of specific workflow improvement 
interventions for rapid delivery of endovascular stroke treatment.
Methods 
This systematic review and meta-analysis was performed according to the Preferred 
Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.10 All data and 
supporting materials are available within the article and its Supplementary material. 
Search strategy
Medline, EMBASE, Cochrane Central, and Web of Science were searched for studies that 
evaluated the effect of one or more workflow interventions on time to endovascular stroke 
treatment, from database inception to November 14th, 2017. Google Scholar and Google 
were searched at November 14th, 2017, and the first 200 hits were included. We developed 
a broad search strategy consisting of a combination of the 2 main topics of this study: 
endovascular stroke treatment and workflow intervention. The complete search strategy is 
available in the Supplementary material. We restricted our search to studies published in 
English and excluded conference abstracts. 
Eligibility criteria
Studies were included if ≥1 (prehospital or in-hospital) interventions in the workflow of 
endovascular stroke treatment were assessed and effect on time to treatment intervals was 
reported. Endovascular stroke treatment was defined as mechanical thrombectomy or 
intra-arterial fibrinolysis in an acute stroke patient with an intracranial large vessel occlusion. 
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Interventions only aimed at the duration of the endovascular treatment itself, for example 
type of mechanical thrombectomy device used, were excluded. Interventions intended only 
to increase the accuracy of patient selection, for example the introduction of a new imaging 
protocol, were also excluded. Studies were included in the systematic review when time to 
endovascular treatment was reported, from symptom onset to start treatment, or any time 
window between symptom onset and start treatment. Randomized and non-randomized 
controlled trials and pre-post intervention studies were included. Observational studies, or 
post-hoc analyses of observational data in trials were only included when a control group 
was reported. Reviews, editorials, and guidelines were excluded. Two authors (Drs Janssen 
and Venema) independently assessed the eligibility of all retrieved studies. Title and abstracts 
were first screened to identify potentially eligible articles, and then full texts were read to 
confirm inclusion. Reference lists of identified eligible papers and review papers were 
scanned for additional relevant studies.
Risk of bias assessment
The risk of bias of each included study was assessed against the following key criteria: 
random sequence generation; allocation concealment; blinding of participants, personnel 
and outcomes; incomplete outcome data; and selective outcome reporting; in accordance 
with the methods recommended by the Cochrane Library.11 The following judgements were 
used: low risk, high risk, or unclear risk of bias (either lack of information or uncertainty on 
the potential for bias). Summary of risk of bias per key criterion was provided for all included 
articles separately. 
Data extraction and outcome variables
Data was extracted from published reports by 2 authors (Drs Janssen and Venema). Workflow 
interventions were described and divided into six predefined categories: (A) anesthetic 
management, (B) prehospital management, (C) in-hospital patient transfer management, 
(D) teamwork, (E) feedback, and (F) other workflow interventions. Other collected data on 
study characteristics included study design, study period, stroke type (anterior or posterior 
circulation stroke, or both), and sample size.
The primary outcome measure in this study was the difference in time to treatment between 
the intervention group and control group. Other study outcomes were good functional 
outcome, defined as modified Rankin Scale (mRS) score 0–2 at 90 days after endovascular 
treatment, symptomatic intracranial hemorrhage, and mortality. 
Statistical analysis
Mean time to treatment with standard deviation (SD) for the intervention group and control 
group was retrieved from each included study. When mean values with SD were not available 
in the publication nor obtained from the authors of the original publication, we used 
reported median time to treatment with interquartile range (IQR) to estimate the sample 
mean and SD using the method described by Wan et al.12 The absolute difference of mean 
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time to treatment with 95% confidence intervals (CI) was calculated for each study using a 
two-sample t-test. 
Studies were included in the meta-analysis when mean time to treatment with SD or median 
time to treatment with IQR was available for both groups. Weighted difference in mean time 
to treatment with 95% CI was calculated using a random-effects inverse variance model, 
with the estimate of heterogeneity being taken from the Mantel-Haenszel model. Subgroup 
analysis of the difference in mean time to treatment was performed for the predefined 
workflow intervention categories A to E and for studies implementing multiple interventions 
simultaneously.
Data on binary outcomes (good functional outcome, symptomatic intracranial hemorrhage, 
and mortality) was pooled using random-effect meta-analysis and expressed as risk ratios. 
Publication bias was assessed by constructing a funnel plot. All statistical analyses were 
conducted with Stata, version 15 (Statacorp LLC, College Station, TX).
Results
Our literature search identified 4,127 potentially relevant unique articles; 211 articles were 
retained for full-text review (Figure 8.1). A total of 51 studies met the inclusion criteria and 
were included in the qualitative synthesis.2,13-62 We contacted authors from 31 of 51 studies 
with requests for additional data necessary for our meta-analysis. These additional data 
were provided for 17 of 31 studies. The sample mean difference in time to treatment with 
SD could be estimated from published data from 8 of 31 studies. After exclusion of the 
remaining 6 studies because of lack of sufficient data, a total of 45 studies was included in 
the meta-analysis on effect of workflow interventions on the time to treatment.
Fifty-one studies with 8,467 patients (4,037 intervention group and 4,430 control group) 
reported the effect of 25 different workflow interventions on the time to endovascular 
treatment (Table 8.1 and 8.2). Two studies reported the effect on time to treatment of two 
interventions separately.50,55 Most frequently reported workflow intervention types concerned 
anesthetic management (n=26), in-hospital patient transfer management (n=14), and 
prehospital management (n=11). Ten studies reported the effect on time to treatment of 
multiple interventions implemented simultaneously. Time to treatment was shorter in the 
intervention group in 48 of 53 interventions (91%) reported in the 51 included studies. Included 
studies differed in study design, with 3 studies randomizing patients for the workflow 
intervention of interest in our study, 13 pre-post intervention studies, and the remaining 35 
studies reporting observational data mostly from hospital stroke registries or randomized 
controlled trials investigating the effect of endovascular stroke treatment versus conservative 
treatment. Data collection was performed retrospectively in 34 studies, and 16 studies collected 
data from ≥1 center. Risk of bias assessment is reported in Supplementary Table 8.1. 
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Random effects meta-analysis of 45 studies (with 47 interventions), including 7,482 patients 
(3,480 intervention group and 4,002 control group) showed a difference in mean time to 
treatment of 26 minutes (95% CI 19 to 32; P<0.001) in favor of the intervention group (Figure 
8.2). I2 value was 85.4%, and Chi-squared value was 314.87 (degrees of freedom 46; P<0.001), 
indicating considerable heterogeneity between studies.
Records identified through 
database searching  
(n = 6,591)
Sc
re
en
in
g
In
cl
ud
ed
 
El
ig
ib
ili
ty
 
Id
en
tif
ic
at
io
n Additional records identified 
through other sources  
(n = 17)
Records after duplicates removed  
(n = 4,127) 
Title and abstracts 
screened  
Records excluded  
(n = 3,916) 
Full-text articles 
assessed for eligibility 
(n = 211)
Full-text articles 
excluded, with reasons 
(n = 160) 
• Reviews/not original 
research (122) 
• Not including 
endovascular stroke 
treatment (5) 
• Workflow intervention 
not described (14) 
• Effect on time to 
treatment not 
described (7) 
• Observational study 
without control group 
(8) 
• Study protocol (2) 
• Case report (1) 
• Duplicate cohort (1)
Studies included in 
qualitative synthesis  
(n = 51)
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 44) 
Figure 8.1. Flowchart of included and excluded articles, following the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines.
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Table 8.1. Studies included in systematic review.
Author Country Study Design Study 
Period*
Anterior, 
posterior  
circulation 
stroke or 
both In
te
rv
en
ti
on
 
gr
ou
p 
(n
)
Co
nt
ro
l 
gr
ou
p 
(n
)
Ty
pe
 o
f 
in
te
rv
en
ti
on
Abou-Chebl  
et al13
USA Retrospective cohort 
study; multicenter
2005–2009 Anterior 552 428 A
Abou-Chebl  
et al14
USA Post hoc analysis 
retrospective NASA 
Registry; multicenter
2012–2013 Both 68 159 A
Abou-Chebl   
et al15
Canada, 
Europe, USA
Post hoc analysis IMS III 
trial; multicenter
2006–2012 Both 269 147 A
Aghaebrahim  
et al16
USA Prospective pre-post 
study; single center
2012–2013/
2013–2014
Both 108 178 B1, 
C1–3, 
D1–2, 
E1, F1
Alotaibi et al17 Canada Retrospective pre-post 
study; single center
2011–2014/
2014–2016
Both 28 17 E2
Van den Berg  
et al18
The 
Netherlands
Retrospective cohort 
study; multicenter
2002–2010 Anterior 278 70 A
Berkhemer  
et al19
The 
Netherlands
Post-hoc analysis MR 
CLEAN trial; multicenter
2010–2014 Anterior 137 79 A
Bracard  
et al2
France Post-hoc analysis 
THRACE trial; 
multicenter
2010–2014 Both 74 69 A
Cerejo  
et al20
USA Retrospective cohort 
study; single center
2014 Anterior 5 5 B2
Davis  
et al21
Canada Retrospective cohort 
study; single center
2003–2009 Both 37 39 A
Eesa  
et al22
Canada Retrospective cohort 
study; single center
2005–2009 Both 71 30 A
Frei  
et al23
USA Retrospective pre-post 
study; single center
2012–2013/
2013–2015
Both 267 113 B1, 
D2–4, 
F1–3
Goyal  
et al24
Canada, 
Europe, USA
Post-hoc analysis IMS III 
trial; multicenter
2006–2012 Both 17 64 B3
Goyal  
et al25
Europe, USA Post-hoc analysis SWIFT 
PRIME trial; multicenter
2012–2014 Anterior 61 35 A
Hassan  
et al26
USA Retrospective cohort 
study; multicenter
2006–2010 Both 83 53 A
Henden  
et al27
Sweden Randomized controlled 
trial; single center
2013–2016 Anterior 45 45 A
Herrmann  
et al28
Germany Pre-post study; 
retrospective data 
pre-intervention, 
prospective data 
post-intervention; 
single center
2006–2009/
2009–2010
Both 23 48 F4
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Author Country Study Design Study 
Period*
Anterior, 
posterior  
circulation 
stroke or 
both In
te
rv
en
ti
on
 
gr
ou
p 
(n
)
Co
nt
ro
l 
gr
ou
p 
(n
)
Ty
pe
 o
f 
in
te
rv
en
ti
on
Jadhav  
et al29
USA Retrospective cohort 
study; single center
2013–2016 Both 111 150 C2
Jagani  
et al30
USA Retrospective cohort 
study; single center
2008–2015 Both 61 38 A
Janssen  
et al31
Germany Retrospective cohort 
study; single center
2012–2014 Anterior 31 53 A
Jeon  
et al32
Korea Retrospective pre-post 
study; single center
2014–2016/
2016
Not 
specified
19 93 B1, C3, 
D2, E1, 
F1–2
John  
et al33
USA Retrospective cohort 
study; single center
2008–2012 Anterior 99 91 A
Jumaa  
et al34
USA Retrospective cohort 
study; single center
2006–2009 Anterior 73 53 A
Just  
et al35
Canada Retrospective cohort 
study; single center
2000–2013 Both 67 42 A
Kamper  
et al36
Germany Retrospective pre-post 
study; single center
2002–2006/
2007–2010
Posterior 20 18 F5
Koge  
et al37
Japan Retrospective pre-post 
study; single center
2008–2014/
2014–2016
Not 
specified
23 19 D3–4, 
E1
Komatsubara  
et al38
Japan Pre-post study; 
retrospective or 
prospective data 
collection not specified; 
single center
2012–2014/
2014–2015
Both 14 14 E1, F1, 
F6
Li  
et al39
USA Retrospective cohort 
study; single center
2006–2012 Both 74 35 A
Liang  
et al40
USA Retrospective cohort 
study; single center
2015–2016 Not 
specified
22 17 B4
Mascitelli  
et al41
USA Retrospective pre-post 
study; single center
2014/
2014–2015
Both 29 27 B1, 
E1–2, 
F1
McTaggart  
et al42
USA Retrospective cohort 
study; multicenter
2015–2016 Anterior 22 48 B4–5, 
C2, D2
Mehta  
et al43
USA Pre-post study; 
retrospective data 
pre-intervention, 
prospective data 
post-intervention; 
single center
2007–2011/
2011–2013
Anterior 51 93 C3, 
D2–4
Menon  
et al44
Canada, 
Ireland, 
South 
Korea, UK, 
USA
Prespecified secondary 
analysis ESCAPE trial; 
multicenter
2013–2014 Anterior 136 15 A
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Author Country Study Design Study 
Period*
Anterior, 
posterior  
circulation 
stroke or 
both In
te
rv
en
ti
on
 
gr
ou
p 
(n
)
Co
nt
ro
l 
gr
ou
p 
(n
)
Ty
pe
 o
f 
in
te
rv
en
ti
on
Miley  
et al45
USA Retrospective cohort 
study; multicenter
2005–2008 Both 52 39 A
Mundiyanapurath 
et al46
Germany Prospective cohort 
study; single center
2013–2014 Both 15 29 A
Nichols  
et al47
USA Post-hoc analysis IMS II 
trial; multicenter
2003–2006 Anterior 40 17 A
Pedragosa  
et al48
Spain Prospective cohort 
study; multicenter
2008–2010 Not 
specified
25 20 B6
Pfaff  
et al49
Germany Prospective cohort 
study with historical 
controls; single center
2014 Both 3 16 C4
Pfaff  
et al50
Germany Prospective cohort 
study with historical 
controls; single center
2014–2016 Anterior 22 28 A
Pfaff  
et al50
Germany Prospective cohort 
study with historical 
controls; single center
2014–2016 Anterior 28 28 C4
Psychogios  
et al51
Germany Retrospective cohort 
study; single center
2016 Not 
specified
30 44 C4
Qureshi  
et al52
USA Retrospective cohort 
study; multicenter
2007–2012 Not 
specified
66 117 C3
Ragoschke  
et al53
Germany Pre-post study; 
retrospective data 
pre-intervention, 
prospective data 
post-intervention; 
single center
2006–2010/
2010–2014
Both 174 81 C5
Rai  
et al54
USA Prospective pre-post 
study; single center
2011–2014/
2015
Both 30 64 B1, 
D2–4, 
F2
Ribo  
et al55
Spain Retrospective cohort 
study; single center
2015–2016 Not 
specified
74 87 C1
Ribo  
et al55
Spain Retrospective cohort 
study; single center
2015–2016 Not 
specified
40 87 C2
Schonenberger 
et al56
Germany Randomized controlled 
trial; single center
2014–2016 Anterior 77 73 A
Schregel  
et al57
Germany Retrospective pre-post 
study; single center
2008–2014/
2014–2015
Both 90 278 C3, D2, 
E1
Simonsen  
et al58
Denmark Randomized controlled 
trial, single center
2015–2017 Anterior 63 65 A
Singer  
et al59
Austria, 
Germany
Post-hoc analysis 
ENDOSTROKE registry; 
both retrospective and 
prospective data 
collection; multicenter
2011–2012 Both 36 691 A
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The mean time to treatment was shorter in the intervention group compared to controls 
in the predefined workflow intervention categories (Table 6.3). The weighted difference in 
mean time to treatment was 12 minutes (95% CI 6 to 17; P<0.001) for anesthetic management, 
37 minutes (95% CI 22 to 52; P<0.001) for prehospital management, 41 minutes (95% CI 27 
to 54; P<0.001) for in-hospital patient transfer management, 47 minutes (95% CI 28 to 67; 
P<0.001) for teamwork, and 64 minutes (95% CI 24 to 104; P=0.002) for feedback. The 
weighted difference in mean time to treatment of studies with multiple interventions 
implemented simultaneously was 50 minutes (95% CI 31 to 69; P<0.001) in favor of the 
intervention group. Forest plots of the difference in mean time to treatment for each type 
of workflow intervention are showed in Supplementary Figure 8.1. The description of used 
time intervals in the studies, mean (SD) estimates for each study group, and a subgroup 
analysis per time interval is provided in Supplementary Table 8.2.
Twenty studies reported the occurrence of favorable outcome, defined as score 0–2 on the 
modified Rankin Scale at 90 days (Supplementary Table 8.3). Meta-analysis showed that 
patients in the intervention group had a higher likelihood of favorable outcome (absolute risk 
difference 12.2%; risk ratio (RR) 1.39; 95% CI 1.15 to 1.66; P<0.001) in comparison with controls. 
Data from 21 studies reporting the prevalence of symptomatic intracranial hemorrhage 
showed no difference between patients in the intervention groups and controls (RR 0.88; 95% 
CI 0.71 to 1.09; P=0.239). Mortality was assessed in 25 studies. Twelve studies reported in-
hospital mortality, 2 studies reported mortality at 30 days, and 11 studies reported mortality 
at 3 months. Patients in the intervention groups had a lower risk of overall mortality (absolute 
risk difference 7.4%; RR 0.74; 95% CI 0.63 to 0.87; P<0.001) compared with controls. 
Author Country Study Design Study 
Period*
Anterior, 
posterior  
circulation 
stroke or 
both In
te
rv
en
ti
on
 
gr
ou
p 
(n
)
Co
nt
ro
l 
gr
ou
p 
(n
)
Ty
pe
 o
f 
in
te
rv
en
ti
on
Slezak  
et al60
Switzerland Prospective cohort 
study; single center
2010–2015 Anterior 135 266 A
Sugg  
et al61
USA Retrospective cohort 
study; single center
2007–2009 Both 57 9 A
Tsujimoto  
et al62
Japan Retrospective cohort 
study; single center
2011–2013 Both 6 16 B7
ENDOSTROKE, Endovascular Stroke Treatment; ESCAPE, Endovascular Treatment for Small Core and Anterior 
circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times; IMS, Interventional 
Management of Stroke; MR CLEAN, Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute 
Ischemic Stroke in The Netherlands; NASA, North American Solitaire Stent-Retriever Acute Stroke; SWIFT PRIME, 
Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke; 
THRACE, Thrombectomie des Artères Cerebrales.
*Study period for pre/post intervention group.
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We found no evidence of a potential publication bias in the funnel plot that was constructed 
after exclusion of two studies with a very large absolute difference in time to treatment 
between intervention group and controls (Figure 8.3).34,36
Table 8.2. Categories of workflow interventions in endovascular stroke treatment.
Anesthetic Management
A = Non-general anesthesia versus general anesthesia
Prehospital Management*
B1 = Pre-notification ED team, CT technologist, and stroke team by EMS
B2 = Mobile Stroke Treatment Unit with CT scanner, point of care laboratory testing, vascular neurologist 
available via telemedicine
B3 = ‘Ship and drip’ for transfer patients versus ‘drip and ship’
B4 = CT-angiography at primary stroke center versus at intervention center
B5 = Cloud based image sharing between primary stroke center and intervention center
B6 = Use of telemedicine assessment by a stroke neurologist at primary stroke center
B7 = Air transfer versus ground transfer
In-hospital Patient Transfer
C1 = Transporting patients directly to CT scanner by EMS
C2 = Transporting (transfer) patients directly to angiosuite by EMS
C3 = ‘No turn around’ approach (not returning to ED after imaging for decision-making)
C4 = Single room used for CT, angiography, and EVT
C5 = Single room for patient evaluation, CT, angiography, and EVT
Teamwork
D1 = Early communication between ED team and stroke team regarding plan of care
D2 = Early activation neurointerventional team
D3 = Parallel processing from ED/hospital ward to CT: clinical assessment, laboratory tests, imaging, 
patient/family education by the teams in a parallel workflow 
D4 = Parallel processing from CT to angiosuite: neurointerventional team meets patient at CT, teams 
evaluate CT/CTA and make treatment decision while angiosuite is set up, patient/family education
Feedback
E1 = Education and feedback all teams
E2 = Smartphone application/digital system for real-time window from stroke onset to puncture for all 
teams, visualizing performance metrics
Other
F1 = Limiting non-essential interventions (e.g. ECG, chest X-ray, additional venous access, bladder catheter 
placement)
F2 = Standard angiography set for all of the devices needed for EVT
F3 = No groin shaving
F4 = Standard operating procedure for intubation at the intensive care unit prior to EVT
F5 = Standard operating procedure for EVT
F6 = Not waiting for effect intravenous alteplase versus waiting for 1 hour
CT, computed tomography; CTA, computed tomography angiography; ECG, electrocardiogram; ED, emergency 
department; EMS, emergency medical service; EVT, endovascular treatment.  
*Prehospital management includes all interventions performed before the patient arrives at the intervention 
center.
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Overall (I-squared = 85.4%)
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Singer 2013
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Ribo 2017-1
Rai 2016
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 Figure 8.2. Forest plot of weighted difference in mean time to treatment for workflow interventions in 
endovascular stroke treatment, using random effect meta-analysis.
Effect of workflow improvements
149
8
0
20
40
60
S
ta
nd
ar
d 
E
rr
or
 o
f A
bs
ol
ut
e 
M
ea
n 
D
iff
er
en
ce
-100 -50 0 50 100 150
Absolute Mean Difference in Time to Treatment (min)
Funnel plot with pseudo 95% confidence limits
Figure 8.3. Funnel plot to detect potential publication bias in 43 studies of workflow interventions 
improvements in endovascular stroke treatment.
Table 8.3. Random-effects meta-analysis of difference in mean time to treatment for categories of workflow 
interventions in endovascular stroke treatment.
Number of 
studies 
Number of patients 
(intervention/control group)
Weighted mean difference, 
minutes (95% CI)
All interventions 47 3,480/4,002 26 (19 to 32)
P<0.001
Anesthetic management 23 2,283/2,445 12 (6 to 17)
P<0.001
Prehospital management 10 442/463 37 (22 to 52)
P<0.001
In-hospital patient 
transfer management
13 730/1150 41 (27 to 54)
P<0.001
Teamwork 7 502/708 47 (228 to 67)
P<0.001
Feedback 4 161/417 64 (24 to 104)
P=0.002
Multiple interventions 
simultaneously
8 531/735 50 (31 to 69)
P<0.001
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Discussion
Our systematic review and meta-analysis showed that interventions in the workflow of 
endovascular treatment for acute ischemic stroke led to a significant reduction in time to 
treatment. This applied to all categories of studied interventions, which were interventions 
aimed at using local anesthesia or conscious sedation, optimizing prehospital management, 
reducing in-hospital patient transfer, improving teamwork, and supplying feedback on 
achieved time intervals to the team. These workflow interventions led to higher likelihood 
of favorable functional outcome after 3 months.
The favorable effect of workflow interventions on the time to treatment are consistent with 
previous studies including acute stroke patients treated with intravenous alteplase. 
Implementation of a national quality improvement initiative organized by the American 
Heart Association/American Stroke Association, including more than 70,000 patients, 
resulted in significant shorter door-to-needle time and significant higher percentage of 
patients treated with intravenous alteplase within 60 minutes.63 Workflow improvement 
strategies were promoting pre-notification of hospitals by EMS, rapid activation of the entire 
stroke team, rapid acquisition of brain imaging, and provision of feedback to the stroke 
team on performance. A single center study showed that the introduction of multiple 
concurrent strategies aimed at reducing in-hospital delay in treatment of acute stroke 
patients with intravenous alteplase led to a remarkable time reduction and final median 
door-to-needle time of 20 minutes.6 
Our results are also consistent with studies on workflow improvement for reperfusion 
treatment of patients with myocardial infarction with ST-segment elevation. A study on 
time-saving strategies in the workflow for patients with acute myocardial infarction, including 
365 hospitals, showed that rapid activation and availability of the entire team and use of 
real-time data feedback by the staff in the ED and angiography suite, reduced mean door-
to-balloon time with 8 to 19 minutes.64
The workflow interventions in this review can easily be implemented in any intervention 
center. A time-saving effect of >1 hour could be achieved by providing feedback on time-
intervals to the entire team. Implementation of regular feedback in the four included studies 
in this meta-analysis was executed by supplying time intervals and outcome to the entire 
team daily using an online bulletin or email, reviewing each patient during weekly or monthly 
meetings, or comparing actually achieved times to target times every 3 months.32,37,41,57 
Evaluation of time intervals can simply be added to existing regularly meetings at intervention 
hospitals. Optimizing in-hospital teamwork by using parallel processing instead of sequential 
processing in the workflow, and by early activation of all team members, requires 
multidisciplinary protocols or standard operating procedures. The time-investment to draft 
and implement such protocols seems well worthwhile, since our meta-analysis showed a 
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mean time reduction of 47 minutes.22,32,37,42,43,54,57 Effects of multiple interventions cannot be 
simply added, but implementing multiple interventions at the same time still led to a very 
large time reduction of 50 minutes and is probably preferred above implementing 1 
intervention at a time.
Anesthetic management in endovascular stroke treatment is a much discussed topic, since 
it possibly influences both time to treatment intervals as cerebral perfusion and thereby 
indirect functional outcome. A meta-analysis including 4,716 patients undergoing 
endovascular stroke treatment showed a difference in time to treatment of 14 minutes in 
favor of patients receiving local anesthesia or conscious sedation compared with general 
anesthesia, and a higher odds of good functional outcome.65 Which studies were used for 
comparing  time to treatment  by type of anesthesia management and the way missing data 
was handled was not disclosed. Our meta-analysis included additional studies on anesthetic 
management and showed a comparable difference in time to treatment of 12 minutes in 
favor of patients receiving local anesthesia or conscious sedation. Both meta-analyses 
included many observational studies with possible selection bias. Only 3 randomized 
controlled trials, randomizing patients for local anesthesia or conscious sedation versus 
general anesthesia, were included in our meta-analysis, showing a non-significant difference 
in treatment intervals in two studies,27,58 and a significant difference in time to treatment in 
1 study of 10 minutes in favor of conscious sedation (95% CI 2 to 18).56 We did not find studies 
comparing conscious sedation with local anesthesia. Regarding anesthetic management in 
endovascular stroke treatment and its effect on time to treatment, results of included 
randomized and non-randomized studies in our analysis varied between a significant 
positive effect or a significant negative effect of local anesthesia or conscious sedation, and 
a non-significant difference compared with general anesthesia. By combining these results 
in a meta-analysis, we showed a potential positive effect of non-general anesthesia on 
workflow.
The favorable effect of reducing time to treatment on functional outcome as described in 
previous studies is confirmed by our study.4,66 Analysis of 5 endovascular stroke treatment 
trials showed a 4% absolute risk difference for a good functional outcome per hour of delay 
between symptom onset and reperfusion.4 Our meta-analysis showed a difference in time 
to treatment effect of 26 minutes, with a total absolute risk difference of good functional 
outcome of 12%, which is higher compared to the ~2% absolute risk difference per half hour 
as seen in the meta-analysis of 5 endovascular stroke treatment trials. However, selection 
bias could have occurred in the non-randomized studies included in our meta-analysis and 
differences in baseline characteristics might have influenced our results. The effect of time 
to treatment on functional outcome might be stronger in clinical practice compared to a 
selected patient population from randomized controlled trials.67 Furthermore, some 
workflow improvements, such as anesthetic management, have an effect on functional 
outcome which is not completely explained by the difference in time to treatment.1
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A meta-analysis of 5 large endovascular stroke trials showed no effect of time to treatment 
on rates of mortality and symptomatic intracranial hemorrhage.4 Our study showed no 
difference in rate of symptomatic intracranial hemorrhage, but a significantly lower mortality 
among patients in the intervention group. However, possible selection bias in the non-
randomized studies included in our meta-analysis, could have influenced the effect of time 
to treatment on mortality.
This study has several limitations. To perform the meta-analysis, we estimated the mean 
time to treatment for 8 studies using the median time to treatment, IQR, and sample size. 
Since the meta-analysis is aimed at the difference in time to treatment between groups, 
rather than the actual time intervals per group, we assume that using the estimation of the 
mean time to treatment has no significant effect on the primary outcome. Considerable 
heterogeneity between included studies was observed. Therefore, we used a random-effects 
inverse variance model for our meta-analysis and categorized the interventions to perform 
separate analyses for each intervention type. Forty-eight of 51 included studies used a non-
randomizing study design, with a high risk of selection bias. Furthermore, most data was 
collected retrospectively in a single center, without blinding of personnel and participants, 
possibly leading to performance bias. Multiple pre-post intervention studies were included 
in our meta-analysis, in which learning effect over time can also effect time to treatment. 
Therefore, generalizability is difficult to assess for the individual studies. However, since we 
included multiple studies on the same subject, these results can give us valuable insight on 
the possible effects in general practice, which is very promising. One of the purposes of a 
systematic review is to identify gaps in our knowledge and point out clinical areas that would 
benefit from more research. The 7 subcategories of pre-hospital intervention with only a 
limited number of studies, suggest that more work can be done in this area. Intervention 
studies and modelling of pre-hospital workflow may provide more insights and effective 
pre-hospital management strategies may have a relatively large effect on outcome.
In conclusion, interventions in the workflow of endovascular stroke treatment lead to a 
significant reduction in time to treatment. Reduction of any delay in time to treatment, by 
workflow interventions aimed at any interval between symptom onset and treatment, leads 
to a higher chance of good functional outcome for each individual patient. Acute stroke care 
should be reorganized by making use of the examples of workflow interventions described 
in this review to ensure the best medical care for patients with acute ischemic stroke.
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Supplementary material
Literature search strategy
Embase
(‘cerebrovascular accident’/exp OR ‘brain ischemia’/exp OR ‘occlusive cerebrovascular 
disease’/de OR ‘middle cerebral artery occlusion’/de OR ‘basilar artery obstruction’/de OR 
‘stroke patient’/de OR ‘brain infarction’/exp OR ((cerebrovascular NEAR/3 accident*) OR cva 
OR stroke* OR ((brain OR cerebr* OR ‘basilar arter*’) NEAR/3 (ischemi* OR ischaemi* OR 
occlu* OR infarct*))):ab,ti) AND (‘thrombectomy’/exp OR ‘endovascular surgery’/de OR 
‘intraarterial drug administration’/de OR (thrombectom* OR endovascular* OR intravascul* 
OR endo-vascular* OR intra-vascul* OR intraarterial* OR intra-arterial*):ab,ti) AND 
(‘workflow’/de OR ‘therapy delay’/de OR ‘time to treatment’/de OR ‘time factor’/de OR 
(workflow* OR work-flow* OR pathway* OR ((therap* OR treat* OR puncture* OR 
reperfusion* OR admission OR care) NEAR/6 (delay* OR time-to OR door-to OR picture-to 
OR arrival* OR onset*)) OR ((Streamlin* OR speed OR rapid OR optimi*) NEAR/3 (treat* OR 
therap* OR recanal* OR reperfus* OR revascular*)) OR ((Intrahospital* OR Intra-hospital* 
OR prehospital* OR pre-hospital*) NEAR/3 (time OR period* OR delay*)) OR (time NEAR/3 
(factor* OR lapse )) OR timing):ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR 
[Note]/lim OR [Editorial]/lim) AND [english]/lim
Medline Ovid
(exp stroke/ OR exp Brain Ischemia/ OR (Cerebrovascular Disorders/ AND Arterial Occlusive 
Diseases/) OR ((cerebrovascular ADJ3 accident*) OR cva OR stroke* OR ((brain OR cerebr* 
OR basilar arter*) ADJ3 (ischemi* OR ischaemi* OR occlu* OR infarct*))).ab,ti.) AND 
(Thrombectomy/ OR Endovascular Procedures/ OR (thrombectom* OR endovascular* OR 
intravascul* OR endo-vascular* OR intra-vascul* OR intraarterial* OR intra-arterial*).ab,ti.) 
AND (workflow/ OR Time-to-Treatment/ OR time factors/ OR (workflow* OR work-flow* OR 
pathway* OR ((therap* OR treat* OR puncture* OR reperfusion* OR admission OR care) 
ADJ6 (delay* OR time-to OR door-to OR picture-to OR arrival* OR onset*)) OR ((Streamlin* 
OR speed OR rapid OR optimi*) ADJ3 (treat* OR therap* OR recanal* OR reperfus* OR 
revascular*)) OR ((Intrahospital* OR Intra-hospital* OR prehospital* OR pre-hospital*) ADJ3 
(time OR period* OR delay*)) OR (time ADJ3 (factor* OR lapse )) OR timing).ab,ti.) NOT (letter 
OR news OR comment OR editorial OR congresses OR abstracts).pt. AND english.la.
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Reference
Overall (I-squared = 20.6%)
Sugg 2010
Slezak 2017
Singer 2013
Simonsen 2018
Schonenberger 2016
Nichols 2010
Mundiyanapurath 2015
Miley 2011
Menon 2016
Li 2014
Jumaa 2010
John 2014
Janssen 2016
Jagani 2016
Henden 2017
Hassan 2012
Goyal 2016
Davis 2012
Bracard 2016
Berkhemer 2016
Berg van den 2015
Abou-Chebl 2014
Abou-Chebl 2010
min (95% CI)
Difference,
Weighted Mean
12 (6, 17)
20 (-26, 66)
22 (-7, 51)
-6 (-23, 12)
16 (-9, 41)
10 (2, 18)
5 (-28, 38)
28 (-32, 88)
1 (-25, 27)
16 (-2, 34)
24 (-30, 78)
-236 (-438, -34)
74 (-43, 191)
20 (11, 29)
26 (-25, 77)
9 (-32, 51)
23 (-95, 141)
5 (-14, 25)
21 (-27, 69)
-10 (-29, 10)
28 (10, 46)
38 (-0, 76)
1 (-25, 27)
10 (-9, 29)
Weight
%
100.00
1.44
3.31
7.17
4.19
16.61
2.64
0.88
3.90
7.16
1.04
0.08
0.22
15.29
1.18
1.69
0.22
6.35
1.33
6.32
6.79
1.97
3.88
6.34
Favours Control Favours Intervention
-200 -100 0 100 200
 
Reference
Overall (I-squared = 85.6%)
Tsujimoto 2015
Rai 2016
Pedragosa 2012
McTaggart 2017
Mascitelli 2016
Liang 2016
Jeon 2017
Goyal 2014
Frei 2017
Cerejo 2015
min (95% CI)
Difference,
Weighted Mean
37 (22, 52)
41 (28, 53)
58 (40, 76)
22 (-2, 46)
56 (35, 77)
77 (30, 124)
15 (5, 25)
109 (68, 151)
-3 (-30, 23)
16 (7, 24)
19 (-28, 66)
Weight
%
100.00
12.56
11.32
10.24
10.85
5.94
12.89
6.62
9.69
13.07
6.83
Favours Control Favours Intervention
-200 -100 0 100 200
 
A.  Anesthetic management
B.  Prehospital management
Supplementary Figure 8.1. Forest plots of weighted difference in mean time to treatment for specific 
intervention types, using random effect meta-analysis. 
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Reference
Overall (I-squared = 93.7%)
Schregel 2016
Ribo 2017-2
Ribo 2017-1
Ragoschke 2015
Quereshi 2014
Psychogios 2017
Pfaff 2017-2
Pfaff 2017-1
Pfaff 2016
Mehta 2013
McTaggart 2017
Jeon 2017
Jadhav 2017
min (95% CI)
Difference,
Weighted Mean
41 (27, 54)
69 (55, 83)
73 (61, 85)
30 (17, 43)
15 (4, 26)
22 (0, 44)
39 (29, 50)
24 (15, 33)
3 (-5, 11)
22 (9, 35)
36 (24, 48)
56 (35, 77)
109 (68, 151)
59 (47, 71)
Weight
%
100.00
7.87
8.09
7.96
8.13
7.03
8.17
8.30
8.37
8.02
8.06
7.19
4.78
8.02
Favours Control Favours Intervention
-200 -100 0 100 200
 
C.  In-hospital patient transfer management
Reference
Overall (I-squared = 91.7%)
Schregel 2016
Rai 2016
Mehta 2013
McTaggart 2017
Koge 2017
Jeon 2017
Frei 2017
min (95% CI)
Difference,
Weighted Mean
47 (28, 67)
69 (55, 83)
58 (40, 76)
36 (24, 48)
56 (35, 77)
14 (-3, 31)
109 (68, 151)
16 (7, 24)
Weight
%
100.00
15.29
14.51
15.62
14.08
14.81
9.63
16.05
Favours Control Favours Intervention
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D.  Teamwork
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Reference
Overall (I-squared = 90.7%)
Schregel 2016
Rai 2016
Mehta 2013
McTaggart 2017
Mascitelli 2016
Koge 2017
Jeon 2017
Frei 2017
min (95% CI)
Difference,
Weighted Mean
50 (31, 69)
69 (55, 83)
58 (40, 76)
36 (24, 48)
56 (35, 77)
77 (30, 124)
14 (-3, 31)
109 (68, 151)
16 (7, 24)
Weight
%
100.00
14.04
13.33
14.34
12.94
8.12
13.61
8.88
14.73
Favours Control Favours Intervention
-200 -100 0 100 200
 
F.  Multiple interventions implemented simultaneously
Reference
Overall (I-squared = 91.3%)
Schregel 2016
Mascitelli 2016
Koge 2017
Jeon 2017
min (95% CI)
Difference,
Weighted Mean
64 (24, 104)
69 (55, 83)
77 (30, 124)
14 (-3, 31)
109 (68, 151)
Weight
%
100.00
28.39
21.25
27.98
22.38
Favours Control Favours Intervention
-200 -100 0 100 200
 
E.  Feedback
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Supplementary Table 8.1. Risk of bias for included studies on effect of workflow improvements on time to 
treatment. 
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Abou-Chebl13 - - ? + + ?
Abou-Chebl14 - - - + + ?
Abou-Chebl15 - - ? + + ?
Aghaebrahim16 - - + + + +
Alotaibi17 - - ? - + -
van den Berg18 - - - + + ?
Berkhemer19 - - - + + ?
Bracard2 - - ? ? + ?
Cerejo20 - - + + + ?
Davis21 - - + + ? ?
Eesa22 - - + + + -
Frei23 - - - ? + +
Goyal24 - - + + + ?
Goyal25 - - - + + ?
Hassan26 - - ? + + ?
Henden27 + + + + + +
Herrmann28 - - - - - +
Jadhav29 - - + + + ?
Jagani30 - - + + ? ?
Janssen31 - - + + + ?
Jeon32 - - + + + +
John33 - - + + + ?
Jumaa34 - - + + + ?
Just35 - - + + + ?
Kamper36 - - - + + +
Koge37 - - + + + +
Komatsubara38 - - + ? + +
Li39 - - - + + ?
Liang40 - - ? + + ?
Mascitelli41 - - + + + +
McTaggart42 - - + + + ?
Mehta43 - - - - + +
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Menon44 - - ? + + ?
Miley45 - - ? + + ?
Mundiyanapurath46 - - - + + ?
Nichols47 - - ? + + ?
Pedragosa48 - - + + + ?
Pfaff49 - - - ? + ?
Pfaff50 - - - + + ?
Psychogios51 - - ? + + ?
Qureshi52 - - ? + + ?
Ragoschke53 - - - - + +
Rai54 - - - + + +
Ribo55 - - ? ? + ?
Schonenberger56 + + + + + +
Schregel57 - - + + + +
Simonsen58 + + + + + +
Singer59 - - - + + ?
Slezak60 - - + ? + ?
Sugg61 - - + + + ?
Tsujimoto62 - - - ? + ?
Total
Low Risk 6% 6% 45% 80% 94% 29%
Unclear risk 0% 0% 24% 14% 4% 67%
High Risk 94% 94% 31% 6% 2% 4%
Low risk is ‘+’ in green, high risk is ‘-’ in red, unclear risk is ‘?’ in yellow.
Supplementary Table 8.1. Contined
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B. Door to start endovascular treatment
Author Time to treatment in minutes, mean (SD)
Intervention group Control group
Abou-Chebl et al14 141 (91) 142 (91)
Berkhemer et al19 134 (60) 162 (69)
Cerejo et al20 52 (24) 71 (39)
Frei et al23 61 (42) 76 (36)
Goyal et al25 97 (42) 103 (48)
Hassan et al26 287 (348) 310 (335)
Herrmann et al28 108 (58) 144 (42)
Jadhav et al29 22 (21) 81 (73)
Jeon et al32 993 (44) 202( 179)
Kamper et al36 248 (165) 581 (823)
Liang et al40 43 (18) 58 (13)
Mascitelli et al41 104 (53) 181 (110)
Mehta et al43 106 (28) 142 (44)
Supplementary Table 8.2. Mean time to treatment for each study group and pooled weighted mean time to 
treatment, for specific time intervals, using random effects meta-analysis .
A. Onset to start endovascular treatment
Author Time to treatment in minutes, mean (SD)
Intervention group Control group
Abou-Chebl et al13 296 (172) 306 (133)
van den Berg et al18 231 (99) 269 (147)
Bracard et al2 254 (57) 244 (60)
Davis et al21 264 (93) 285 (115)
Goyal et al24 229 (49) 225 (42)
Henden et al27 190 (88) 199 (110)
Jagani et al30 256 (119) 282 (126)
Jumaa et al34 654 (804) 418 (291)
Li et al39 276 (120) 300 (138)
McTaggart et al42 112 (31) 168 (56)
Nichols et al47 232 (55) 237 (58)
Simonsen et al58 186 (72) 202 (71)
Slezak et al60 277 (126) 299 (157)
Tsujimoto et al62 233 (12) 273 (15)
Number of patients (intervention/control group): 1,466/1,243
Pooled weighted mean difference, minutes (95% CI): 18 (4 to 32), P=0.01
Effect of workflow improvements
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C. Imaging to start endovascular treatment
Author Time to treatment in minutes, mean (SD)
Intervention group Control group
Janssen et al31 59 (22) 79 (18)
Koge et al37 56 (24) 70 (30)
Menon et al44 56 (28) 72 (34)
Miley et al45 173 (57) 174 (66)
Pfaff et al49 39 (8) 61 (17)
Pfaff et al50 –1 42 (18) 45 (12)
Pfaff et al50 –2 45 (12) 69 (20)
Number of patients (intervention/control group): 305/198
Pooled weighted mean difference, minutes (95% CI): 15 (7 to 23), P<0.001
D. Onset to recanalization
Author Time to treatment in minutes, mean (SD)
Intervention group Control group
John et al33 436 (189) 510 (538)
Mundiyanapurath et al46 246 (90) 274 (99)
Number of patients (intervention/control group): 114/120
Author Time to treatment in minutes, mean (SD)
Intervention group Control group
Pedragosa et al48 47 (31) 69 (45)
Psychogios et al51 21 (6) 61 (35)
Qureshi et al52 158 (68) 180 (79)
Ragoschke et al53 106 (30) 121 (46)
Rai et al54 92 (37) 151 (51)
Ribo et al55 –1 60 (29) 90 (53)
Ribo et al55 –2 17 (8) 90 (53)
Schonenberger et al56 66 (20) 76 (29)
Schregel et al57 73 (42) 142 (93)
Singer et al59 92 (53) 86 (32)
Sugg et al61 141 (52) 161 (66)
Number of patients (intervention/control group): 1,595/2,441
Pooled weighted mean difference, minutes (95% CI): 33 (23 to 43), P<0.001
Supplementary Table 8.2.  Continued
B.
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Supplementary Table 8.3. Efficacy and safety outcomes for workflow interventions aimed at reducing time to 
endovascular stroke treatment. 
Intervention 
group
Control group Absolute risk 
difference (%)
Risk ratio 
(95% CI)
mRS 0–2 at 90 days 42.9%
(946/2,206)
30.7%
(690/2,246)
12.2 1.39 
(1.15 to 1.66)
P<0.001
Symptomatic intracranial 
hemorrhage
7.7%
(183/2,368)
8.2%
(154/1,883)
-0.5 0.88 
(0.71 to 1.09)
P=0.239
Mortality (all) 17.7%
(411/2,325)
25.1%
(535/2,133)
-7.4 0.74 
(0.63 to 0.87)
P<0.001
In-hospital mortality 15.0%
(197/1,316)
24.2%
(190/785)
-9.2 0.71 
(0.54 to 0.94)
P=0.017
Mortality at 30 days 14.4%
(28/194)
19.8%
(23/116)
-5.4 0.62 
(0.31 to 1.24)
P=0.175
Mortality at 3 months 22.8%
(186/815)
26.1%
(322/1,232)
-3.3 0.79 
(0.64 to 0.96)
P=0.019
167
 

Treat in the right place
Part III

Esmee Venema, Hester F. Lingsma, Vicky Chalos, Maxim J.H.L. Mulder,  
Maarten M.H. Lahr, Aad van der Lugt, Adriaan C.G.M. van Es, Ewout W. Steyerberg, 
M.G. Myriam Hunink, Diederik W.J. Dippel,and Bob Roozenbeek
Personalized prehospital triage in acute ischemic stroke: 
a decision-analytic model
Stroke, 2019
Chapter 9
Part III  |  Chapter 9
172
Abstract 
Background and purpose
Direct transportation to a center with facilities for endovascular treatment might be 
beneficial for patients with acute ischemic stroke, but it can also cause harm by delay of 
intravenous treatment. Our aim was to determine the optimal prehospital transportation 
strategy for individual patients and to assess which factors influence this decision.
Methods
We constructed a decision tree model to compare outcome of ischemic stroke patients after 
transportation to a primary stroke center versus a more distant intervention center. The 
optimal strategy was estimated based on individual patient characteristics, geographical 
location and workflow times. In the base case scenario, the primary stroke center was 
located at 20 minutes and the intervention center at 45 minutes. Additional sensitivity 
analyses included an urban scenario (10 versus 20 minutes) and a rural scenario (30 versus 
90 minutes). 
Results
Direct transportation to the intervention center led to better outcomes in the base case 
scenario when the likelihood of large vessel occlusion (LVO) was >33%. With a high likelihood 
of LVO (66%, comparable with a Rapid Arterial Occlusion Evaluation score of 5 or above), 
the benefit of direct transportation to the intervention center was 0.10 quality-adjusted life 
years (=36 days in full health). In the urban scenario, direct transportation to an intervention 
center was beneficial when the risk of LVO was 24% or higher. In the rural scenario, this 
threshold was 49%. Other factors influencing the decision included door-to-needle times, 
door-to-groin times and the door-in-door-out time. 
Conclusions
The preferred prehospital transportation strategy for suspected stroke patients depends 
mainly on the likelihood of LVO, driving times, and in-hospital workflow times. We 
constructed a robust model that combines these characteristics and can be used to 
personalize prehospital triage, especially in more remote areas.  
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Introduction
Inter-hospital transfer for endovascular treatment (EVT) of patients with acute ischemic 
stroke due to an intracranial large vessel occlusion (LVO) is one of the major causes of 
treatment delay.1-5 Delay of EVT is associated with poor functional outcome.6,7 Early 
identification of patients eligible for EVT followed by direct transportation to an endovascular-
capable center might reduce transfer-related delay and thereby improve outcome. For this 
purpose, several prehospital stroke scales have been developed to identify patients who 
are at high risk of having an intracranial LVO based on their clinical symptoms. Currently, 
there is no evidence on superiority of one of these scales and more prospective validation 
in the prehospital setting is needed to reliable assess their accuracy.8,9 
Other factors that might be of importance for the prehospital triage of suspected stroke 
patients include the prognosis of an individual patient and the expected benefit of EVT. 
Especially since the large majority of ischemic stroke patients is not eligible for EVT and only 
benefits from rapid treatment with intravenous thrombolytics (IVT), the harm of delaying 
IVT should be taken into account as well. The time-dependent effect of both treatments 
requires a trade-off between reducing delay of IVT by transportation to the nearest primary 
stroke center, and avoiding transfer-related delay of EVT by direct transportation to an 
intervention center.
Our aim was to determine the optimal prehospital transportation strategy for individual 
patients with suspected ischemic stroke and to assess which factors influence this decision.
Methods
Decision model
We constructed a decision tree model to compare outcome of patients with ischemic stroke 
after two different prehospital strategies: transportation to the nearest primary stroke 
center versus direct transportation to a more distant intervention center (Figure 9.1). The 
outcome of each strategy was estimated based on individual patient characteristics, 
geographical location and treatment times. We combined a short-run model including 3 
months outcome data from randomized controlled trials and a long-run Markov model that 
simulated 40 annual cycles. The benefit of direct transportation to the intervention center 
was defined as the average amount of quality-adjusted life years (QALYs) gained by this 
strategy. We considered a difference of more than 0.02 QALYs (=1 week in full health) to be 
clinically relevant. 
Our study did not need approval by an ethics committee since we did not use individual 
patient data. Analytic methods and study materials that support the findings of this study 
are available from the corresponding author upon reasonable request. 
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Model parameters
Individual input parameters consisted of age, sex, time since onset of stroke symptoms, 
likelihood of LVO, driving time from scene to the primary stroke center, driving time from 
scene to the intervention center, and driving time between the primary stroke center and 
the intervention center. The base case used in our analyses was a 68-year old man with 
suspected stroke symptoms since one hour and an average risk of 30% to have an LVO 
causing the ischemic stroke. The nearest primary stroke center in the base case scenario 
was located at a 20 minutes drive by ambulance, while the intervention center was located 
at 45 minutes. Driving time between the centers was 35 minutes. Total time to treatment 
was calculated based on the driving times and in-hospital workflow characteristics (Tables 
9.1 through 9.3). These parameters were varied in several sensitivity analyses. 
Other model parameters were estimated based on previous literature and expert opinion 
of two neurovascular specialists (Drs Dippel and Roozenbeek, Supplementary Table 9.1). 
The β coefficients of treatment effect and time-dependent decline of treatment effect were 
Figure 9.1. Schematic overview of the model structure. The model starts with the initial decision of 
transportation to the nearest primary stroke center or to the nearest intervention center. The short-run model 
calculates the probability of every possible pathway and the associated distribution of the modified Rankin 
Scale (mRS) score after 3 months. It takes into account driving times, in-hospital workflow characteristics, 
and time-dependent treatment effects. In each annual cycle of the following Markov model, patients can 
remain in the same health state or die. These probabilities are based on the age and sex dependent annual 
mortality rates, adjusted for previously reported death hazard rate ratios of stroke patients. The decision node 
is represented with a square. The circles represent chance nodes, the circles marked with an M represent 
Markov models and the triangles represent terminal nodes.
EVT, endovascular treatment; IVT, treatment with intravenous thrombolytics; LVO, large vessel occlusion.
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estimated with an ordinal logistic regression model using previously reported outcome 
distributions of treated patients and control patients in different time intervals.6,10 The effect 
of the uncertainty around these estimates was assessed with a probabilistic sensitivity 
analysis.
Likelihood of LVO
We modeled the entire range from 0% to 100% likelihood of having an LVO as cause of the 
ischemic stroke, and we calculated the threshold at which direct transportation to the 
intervention center would be beneficial. The average prevalence of LVO ranges mostly 
between 20% and 40% in different populations of ischemic stroke patients,11 but prehospital 
stroke scales can be used in individual patients to distinguish between lower and higher 
Table 9.1. Driving times used in the various analyses, in minutes.
Base case 
scenario
Urban 
scenario
Rural scenario
From scene to primary stroke center 20 10 30
From scene to intervention center 45 20 90
From primary stroke center to intervention center 35 15 75
Table 9.2. In-hospital workflow characteristics used in the various analyses, in minutes.
Base case analysis Sensitivity analysis
Door-to-needle time (primary stroke center) 30 60
Door-to-needle time (intervention center) 30 30
Door-in-door-out time (primary stroke center) 60 90
Door-to-groin time (directly admitted) 80 80
Door-to-groin time (transferred) 50 50
Table 9.3. Calculations of treatment times in the model, in minutes.
Time to IVT (primary stroke center) Time since onset of symptoms + driving time from scene to primary 
stroke center + door-to-needle time in primary stroke center
Time to IVT (intervention center) Time since onset of symptoms + driving time from scene to 
intervention center + door-to-needle time in intervention center
Time to EVT (directly admitted) Time since onset of symptoms + driving time from scene to 
intervention center + door-to-groin time for directly admitted 
patients
Time to EVT (transferred) Time since onset of symptoms + driving time from scene to primary 
stroke center + door-in-door-out time + driving time from primary 
stroke center to intervention center + door-to-groin time for 
transferred patients
IVT, treatment with intravenous thrombolytics; EVT, endovascular treatment.
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risk. To illustrate this, we calculated the likelihood of LVO in case of a positive test (positive 
predictive value) and in case of a negative test (1 minus the negative predictive value) for 
the Los Angeles Motor Scale (LAMS), the Rapid Arterial Occlusion Evaluation (RACE), and the 
3-Item Stroke Scale (3I-SS), using the pooled sensitivity and specificity rates reported in a 
previous meta-analysis (Table 9.4).8 In the sensitivity analyses, we used the RACE scale as 
an example of low risk (14%) and high risk (66%). 
Outcome measures
Primary outcome of the short-run model was the distribution of modified Rankin Scale (mRS) 
scores after 3 months. The mRS is a 7-point scale to assess functional outcome and disability, 
and ranges from 0 (no symptoms) to 6 (death). The outcome distributions of untreated 
ischemic stroke patients with and without an LVO were based on the control groups of 
previously reported randomized clinical trials (Supplementary Figure 9.1).10,12 These 
distributions were shifted for different outcomes based on the estimated treatment effect. 
To do so, we first transformed the probabilities of each of the baseline mRS scores to the 
log-odds scale, using the formula log-odds(p)= log(p/(1-p)). We then adjusted these log-odds 
for the effect of IVT and EVT by adding the βcoefficient (=log odds ratio) for the treatment 
effect at time 0 minus the decline in treatment effect over time (Tables 9.5 and 9.6). The 
adjusted log-odds were then converted back to probabilities using the inverse logit function: 
p(log-odds) = 1/(1+exp(-log-odds)). This resulted in the adjusted mRS distributions for treated 
patients. 
All mRS scores were considered to be separate health states with an associated utility score 
to calculate the average amount of QALYs per strategy. This is a commonly used measure 
to assess both the length and the quality of life.13 Utility scores represent the quality of life, 
and range from 1 (perfect quality of life) to 0 (death), or lower for states considered worse 
Table 9.4. Likelihood of large vessel occlusion based on several prehospital stroke scales. 
Stroke scale Sensitivity* Specificity* Prior probability  
= 20%
Prior probability  
= 30%
Prior probability  
= 40%
PPV 1-NPV PPV 1-NPV PPV 1-NPV
LAMS ≥4 38% 87% 42% 15% 56% 23% 66% 32%
RACE ≥5 67% 85% 53% 9% 66% 14% 75% 21%
3I-ISS ≥4 19% 97% 61% 17% 73% 26% 81% 36%
The different prior probabilities illustrate the prevalence of large vessel occlusion in different populations of 
ischemic stroke patients. 
*Pooled sensitivity and specificity rates as reported previously.8 
3I-SS, 3-Item Stroke Scale; LAMS, Los Angeles Motor Scale; NPV, negative predictive value; PPV, positive predictive 
value; and RACE, Rapid Arterial Occlusion Evaluation.
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than death. We used previously reported utility scores for ischemic stroke patients: 0.95 for 
mRS 0; 0.93 for mRS 1; 0.83 for mRS 2; 0.62 for mRS 3; 0.42 for mRS 4; and 0.11 for mRS 5.14 
The average life expectancy was calculated for every mRS category with a long-run Markov 
model that simulated 40 annual cycles. Age and sex dependent annual mortality rates were 
adjusted for previously reported death hazard rate ratios of stroke patients (Supplementary 
Table 9.1).15 Life years were discounted with 3% per year. We calculated the total number 
of QALYs by multiplying the utility scores of each mRS category with the corresponding life 
expectancy in years. 
Model assumptions
The model was used for scenarios in which the nearest hospital is not an intervention center, 
since there has to be decisional uncertainty about the optimal transportation strategy. 
Outcome was modeled for patients with ischemic stroke only, disregarding other diagnoses. 
A substantial proportion of all patients suspected of ischemic stroke have an intracerebral 
hemorrhage, a transient ischemic attack or a stroke-mimic, but we assumed the outcome 
of these patients to be unrelated to the transportation strategy. Because our analyses 
concerned the trade-off between IVT and EVT, we did not consider patients presenting >4.5 
hours after onset of symptoms.
We assumed that IVT could be given within 4.5 hours after onset of symptoms and EVT 
within 6 hours after onset. We modeled the decrease in treatment effect of IVT and EVT 
consistently over time and similar for all patients. Since large pooled analyses showed no 
significant interaction between age or gender and treatment effect, we did not include age 
or gender specific treatment effects in our model.12,16 The relative treatment effect of IVT 
was not influenced by stroke severity, which implies a smaller absolute treatment effect for 
patients with a more severe stroke. The importance of these model assumptions was 
assessed in several sensitivity analyses. 
Sensitivity analyses
In addition to the base case scenario, we also assessed examples of an urban scenario (10 
minutes from scene to primary stroke center; 20 minutes from scene to intervention center; 
and 15 minutes inter-center driving time) and a more rural scenario (30, 90, and 75 minutes 
respectively). We used a Tornado-analysis to explore the relative importance of the model 
parameters, by varying each parameter at a time while the others were held constant. 
Additional sensitivity analyses were performed with: increased workflow times in the primary 
stroke center (Table 9.2); a female patient; a patient with contra-indications for IVT; an absent 
effect of IVT for patients with LVO; and utility weights as defined in a study of Chaisinanunkul 
et al.17 
We performed a probabilistic sensitivity analysis using second-order Monte-Carlo simulations 
to assess decisional uncertainty around the model parameters. This involves running the 
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model 10,000 times and calculating the optimal transportation strategy every single time. 
In each simulation, the estimates of the model parameters were randomly sampled from 
the prespecified distribution of each parameter (β, (log)normal or triangular) (Supplementary 
Table 9.1). We reported the percentage of simulations in which transportation to the primary 
stroke center or direct transportation to the intervention center was preferred, and the 
median benefit of direct transportation to an intervention center with a 95% credible interval. 
We constructed an online tool in which input factors and regional workflow times can be 
adjusted for an individual patient in a specific scenario. We used R statistical software (version 
3.4.4) with the dampack package (version 0.0.0.9) and the R Shiny package (version 1.0.5). 
Results
Base case analysis
Direct transportation to the intervention center was preferred for the 68-year old man in 
the base case scenario, with a primary stroke center located at 20 minutes and an 
intervention center at 45 minutes, when the likelihood of LVO was 34% or above (Figure 
9.2). When the risk of having an LVO was 66%, comparable with a RACE score of 5 or more, 
the benefit of direct transportation to the intervention center was 0.10 QALYs (=36 days). 
When the risk of having an LVO was 14%, comparable with a RACE score below 5, 
transportation to the primary stroke center was preferred with a difference of 0.03 QALYs 
(=11 days). 
Sensitivity analyses
In the urban scenario (10 minutes to the primary stroke center, 20 minutes to the intervention 
center), the threshold for direct transportation to the intervention center was lower than 
in the base case scenario (24%, Figure 9.2). In the rural scenario (30 minutes to the primary 
stroke center and 90 minutes to the intervention center), direct transportation to the 
intervention center was only preferred for patients with an LVO likelihood of 49% or above. 
Other factors that strongly affected the decision threshold in the Tornado-analysis were the 
in-hospital workflow characteristics (Supplementary Figure 9.3). While remaining the other 
parameters of the base case constant, transportation to the primary stroke center was 
beneficial when the door-to-groin time for directly transported patients was above 102 
minutes, the door-to-groin time for transferred patients was below 28 minutes, or the door-
in-door-out time in the primary stroke center was <38 minutes. Age did not influence the 
preferred strategy, although it was important for the general prognosis of individual patients. 
In the analysis with increased workflow times in the primary stroke center, transportation 
to the intervention center was more favorable (Supplementary Figure 9.4). As might be 
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expected, we found that transportation to the primary stroke center was never preferred 
for a patient with contra-indications for IVT. In all other exploratory sensitivity analyses, the 
decision threshold remained relatively unchanged. 
Probabilistic sensitivity analysis
The uncertainty around the estimates of the model parameters caused little decisional 
uncertainty in the probabilistic sensitivity analysis (Supplementary Table 9.2). When the risk 
of having an LVO in the base case scenario was high, transportation to the intervention 
center was associated with a clinically relevant benefit in 94% of the simulations with a 
median difference of 0.09 QALYs (=33 days in full health, 95% credible interval: 0.00 to 0.20). 
When the risk of having an LVO was low, direct transportation to the intervention center 
was preferred in only 6% of the simulations, with a median difference of -0.03 QALYs (95% 
credible interval: -0.09 to 0.03). 
Figure 9.2. The optimal transportation strategy based on the likelihood of large vessel occlusion.
Primary stroke center: the nearest nonendovascular-capable stroke center; intervention center: the nearest 
endovascular-capable stroke center. A, represents the base case scenario (primary stroke center at 20 minutes 
and intervention center at 45 minutes); B, the urban scenario (10 and 20 minutes, respectively); and C, the 
rural scenario (30 and 90 minutes).
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Online tool
The effect of simultaneous changes in individual patient characteristics and regional 
workflow characteristics on the optimal prehospital transportation strategy for individual 
patients can be further explored by using the online tool at mrpredicts.shinyapps.io/triage 
(Figure 9.3).
Figure 9.3. Screenshot of the online tool. This interactive tool can be used at mrpredicts.shinyapps.io/triage. 
It shows the effect of changes in individual patient characteristics and regional workflow times on the optimal 
transportation strategy based on the likelihood of large vessel occlusion.  
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Table 9.5. Calculations of treatment effect in the model.
Probability of receiving IVT If treatment is possible within 4.5 hours after onset of symptoms: 
55%, otherwise: 0%
Probability of early reperfusion If LVO present and treated with IVT: 11%, otherwise: 0%
Probability of receiving EVT If treatment is possible within 6 hours after onset of symptoms: 85%, 
otherwise 0%
Treatment effect IVT  
(β coefficient)*
0.56 (=odds ratio 1.75) at time 0, minus 0.0019 x time to IVT in minutes
Treatment effect EVT  
(β coefficient)*
1.35 (=odds ratio 3.85) at time 0, minus 0.0026 x time to EVT in minutes
*The time-dependent decrease in treatment effect is illustrated in Supplementary Figure 9.2.
IVT, treatment with intravenous thrombolytics; EVT, endovascular treatment.
Table 9.6. Calculations of treatment effect in the model.
Primary stroke center Intervention center
Outcome with large vessel occlusion (log-odds)*
Early reperfusion  
after IVT
1.35 + (-0.0026 x time to IVT (primary 
stroke center)) + log-odds from 
baseline mRS distribution with LVO
1.35 + (-0.0026 x time to IVT 
(intervention center)) + log-odds from 
baseline mRS distribution with LVO
EVT (with or without  
prior IVT)
1.35 + (-0.0026  x time to EVT 
(transferred)) + log-odds from 
baseline mRS distribution with LVO
1.35 + (-0.0026 x time to EVT (directly 
admitted)) + log-odds from baseline 
mRS distribution with LVO
No EVT Log-odds from baseline mRS 
distribution with LVO
Log-odds from baseline mRS 
distribution with LVO
Outcome without large vessel occlusion (log-odds)*
IVT 0.56 + (-0.0019 x time to IVT (primary 
stroke center)) + log-odds from 
baseline mRS distribution without 
LVO
0.56 + (-0.0019 x time to IVT 
(intervention center)) + log-odds from 
baseline mRS distribution without 
LVO
No IVT Log-odds from baseline mRS 
distribution without LVO
Log-odds from baseline mRS 
distribution without LVO
*The baseline mRS distribution with LVO and without LVO is illustrated in Supplementary Figure 9.1. The 
corresponding probability of a certain outcome was calculated as: 1/(1+exp(-log-odds)). 
EVT, endovascular treatment; IVT, treatment with intravenous thrombolytics; LVO, large vessel occlusion; and 
mRS, modified Rankin Scale.
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Discussion
Our decision model shows that direct transportation to an intervention center can be 
beneficial for patients with a high risk of having an LVO, but will likely lead to worse outcomes 
when the risk is low, especially in scenarios with longer driving times. Combining individual 
likelihood of LVO and estimated driving times on a case-by-case basis could improve 
prehospital triage decisions, decrease treatment delay and thereby improve functional 
outcome of individual patients. In-hospital workflow characteristics such as the door-in-
door-out and door-to-groin times have a large effect on the optimal strategy as well. Our 
online tool allows individual and regional input to inform prehospital triage strategies in 
different settings. 
No single time threshold can be given to optimize triage decisions without considering the 
probability of being eligible for EVT, as was described by other models.18-21 As a measure for 
the likelihood of LVO, these models used previously reported cutoffs of one or multiple 
prehospital stroke scales. However, prospective prehospital validation is required to assess 
and compare the accuracy of these scales when used by emergency medical services in a 
broad population of suspected stroke patients.8 The full dependence of these models on 
insufficiently validated prehospital stroke scales limits the validity of their results. Therefore, 
we did not depend our model on a specific prehospital stroke scale, but assessed the entire 
range from 0% to 100% likelihood of LVO. Several prehospital stroke scales may be used to 
estimate this likelihood, preferably after more extensive validation. 
Our study also has some limitations. Decision-analytic modeling requires the use of 
estimated model parameters and multiple assumptions. In extensive sensitivity analyses, 
we found no substantial decisional uncertainty. Nevertheless, the assumptions we made 
about the treatment effect of IVT and EVT might have influenced our results. We used 
reported outcomes and effect sizes of IVT based on studies that did not assess LVO status, 
since randomized trials on the effect of IVT were performed before the introduction of CT 
angiography as standard of care for acute stroke patients. To calculate a common odds 
ratio for the decay in effect of IVT, we used mRS distributions at different time points 
provided by a pooled analysis from 2004.10 A more recent study with a larger sample size 
only reported odds ratios specific for the cutoff of mRS 0-1,16 which are not valid to use in 
shift-analyses of total mRS score. Although the effect of IVT tends to diminish with more 
proximally located occlusions,22,23 we included a consistent relative treatment effect of IVT 
in the range of the National Institute of Health Stroke Scale score of 5 to 22.16 Since the 
baseline outcome distribution is less favorable for patients with an LVO, the same relative 
treatment effect will give a smaller absolute effect in LVO stroke. The precise benefit of IVT 
prior to EVT is still uncertain, since the available studies are flawed by confounding by 
indication.24,25 The results of ongoing randomized controlled trials comparing EVT and EVT 
with prior IVT have to provide more insight on this matter.  
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Outcome of stroke mimics, such as migraine, epilepsy and conversion disorder, were 
considered to be independent of time, since there are no time-dependent treatment options 
that would require transportation to the nearest hospital. Patients with an intracerebral 
hemorrhage might benefit from transportation to a specialized center, but there is currently 
insufficient evidence to include the effect of rapid treatment in our model. Recent studies 
showed that EVT can be effective in a subgroup of stroke patients presenting between 6 
and 24 hours after onset.26,27 Other factors might be important to optimize triage of these 
patients and our results therefore only apply to patients presenting within 6 hours. 
Furthermore, we did not include costs in our model. Because outcome was measured based 
on functional outcome, we were only able to model harm due to delayed treatment. 
Inconvenience of unnecessary transportations for patients and their relatives, as well as 
inefficient resource utilization was not integrated in the model. It is likely that unnecessary 
transportation to an intervention center will cause crowding at the emergency department, 
which might have financial consequences and a negative effect on the in-hospital workflow. 
It is therefore important to further explore the cost-effectiveness of different prehospital 
triage strategies. 
We constructed a decision model that predicts the optimal strategy based on individual 
patient characteristics, and that can easily be adjusted for differences in geographical 
location or in-hospital workflow characteristics. Our online tool forms the basis of 
personalized prehospital triage of suspected ischemic stroke patients. Clinicians and 
researchers can plug in the specific characteristics of their own region into this tool to guide 
local prehospital triage policies. Although a fixed threshold the likelihood of LVO might be 
suitable for triage in urbanized regions with small distances between centers, our model 
showed that a higher threshold should likely be considered in more remote areas. After 
more extensive validation of the prehospital stroke scales, the tool can be used to combine 
the individual’s likelihood of LVO with estimated driving and local workflow times to improve 
prehospital triage decisions on a case-by-case basis. Future integration with a GPS-controlled 
navigation application will further facilitate personalized triage based on real-time 
information about driving and local workflow times. 
Conclusions
The preferred prehospital transportation strategy for suspected stroke patients depends 
mainly on the likelihood of LVO, driving times and in-hospital workflow times. We constructed 
a robust model that combines these characteristics and can be used to personalize 
prehospital triage, especially in more remote areas.  
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Supplementary material
Supplementary Table 9.1. Overview of the model parameters used in the probabilistic sensitivity analysis.
Model parameter Estimated 
value
SE Distribution Source
Treatment characteristics
Probability of receiving IVT  
if presenting <4.5h with  
an ischemic stroke
0.55 ±10% β Expert opinion
Effect of IVT, beta 0.56 
at time 0
0.18 Normal Hacke et al.1 (n=2763)
Time-dependent decrease  
in effect of IVT, beta 
-0.0019 
per minute
0.001 Normal Hacke et al.1 (n=2763)
Probability of early reperfusion  
after IVT
0.11 0.008 β Tsivgoulis et al.2 (n=1561)
Probability of receiving EVT  
if presenting<6h with an LVO
0.85 ±10% β Expert opinion
Effect of EVT, beta 1.35 
at time 0
0.29 Normal Saver et al.3 (n=1275)
Time-dependent decrease  
in effect of EVT, beta
-0.0026
per minute
0.001 Normal Saver et al.3 (n=1275)
Outcome parameters
Utility values
mRS scores 0
mRS scores 1
mRS scores 2
mRS scores 3
mRS scores 4
mRS scores 5
0.95
0.93
0.83
0.62
0.42
0.11
0.08
0.04
0.04
0.05
0.04
0.05
β
β
β
β
β
β
Dijkland et al.4
(n=7)
(n=36)
(n=84)
(n=87)
(n=133)
(n=45)
Death hazard rate ratios 
mRS scores 0-1
mRS scores 2
mRS scores 3
mRS scores 4
mRS scores 5
1.00
1.11
1.27
1.71
2.37
NA
1.0-1.5
1.2-1.4
1.3-2.0
1.5-4.0
NA
Triangular
Triangular
Triangular
Triangular
Samsa et al.5
EVT, endovascular treatment; IVT, treatment with intravenous thrombolytics; mRS, modified Rankin Scale; NA, 
not applicable; SE, standard error.
Corresponding references
1 Lancet 2004;363:768-774.
2 Stroke 2018;49:232-235.
3 JAMA 2016;316:1279-1288.
4 Stroke 2018;49:965-971.
5 J Clin Epidemiol 1999;52:259-271.
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Supplementary Table 9.2. Results of the probabilistic sensitivity analysis using 10,000 Monte Carlo simulations. 
Probability of large 
vessel occlusion
Optimal transportation strategy
(percentage of simulations)
Median benefit of 
direct transportation 
to intervention center, 
QALYs (95% credible 
interval)
Primary 
stroke 
center
Indifferent Intervention 
center
Base case scenario
    Low risk (14%) 60% 35% 6% -0.03 (-0.09 to 0.03)
    Average risk (30%) 20% 43% 37% 0.01 (-0.06 to 0.08)
    High risk (66%) 1% 7% 92% 0.09 (-0.01 to 0.20)
Urban scenario
    Low risk (14%) 8% 82% 10% 0.00 (-0.03 to 0.03)
    Average risk (30%) 1% 33% 66% 0.03 (-0.01 to 0.08)
    High risk (66%) <1% 4% 96% 0.09 (0.01 to 0.19)
Rural scenario
    Low risk (14%) 87% 9% 4% -0.10 (-0.25 to 0.03)
    Average risk (30%) 68% 18% 14% -0.05 (-0.19 to 0.07)
    High risk (66%) 10% 16% 74% 0.06 (-0.07 to 0.20)
The percentage of simulations in which transportation to the primary stroke center or direct transportation to 
the intervention center was preferred and the median difference in expected outcome between the two 
strategies is shown for different scenarios and different likelihood of large vessel occlusion. The percentages 
may not add up to 100% due to rounding. 
QALYs, quality-adjusted life years. 
Supplementary Figure 9.1. Distribution of the baseline modified Rankin Scale (mRS) scores. Outcome for 
untreated ischemic stroke patients without large vessel occlusion (A) and untreated ischemic stroke patients 
with large vessel occlusion (B). 
A. Hacke et al. placebo group, n=1384 (Lancet 2004;363:768-774).
B. Goyal et al. control group, n=644 (Lancet 2016;387:1723–1731).
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Supplementary Figure 9.2. The time-dependent decrease in treatment effect as used in the model.
EVT, endovascular treatment; IVT, treatment with intravenous thrombolytics.
Supplementary Figure 9.3. Tornado-plot with the effect of changes in model parameters on the optimal 
transportation strategy. The bars illustrate the effect of changes in the model parameter estimates, within the 
indicated ranges, on the optimal transportation strategy. The bars are ordered according to their impact on 
the difference in outcome. 
EVT, endovascular treatment; IVT, treatment with intravenous thrombolytics; LVO, large vessel occlusion.
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Supplementary Figure 9.4. Results of the sensitivity analyses. The bars show the optimal transportation 
strategy for different likelihood of large vessel occlusion in the base case scenario (primary stroke center at 
20 minutes and intervention center at 45 minutes); the urban scenario (primary stroke center at 10 minutes 
and intervention center at 20 minutes); and the rural scenario (primary stroke center at 30 minutes and 
intervention center at 90 minutes). 
0. Base case analysis.
1.  Sensitivity analysis with increased workflow times in primary stroke center (door-to-needle time 60 
minutes and door-in-door-out time 90 minutes).
2. Sensitivity analysis with female patient. 
3. Sensitivity analysis with contra-indications for treatment with intravenous thrombolytics.
4.  Sensitivity analysis with absent effect of treatment with intravenous thrombolysis for patients with a large 
vessel occlusion.
5.  Sensitivity analysis with utility weights as defined in the study of Chaisinanunkul et al (Stroke 2015;46:2238-
2243).
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Abstract 
Introduction
The efficacy of both intravenous treatment (IVT) and endovascular treatment (EVT) for 
patients with acute ischemic stroke strongly declines over time. Only a subset of patients 
with ischemic stroke caused by an intracranial large vessel occlusion (LVO) in the anterior 
circulation can benefit from EVT. Several prehospital stroke scales were developed to identify 
patients that are likely to have an LVO, which could allow for direct transportation of EVT 
eligible patients to an endovascular-capable center without delaying IVT for the other 
patients. We aim to prospectively validate these prehospital stroke scales simultaneously 
to assess their accuracy in predicting LVO in the prehospital setting.
Methods and analysis
Prehospital triage of patients with suspected stroke symptoms (PRESTO) is a prospective 
multicenter observational cohort study in the southwest of the Netherlands including adult 
patients with suspected stroke in the ambulance. The paramedic will assess a combination 
of items from five prehospital stroke scales, without changing the normal workflow. Primary 
outcome is the clinical diagnosis of ischemic stroke with an intracranial LVO in the anterior 
circulation. Additional hospital data concerning the diagnosis and provided treatment will 
be collected by chart review. Logistic regression analysis will be performed and performance 
of the prehospital stroke scales will be expressed as sensitivity, specificity and area under 
the receiver operator curve (AUC). 
Ethics and dissemination
The Institutional Review Board of the Erasmus MC University Medical Center has reviewed 
the study protocol and confirmed that the Dutch Medical Research Involving Human Subjects 
Act (WMO) is not applicable. The findings of this study will be disseminated widely through 
peer-reviewed publications and conference presentations. The best performing scale, or 
the simplest scale in case of clinical equipoise, will be integrated in a decision model with 
other clinical characteristics and real-life driving times to improve prehospital triage of 
suspected stroke patients. 
Trial registration number NTR7595 (www.trialregister.nl)
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Introduction
Rapid treatment with intravenous thrombolytics (IVT) is effective for patients with an 
ischemic stroke of less than 4.5 hours after onset.1,2 However, the effect of IVT is limited for 
ischemic stroke caused by an intracranial large vessel occlusion (LVO) in the anterior 
circulation, which accounts for approximately 30% of the patients.3 These patients can 
benefit from endovascular treatment (EVT), preferably started within 6 hours after onset of 
symptoms, but this treatment can only be performed in specialized intervention centers.4 
The effect of both treatments strongly declines over time.5-7 In current clinical practice, most 
suspected stroke patients are transported by ambulance to the nearest hospital for 
immediate treatment with IVT. Patients can subsequently be transferred to an endovascular-
capable center, if eligible for EVT. This is one of the main causes of treatment delay and  is 
associated with worse functional outcomes after EVT.8,9
Several prehospital stroke scales were developed to identify patients that are likely to have 
an LVO, which could allow for direct transportation of EVT eligible patients to an 
endovascular-capable center without delaying IVT for the other patients.10,11 Most of these 
scales were derived from the National Institute of Health Stroke Severity (NIHSS) score and 
external validation was often attempted by retrospective assessment of the items based 
on the NIHSS score completed by the treating physician at the emergency department.12-14 
The results of existing prehospital validation studies are limited due to small sample sizes, 
selected populations or the exclusion of stroke mimics.15-18 Further prospective validation 
• Prospective simultaneous validation of several prehospital stroke scales allows for direct 
comparison of their accuracy.
• In contrast to previous studies based on in-hospital assessment by experienced
physicians, assessment of the prehospital stroke scales will be performed by paramedics 
in daily clinical practice.
• The results of this study will provide unique insight in the characteristics of an unselected
group of patients with suspected stroke in the prehospital setting.
• The best performing scale will be integrated in a prehospital decision tool with other
clinical characteristics and real-life driving times to select those patients that benefit
from direct transportation to an endovascular-capable center.
• Performance will be measured with the area under the receiver operator curve (AUC),
which does not always relate directly to the clinical usefulness of these scales.
Box 11.1 Strengths and limitations of this study.
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is therefore required to assess and compare the accuracy of these scales when used by 
emergency medical services (EMS) personnel in a broad population of suspected stroke 
patients under circumstances that reflect usual care. 
Objective
The primary objective of this study is to prospectively validate several prehospital stroke 
scales simultaneously to assess their accuracy in predicting the likelihood of ischemic stroke 
caused by an intracranial LVO in the prehospital setting. 
Methods and analysis
Study design
Prehospital triage of patients with suspected stroke symptoms (PRESTO) is a prospective 
multicenter observational cohort study. Patients will be recruited in the ambulance and a 
combination of items from different prehospital stroke scales will be assessed by the 
paramedic. The normal workflow will not be affected and there is no intervention. Additional 
hospital data will be collected by chart review. Routinely performed neuro-imaging will be 
collected and centrally assessed. Follow-up will only be performed in patients with a final 
diagnosis of ischemic stroke. 
Study population
We will include patients in the southwest of the Netherlands, a region with approximately 
2 million inhabitants. Participating paramedics have ample experience with the initial 
management of patients with acute neurological deficits and they received additional 
training before the start of the study with regards to the study procedures and the use of 
the prehospital stroke scales. Additional to the prior training, an instruction video is available 
for all paramedics. Also, during the duration of the study, regular visits are paid to all 
ambulance stations to provide feedback and address uncertainty or questions of the 
paramedics. All adult patients with acute neurologic deficit, defined as at least 1 point on 
the Face-Arm-Speech-Test (FAST), and a suspected diagnosis of stroke by the paramedic, 
will be included. Patients with a blood glucose level below 2.5 mmol/L will be excluded. 
Prehospital stroke scales
We choose five well known prehospital stroke scales to validate: the Los Angeles Motor 
Scale (LAMS),19,20 the Rapid Arterial oCclusion Evaluation (RACE),18 the Cincinnati Stroke Triage 
Assessment Tool (C-STAT),21 the Prehospital Acute Stroke Severity scale (PASS),22 and the 
Gaze-Face-Arm-Speech-Test (G-FAST).23 These scales have many similarities in the items that 
are being used, but there are differences in the scoring systems and the degree of complexity 
of these scores. In the PRESTO study, we will assess a combination of the items used in 
these five scales (Table 11.1).
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Table 11.1. Overview of the items and corresponding scores used in the prehospital stroke scales.
LA
M
S
RA
CE
C-
ST
AT
PA
SS
G
-F
AS
T
Ite
m
s 
co
lle
ct
ed
 
in
 th
is
 s
tu
dy
 
Answering questions (age and current month)
Correctly answers both questions 0 0 0
Correctly answers one question
1* 1 1
Does not correctly answer either question
Following commands (‘close your eyes, ‘make a fist’)
Correctly performs both tasks 0† 0 0
Correctly performs one task 1†
1*
1
Does not correctly perform either task 2† 2
Head and gaze deviation
Normal; able to follow pen or finger to both sides 0 0 0 0 0
Gaze palsy or deviation (total or partial) 1 2 1 1 1
Facial palsy
Normal and symmetrical movement
0
0 0 0
Mild palsy (flattened nasolabial fold or minor asymmetry in smile) 1
1
1
Moderate to severe palsy 1 2 2
Grip strength
Normal grip strength 0 0
Weak grip strength 1 1
No grip possible 2 2
Motor function arm
Normal 0
0 0
0 0
0
Drift (minimal drift with closed eyes)
1
1 1Mild palsy (arm drifts down within 10 seconds) 1
1
1
Severe palsy (not able to lift arm) 2 2 2
Motor function leg
Normal
0 0
Drift (minimal drift with closed eyes)
Mild palsy (leg drifts down within 5 seconds) 1 1
Severe palsy (not able to lift leg) 2 2
Language
Normal speech 0 0
Speech problems (dysarthria, language abnormality,  
or unable to speak) 1 1
Agnosia
Patient recognises his/her arm and the impairment 0‡ 0‡
Does not recognises his/her arm or the impairment 1‡ 1‡
Does not recognises his/her arm nor the impairment 2‡ 2‡
*1 point if the patient answers at least one question incorrect and does not follow at least one command. †Only
scored if right hemiparesis. ‡Only scored if left hemiparesis.
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Data collection
Eligible patients presenting with suspected stroke symptoms will be recruited in the 
ambulance. The items from the prehospital stroke scales will be assessed by the paramedic 
and entered in a web-based database (LimeSurvey GmbH/Carsten Schmitz, www.limesurvey.
org). The paramedic will also enter the transportation number (to link with EMS data and 
hospital data), the time of symptom onset or last known well (according to patient or 
bystander), the side of the hemiparesis (if applicable), and the presence of a known 
neurological deficit on the symptomatic side. Data concerning demographics, vital functions, 
general neurological examination and transportation times will be collected from the EMS 
databases. 
After arrival in the hospital, patients will receive the usual care. A non-contrast CT scan and 
additional imaging (eg, CT angiography (CTA), digital subtraction angiography (DSA) and/or 
CT perfusion) can be performed as part of the regular workup of a suspected stroke. No 
additional imaging will be performed in the context of this study. Clinical data concerning 
the medical history, medication use, laboratory results, physical examination, and diagnosis 
will be collected by chart review. All diagnostic neuro-imaging data and radiology reports 
will be collected. If applicable, we will also collect information on the given treatment and 
corresponding treatment times (eg, the door-to-needle time, the door-to-groin time, the 
imaging-to-treatment time, and the door-in-door-out time of transferred patients).
Follow-up will only be collected for patients with a final diagnosis of ischemic stroke. We will 
use the outcome registration of the hospitals to collect length of hospital stay, discharge 
destination, and the modified Rankin Scale (mRS) score after 90 days.
Outcome measures
Primary outcome will be the clinical diagnosis of ischemic stroke with an intracranial LVO 
in the anterior circulation, defined as an occlusion of the internal carotid artery, the middle 
cerebral artery segment M1 or M2, or the anterior cerebral artery segment A1 or A2 
(assessed on CTA or DSA). Secondary outcome measures include the presence of an LVO 
in the posterior circulation (vertebral artery or basilar artery); the final diagnosis at hospital 
discharge; the given treatment (IVT, EVT, or both) and corresponding treatment times; and 
the functional outcome, measured with the 90-day mRS. 
Sample size calculation
At least 100 events (ie, intracranial LVOs) are required for the external validation of 
predictive models.24,25 The annual incidence of suspected ischemic stroke within 6 hours 
after onset of symptoms is estimated to be 50 per 100,000 people, based on an earlier 
cohort study.14 In the catchment area of the participating EMS (approximately 2 million 
inhabitants), this would imply 1,000 patients every year presenting with stroke symptoms 
within the 6-hour time window. Of these 1,000 patients, approximately 15% are assumed 
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to have an ischemic stroke due to an LVO; 31% an ischemic stroke without the presence 
of an LVO; 9% a transient ischemic attack (TIA); 10% an intracerebral hemorrhage; and 35% 
a stroke mimic.14 To reach the required number of 100 stroke patients with an LVO, we will 
have to include at least (number of cases / prevalence = 100 / 0.15) 667 patients with stroke 
symptoms of less than 6 hours. To allow for a 5% loss of follow up, we will aim for a sample 
size of 700 patients.
After inclusion of the first 500 patients, we will perform an interim analysis to calculate the 
percentage of LVO in our study population. If necessary, the required sample size will be 
adjusted based on this information. Although patients presenting after 6 hours will be 
included in the study, they will not count for the required sample size.
Data analysis plan
After completion of the last inclusion, the data will be checked and the database will be 
locked for statistical analyses. We will report the absolute numbers and percentages of 
patients based on the final diagnosis (eg, ischemic stroke, hemorrhagic stroke, TIA or stroke 
mimic) and, if applicable, the location of the intracranial LVO. For ischemic stroke patients, 
we will report the given treatment (IVT, EVT, or both) and corresponding treatment times, 
the number of inter-hospital transfers, and the functional outcome after 90 days. Missing 
values will be imputed with simple imputation based on the mean or mode (if less than 5% 
missing) or multiple imputation based on relevant covariates and outcome (if more than 
5% missing). 
The different prehospital stroke scales will be reconstructed based on the items assessed 
in the ambulance (Table 11.1). We will validate the prehospital stroke scales for patients 
presented within 6 hours after symptom onset using a logistic regression model with the 
presence of an LVO in the anterior circulation as outcome measure. We will analyze the 
scores both continuously and  dichotomised, based on the previously reported cut points 
in the original studies. Sensitivity and specificity of all cut points will be reported separately. 
The global performance of the prehospital stroke scales will be expressed as the area under 
the receiver operator curve (AUC). 
Prespecified sensitivity analyses will be performed for patients that presented more than 
6 hours after symptom onset, for the separate occlusion locations, and for the presence of 
an LVO in the posterior circulation. We will also assess the original outcome definitions as 
defined in each prehospital stroke scale instead of our own primary outcome and we will 
analyse the correlation between the prehospital stroke scales and the NIHSS assessed at 
the emergency department. Additional analyses will be performed to predict the probability 
of treatment with EVT based on the prehospital stroke scales and relevant factors in the 
medical history, medication use or vital signs. 
Part III  |  Chapter 11
216
Patient and public involvement
Patients and public were not involved in the development of the research questions or the 
design of this study. All study participants and every interested person in the public will 
have the possibility to read regular project updates on the project website (www.presto-
studie.nl).
Duration and current status of the study
The study was registered in The Netherlands Trial Register on November 11, 2018 under 
number NTR7595 (www.trialregister.nl). The study started on August 13, 2018 in the region 
Zuid-Holland Zuid and on September 1, 2018 in the region Rotterdam-Rijnmond. Recruitment 
of patients is ongoing and at the time of submission, April, 2019, 665 patients have been 
included in the study within 6 hours of symptom onset. In anticipation of a formal interim 
analysis, first raw data analysis shows a prevalence of 8% LVO in our study population. Based 
on this information, we increased our sample size to 1250 patients. With the current inclusion 
rate, we expect to reach the required sample size of 1250 patients by September 2019. 
Ethics and dissemination
Ethical aspects and informed consent
This study will be conducted in accordance with the principles of Good Clinical Practice, the 
Dutch Agreement on Medical Treatment Act (WGBO), and the European General Data 
Protection Regulation (GDPR). The Institutional Review Board of the Erasmus MC University 
Medical Center has reviewed the study protocol and confirmed that the Dutch Medical 
Research Involving Human Subjects Act (WMO) is not applicable.
Acquiring informed consent can be very challenging in the prehospital inclusion of suspected 
stroke patients. Many patients suffer from a language deficit, anosognosia, or other cognitive 
symptoms that impede an informed consent procedure, and often there is no (legal) 
representative of the patient present in the prehospital setting. Furthermore, an adequate 
informed consent procedure takes time, which is not available in the prehospital setting. 
Sometimes a deferred consent procedure can be used, but in the context of the WGBO this 
should be done by the treating physician. Since our unselected population of patients, 
including many stroke mimics, will spread towards different directions after presentation 
in the hospital, a disproportionate number of health care providers from a variety of 
specialisms (eg, neurologists, emergency physicians, internists, cardiologists) should be 
involved in the research to enable a deferred consent procedure.
The extent of the effort by a large number of health care providers needed to obtain 
permission from the participating patients is disproportionate to the relatively limited 
sensitivity of the collected and linked personal data and the related limited intrusion to the 
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personal privacy. We will therefore use an opt-out procedure in this study. The including 
paramedic will provide a leaflet with information about the study to the patient or their 
relatives. In this leaflet, we will explain that some routinely collected data can be collected 
from the EMS databases and the hospital charts for further analysis. Patients or their 
relatives are offered the opportunity to object to the use of these data in this study. When 
a patient or relative objects to study participation, all data will be destroyed and the patient 
will be excluded from the study. 
Dissemination plan
The main study results will be disseminated via publication in an international peer-reviewed 
journal and presentation at international conferences for stroke and emergency medicine 
experts. Representatives of the EMS providers and participating hospitals will be given the 
opportunity to comment on the manuscript and to participate as co-author, following the 
recommendations of the International Committee of Journal Editors (ICMJE). We plan to 
disseminate the results of the planned secondary analyses in one or more separate papers.
The best performing scale, or the simplest scale in case of clinical equipoise, will be integrated 
in a decision model with other clinical characteristics and real-life driving times.26 This model 
can be implemented in an online tool to improve prehospital triage of patients with 
suspected stroke symptoms without harming those patients that benefit from rapid IVT in 
the nearest hospital. Patients eligible for EVT will be directly transported to an endovascular-
capable center, which will lead to an increased number of treated patients, reduced 
treatment times and improved patient outcomes. Moreover, avoiding unnecessary inter-
hospital transfers will lead to more efficient use of EMS resources. 
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The overall aim of this thesis was to increase the benefit of endovascular treatment for 
ischemic stroke by optimizing prediction of outcome and treatment effect, reducing 
treatment delay, and improving prehospital triage strategies. In this final chapter, I present 
the main findings, followed by recommendations for clinical practice and future research. 
Treat the right patient
Endovascular treatment (EVT) greatly improves the overall functional outcome of patients 
with ischemic stroke due to a proximal, intracranial large vessel occlusion (LVO) in the 
anterior circulation.1 However, to maximize the effect and reduce potential harms or costs, 
it is important to identify those patients who are likely to benefit and those who are not. 
Although subgroup analyses are valuable to explore potential differences in the relative 
treatment effect, they are insufficient for individual treatment decisions.2 Patients are placed 
in a specific subgroup based on a single feature, such as old age or poor collateral score, 
without taking into account the large variation between individual patients. Also, subgroup 
analyses are mostly underpowered and prone to false-negative and false-positive results.3,4
Therefore, we developed the MR PREDICTS decision tool which combines the effect of 
multiple clinical and imaging characteristics on outcome and treatment effect simultaneously 
(Chapters 2 and 3). Included in the model were age, baseline National Institute of Health 
Stroke Severity (NIHSS) score, systolic blood pressure, history of ischemic stroke, history of 
diabetes mellitus, degree of pre-stroke disability, prior intravenous treatment with alteplase 
(IVT), Alberta Stroke Program Early Computed Tomography Score (ASPECTS), location of the 
occlusion, collateral score, and time from onset to start of treatment, defined as groin 
puncture. We found large differences in the predicted benefit between individual patients, 
but almost no harm was predicted. Even in subgroups were previous subgroup analyses 
showed absence of treatment effect (ie, patients with no collaterals or poor ASPECTS), the 
model identified a substantial proportion of patients who would benefit. 
External validation of MR PREDICTS with data from the HERMES trials and the MR CLEAN 
Registry showed reasonable to good model performance for the prediction of outcome 
(Chapter 4). However, prediction of treatment benefit, defined as the difference between 
the probability of functional independence with and without EVT, is more complex. The 
observed treatment benefit in HERMES was systematically larger than predicted, especially 
in the quintile of patients with the lowest predicted benefit. This might be explained by the 
strict selection of patients who were included in the HERMES trials; patients with unfavorable 
imaging characteristics were only randomized when a large treatment effect was expected 
based on other characteristics. Patient selection in the MR CLEAN Registry was less strict, 
but treatment benefit could not be assessed directly due to the lack of a control group. 
However, patients with small predicted treatment benefit had low rates of functional 
independence at 3 months, irrespective of their reperfusion status after the intervention, 
which might suggest absence of treatment benefit.
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Can we reliably and accurately predict outcome and treatment benefit of 
endovascular treatment for individual patients?
We developed and validated a prediction model (MR PREDICTS) that combines 
multiple baseline clinical and radiological characteristics to predict outcome with 
and without endovascular treatment. This model performed reasonably well in 
several validation cohorts and can support clinical judgement in distinguishing 
between patients who are likely to benefit from endovascular treatment and those 
who are not. Individual outcome predictions can be improved one day after the 
intervention using our post-procedural model (MR PREDICTS@24H), which showed 
excellent discriminative ability.
What are the main causes of prehospital and in-hospital delay of endovascular 
treatment?
Inter-hospital transfer proved to be the main determinant of treatment delay and a 
significant cause of poor outcomes even in the Netherlands, where the between-
center distances are relatively small. In-hospital workflow processes in the emergency 
department and the angiosuite should be streamlined to ensure rapid treatment. 
How do workflow improvements effect treatment delay and outcome?
Workflow interventions aimed at reducing any delay in the time between symptom 
onset and treatment, lead to a higher chance of good functional outcome for 
individual patients, especially when multiple interventions are combined. Effective 
interventions concern prehospital triage and transportation, in-hospital patient 
transfers, parallel workflow processes, anesthetic management, teamwork, and 
feedback on target times.
Which factors should influence the decision to transport individual patients directly 
to an intervention center?
Prehospital triage decisions should be based on the individual likelihood of large 
vessel occlusion, transportation times to the nearest primary stroke center and 
nearest intervention center, and in-hospital workflow characteristics such as the 
door-in-door-out time and door-to-groin time.
What is the optimal prehospital triage strategy for suspected stroke patients?
The use of a prehospital stroke scale to directly transport patients with suspected 
large vessel occlusion to an intervention center can improve outcomes, but the 
optimal triage strategy depends on geographic and organizational characteristics. 
We constructed a decision model that can be used to inform personalized triage 
decisions and to evaluate triage policies for specific regions.
Box 12.1 Overview of the main findings per research question
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Outcome predictions are more accurate when taking into account post-procedural variables 
such as the degree of reperfusion achieved and the National Institute of Health Stroke Scale 
(NIHSS) score after 24 hours. We used data available within one day after the intervention 
to develop MR PREDICTS@24H, a simple tool that combines nine variables to predict 
functional outcome following EVT (Chapter 5). The severity of stroke symptoms after one 
day, measured with the NIHSS, was the strongest predictor for functional outcome after 3 
months. External validation with MR CLEAN Registry data showed excellent discriminative 
performance, but suboptimal calibration. The model was therefore updated with a separate 
intercept to reflect the baseline risk of the population treated in clinical practice. Although 
this model does not affect the decision to provide EVT, it may guide physicians in 
personalizing a patients’ treatment and rehabilitation plan based on the probability of full 
recovery. 
Several other pre-procedural models for the prediction of functional outcome following EVT 
exist, with c-statistics ranging between 0.60 and 0.80, but none of these predict outcome 
with and without EVT to assess the absolute treatment effect.5 The most frequently used 
predictors are age, baseline NIHSS score, and some kind of imaging characteristic. The 
addition of collateral score improves the predictive performance of existing models, which 
strengthens the hypothesis that collateral blood flow is a major predictor of outcome and 
treatment effect.6 Two models found potential subgroups of patients with small treatment 
benefit, based on a poor outcome irrespective of the reperfusion status, but these results 
need further validation in larger samples.7,8 Of the previously published post-procedural 
models, only three were externally validated and these are all developed with data from 
the period before the proven effectiveness of EVT.9-11
Overall, MR PREDICTS and MR PREDICTS@24H showed large variations in anticipated 
outcome and treatment benefit of individual patients based on multiple characteristics. 
Both models were developed and validated using recent high-quality datasets of patients 
treated within 6 hours after stroke onset. The updated models are available online to aid 
patient selection and outcome prediction in daily clinical practice (www.mrpredicts.com). 
Treatment benefit in perspective
With a number needed to treat of 2.6 to reduce disability with one level on the modified 
Rankin Scale (mRS), EVT ranks among the most effective treatments in the medical field.1 
However, it is important to realize that the total benefit on population-level is not only 
affected by the size of the treatment effect, but also to a large extent by the number of 
eligible patients. Treatments with a small effect for the individual patient, might have a large 
effect on the whole population when applicable to a larger proportion of patients. Organized 
stroke unit care by a multidisciplinary team, for example, has a small absolute treatment 
benefit, but leads to a high increase in the number of patients achieving functional 
independence. EVT has the largest effect on individual patients, but the effect size on 
General discussion
225
12
Ta
bl
e 
12
.1
 A
n 
ill
us
tr
at
io
n 
of
 th
e 
an
nu
al
 e
ff
ec
t o
f i
sc
he
m
ic
 s
tr
ok
e 
in
te
rv
en
tio
ns
 in
 th
e 
N
et
he
rl
an
ds
, b
as
ed
 o
n 
29
,0
82
 h
os
pi
ta
liz
at
io
ns
 in
 2
01
8.
12
 
Ta
rg
et
 p
op
ul
at
io
n
Es
ti
m
at
ed
 
nu
m
be
r 
of
 
el
ig
ib
le
 
pa
ti
en
ts
  
(%
 o
f t
ot
al
)
Pe
rc
en
ta
ge
 o
f p
at
ie
nt
s 
ac
hi
ev
in
g 
fu
nc
ti
on
al
 
in
de
pe
nd
en
ce
 (m
RS
 0
-2
)
A
bs
ol
ut
e 
ri
sk
 
d
iff
er
en
ce
A
dd
it
io
na
l 
nu
m
be
r 
of
 
pa
ti
en
ts
 
ac
hi
ev
in
g 
fu
nc
ti
on
al
 
in
de
pe
nd
en
ce
(%
 o
f t
ot
al
)
St
ro
ke
 u
ni
t c
ar
e
Al
l i
sc
he
m
ic
 s
tr
ok
e 
pa
tie
nt
s 
ad
m
itt
ed
  
to
 th
e 
ho
sp
ita
l
29
,0
82
 
(1
00
%
)
Tr
ea
tm
en
t 4
9.
6%
Co
nt
ro
l 3
9.
8%
13
9.
8%
 
(N
N
T 
= 
10
)
2,
85
0
(9
.8
%
)
IV
 tr
ea
tm
en
t w
ith
 a
lte
pl
as
e
Pa
tie
nt
s 
w
ith
 is
ch
em
ic
 s
tr
ok
e 
pr
es
en
tin
g 
w
ith
in
 4
.5
 h
ou
rs
 a
ft
er
 o
ns
et
 o
f s
ym
pt
om
s 
or
 la
st
 s
ee
n 
w
el
l
5,
91
71
2
(2
0.
3%
)
Tr
ea
tm
en
t 4
5.
9%
Co
nt
ro
l 3
9.
5%
14
6.
4%
 
(N
N
T 
= 
16
)
33
3
(1
.1
%
)
En
do
va
sc
ul
ar
 tr
ea
tm
en
t
Pa
tie
nt
s 
w
ith
 is
ch
em
ic
 s
tr
ok
e 
du
e 
to
  
an
 in
tr
ac
ra
ni
al
 L
VO
 in
 th
e 
an
te
ri
or
 
ci
rc
ul
at
io
n,
 p
re
se
nt
in
g 
w
ith
in
 6
 h
ou
rs
 
af
te
r 
on
se
t o
f t
re
at
m
en
t o
r 
la
st
 s
ee
n 
w
el
l
1,
90
61
2
(6
.6
%
)
Tr
ea
tm
en
t 4
6.
0%
Co
nt
ro
l 2
6.
5%
1
19
.5
%
 
(N
N
T 
= 
5)
37
2
(1
.3
%
)
D
ec
om
pr
es
si
ve
 h
em
ic
ra
ni
ec
to
m
y
Is
ch
em
ic
 s
tr
ok
e 
pa
tie
nt
s 
un
de
r 
60
 y
ea
rs
 
w
ith
 m
al
ig
na
nt
 m
id
dl
e 
ce
re
br
al
 a
rt
er
y 
in
fa
rc
tio
n
87
 
(0
.3
%
15
)
Tr
ea
tm
en
t 2
6.
7%
Co
nt
ro
l 1
3.
9%
16
(m
RS
 0
-3
) 
12
.8
%
(N
N
T 
= 
8)
11
 
(0
.0
4%
)
Ea
rl
y 
an
tip
la
te
le
t t
he
ra
py
Al
l i
sc
he
m
ic
 s
tr
ok
e 
pa
tie
nt
s 
pr
es
en
tin
g 
w
ith
in
 2
 w
ee
ks
 a
ft
er
 s
tr
ok
e 
on
se
t
29
,0
82
 
(1
00
%
)
Tr
ea
tm
en
t 5
4.
3%
Co
nt
ro
l 5
3.
0%
17
1.
3%
(N
N
T 
= 
79
)
37
8
(1
.3
%
)
IV
, i
nt
ra
ve
no
us
; L
VO
, l
ar
ge
 v
es
se
l o
cc
lu
si
on
; m
RS
, m
od
ifi
ed
 R
an
ki
n 
Sc
al
e;
 N
N
T,
 n
um
be
r 
ne
ed
ed
 to
 tr
ea
t.
Chapter 12
226
population-level is comparable to the effect of IVT or early treatment with antiplatelet agents 
(Table 12.1). 
Strict selection of patients with a high expected treatment benefit, for example based on 
favorable imaging characteristics, will increase the treatment effect found in a study, but 
decreases the total number of patients treated in clinical practice and thereby the overall 
impact on the stroke population.18 A clear example is the large treatment effect that was 
shown in the recent randomized controlled trials (RCTs) on EVT for patients presenting 
between 6 and 24 hours since symptom onset or last seen will.19-21 The reported absolute 
risk difference of 28-36% for achieving functional independence suggests an enormous 
effect of treatment in the late time window, but the overall impact is limited due to the small 
percentage of eligible patients.22,23 Further studies on late treatment should therefore focus 
on expanding the number of treatable patients. Within the 6 hour time window, benefit of 
EVT is considerable within all subgroups. MR PREDICTS should not be used to select patients 
with the highest expected benefit, but only to identify patients for whom treatment would 
likely be futile. Referral of these patients to an intervention center is costly for the health 
system and unnecessarily inconvenient for their families.
Treat at the right time
Time is brain and rapid initiation of EVT is of great importance to maximize outcomes of 
ischemic stroke patients with intracranial LVO.24,25 Any delay between onset of symptoms 
and achieving reperfusion directly translates to a decreased chance of a favorable outcome. 
Early recognition of stroke symptoms and public awareness of the importance of rapid 
treatment are necessary to avoid patient delay in seeking medical attention.26-28 In-hospital 
determinants of delay in the MR CLEAN trial were presentation during off-hours and the 
use of general anesthesia (Chapter 6), which was confirmed in several studies.29-33 Analyses 
of treatment delay in two other RCTs, Endovascular Treatment for Small Core and Proximal 
Occlusion Ischemic Stroke (ESCAPE) and Solitaire With the Intention for Thrombectomy as 
Primary Endovascular Treatment (SWIFT PRIME), did not find a significant association with 
off-hour treatment, but these trials were focused on improving workflow and participating 
centers were trained in the delivery of fast care and logistics.34,35 Prior IVT was not associated 
with treatment delay, which is likely explained by the streamlined protocols for the 
administration of alteplase while preparing for CT angiography and transferring the patient 
to the angiosuite, without waiting for a clinical response. 
The most significant modifiable source of delay in the delivery of EVT is the transportation 
from a primary stroke center to an intervention center.34-37 In the MR CLEAN trial, 44% of all 
patients were transferred, and time from onset to treatment was increased with more than 
one hour in these patients (Chapter 6). The total delay that occurred in the primary stroke 
center was much larger, but part of this delay was compensated by a faster work-up in the 
intervention center. Similar results were found for transferred patients in the MR CLEAN 
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Registry, reflecting current clinical practice (Chapter 7). The probability of achieving functional 
independence decreases with 8.5% when a patient was first presented in a primary stroke 
center. In addition, there are probably also patients who were not transferred to an 
intervention center because the time window for EVT does not allow for the transfer time. 
On the other hand, patients without LVO may have benefited from early admission to a 
primary stroke center by receiving IVT as early as possible, but these patients were not 
included in the Registry.
Although transferred patients arrive later after stroke onset at the intervention center, they 
are treated more quickly after arrival than directly admitted patients (Chapters 6 and 7). 
This finding is probably explained by the fact that part of the diagnostic work-up and 
treatment, including IVT, is already performed in the primary stroke center. Also, pre-
notification allows for the interventional team to prepare in advance. The short door-to-groin 
time of transferred patients suggests that in-hospital workflow times can also be improved 
for directly admitted patients by streamlining processes on the emergency department and 
in the angiosuite. 
Workflow improvements
In a systematic review and meta-analysis, we showed that interventions in the workflow of 
EVT lead to better clinical outcomes, and that this effect increases when multiple 
interventions are combined (Chapter 8). Strategies that reduced transfer-related delay 
include requiring the emergency medical services to wait at the primary stroke center until 
the decision of EVT eligibility has been made, improving cloud-based image sharing with 
the intervention center, and transporting transfer patients directly to the angiosuite. In 
regions with very large between-center distances, the additional use of air ambulance 
services for inter-hospital transportation should also be considered. Another possibility 
would be to bypass the primary stroke center by using a mobile stroke unit. This is an 
ambulance with a CT scanner and a specialized team on board, allowing in-ambulance 
initiation and administration of IVT and direct transportation to the intervention center.38-41 
Despite its potential advantages, the clinical benefit and cost-effectiveness of this strategy 
are unclear and warrant further research.42
Interventions that reduced in-hospital delay were focused on pre-notification by the 
emergency medical services, direct activation of the entire stroke team, rapid acquisition 
of brain imaging, and provision of feedback on workflow times to the entire team. Parallel 
workflow processes for the administration of IVT without delaying EVT might be improved 
by the use of novel thrombolytic agents such as IV tenecteplase, that do not depend on a 
60-minute infusion duration.43,44 The 24/7 in-house presence of a vascular neurologist and 
an interventional team could further improve treatment times during off-hours, but this 
might be limited by the low number of stroke patients currently eligible for EVT.45 It has also 
been suggested that increased experience, reflected in higher volumes of patients treated 
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with EVT, leads to shorter treatment times.46 Centralization of stroke care could increase 
the experience of stroke teams and neuro-interventional teams, but should be weighed 
against the harm of longer transportation times that will emerge. Finally, procedural factors 
also affect the time between groin puncture and reperfusion, but this is beyond the scope 
of this thesis.
The significant effect of workflow interventions on time to treatment is consistent with 
previous studies related to IVT. Studies that successfully reduced treatment times used a 
combination of several interventions, a multidisciplinary approach, intensive training, and 
frequent evaluation. After implementation of a national quality improvement initiative and 
education program by the American Heart Association/American Stroke Association (AHA/
ASA), the percentage of patients treated within 60 minutes increased from 29.6% to 53.3% 
in participating centers.47 A Dutch multicenter study proved cost-effectiveness of an intensive 
implementation program to increase the proportion of patients treated with IVT, although 
it was lacking power to show an effect on functional outcome.48,49 Reported factors of delay 
in patients with door-to-needle times of >60 minutes include delayed diagnosis, inability to 
determine eligibility, and difficulties in the management of comorbidities.50 A dedicated 
center in Helsinki systematically implemented multiple interventions over a period of more 
than 10 years and was able to reduce the median door-to-needle time to 20 minutes.51 In 
2018, the median door-to-needle time in the Netherlands was 24 minutes (IQR 18–34) and 
the proportion of patients receiving IVT is currently among the highest of Europe.12,52
Target times
Specified target times can be used to improve workflow and compare between centers, but 
what times are reasonable to achieve in clinical practice? Many different time metrics are 
proposed in the literature, but one should always keep in mind that the total time interval 
from symptom onset to reperfusion is relevant for patients. 
The door-in-door-out time reflects the total workflow in the primary stroke center from 
arrival at the emergency department until departure to an intervention center. A recent 
study suggested a median target time of <45 minutes, which was the top 15th percentile of 
Table 12.2 Proposed target times and real-world time metrics of Dutch intervention centers, in minutes. 
Target times Time metrics in the Netherlands
AHA/ASA56 This thesis
MR CLEAN 
trial
MR CLEAN 
Registry
Dutch Acute 
Stroke Audit 
201812
Door-to-groin time 
transferred patients
60 25 96 
(75–120)
47 
(31–70)
26 
(17–39)
Door-to-groin time 
directly admitted patients
90 60 170 
(142–205)
104 
(80–135)
69 
(54–93)
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their own door-in-door-out times.53 This target might be too ambitious, considering the 
median door-in-door-out time of 88 minutes (IQR 68 to 117) in the MR CLEAN Registry and 
approximately 100 minutes in another large registry in the United States.37 The so called 
picture-to-puncture time, defined as the time from first imaging to groin puncture, describes 
the total workflow for transferred patients in both centers, with a proposed target time of 
<90 minutes.54,55 Since this measure includes the driving time between the centers, which 
is a non-modifiable part of the workflow that depends on the local distribution of hospitals, 
it should only be used to describe regional workflow characteristics.
For the workflow in the intervention center, the HERMES collaborators proposed a median 
door-to-groin time of <75 minutes, which was achieved in only 11.5% of the patients treated 
in the MR CLEAN trial (Chapter 6). It seems more appropriate to determine specific target 
times for patients that arrive directly at the intervention center and patients that are referred 
from a primary stroke center, as proposed by the AHA/ASA Target: Stroke Phase III initiative 
(Table 12.2). 
As a last remark, I would like to emphasize that these target times might not be sufficient 
to ensure rapid treatment of the majority of stroke patients by focusing on the median. By 
its definition, only 50% of the ischemic stroke population is treated within a median target 
time, while significant delay may occur in the other 50%. It is therefore always important to 
assess the interquartile range, and maybe even the 90th percentile, when evaluating 
treatment times.57
Treat in the right place
Prehospital triage of suspected stroke patients involves the trade-off between allowing rapid 
IVT in the nearest hospital versus avoiding transfer-related delay by direct transportation 
to an intervention center. We constructed a robust decision tree model to predict the optimal 
strategy based on individual and regional characteristics (Chapter 9). Factors that influence 
optimal triage decisions are the likelihood of LVO, estimated driving times to the primary 
stroke center and the intervention center, and local in-hospital workflow times. This finding 
is consistent with the results of other (mathematical) models, which used fixed values for 
the probability of LVO.58-62 Our model is based on the entire range from 0% to 100% likelihood 
of LVO, and can therefore be used with different prehospital stroke scales as input. It can 
also be used to assess which differences in sensitivity or specificity between different stroke 
scales would be clinically relevant.
In Chapter 10, the decision model was combined with a geographic information system 
analysis to estimate the effect of nationwide, state-level, and county-level implementation 
of several prehospital triage strategies in the US. We evaluated the current AHA Mission: 
Lifeline® Stroke algorithm, which recommends direct transportation of suspected LVO 
patients (based on any positive prehospital stroke scale) to an intervention center when the 
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additional driving time will not disqualify for IVT and the total driving time from scene to 
the nearest intervention center is less than 30 minutes.63 The results showed that nationwide 
implementation of this AHA algorithm prevents death or severe disability in 692 patients 
per year compared to transportation of all patients to the nearest center, but is suboptimal 
compared to strategies that allow to bypass the primary stroke center even when leading 
to delays of 30 minutes or beyond. The current AHA algorithm is only preferred in scenarios 
with very short driving times, a low prevalence of LVO, very efficient workflow times in the 
primary stroke centers, or a low number of additional patients without LVO accepted in the 
intervention centers. A modified algorithm without a time limit for the transportation of 
LVO-suspected patients would be optimal in the majority of states and could greatly improve 
outcomes of the ischemic stroke population in the United States. 
There is no randomized data available to support these findings, and although clinical data 
showed better outcomes for patients directly transported to an intervention center, these 
studies did not take into account the negative effect of bypassing the primary stroke center 
for patients without LVO.64 An ongoing RCT in Catalonia, Spain, will be the first to directly 
compare standard transportation to the nearest hospital to prehospital triage with the Rapid 
Arterial Occlusion Evaluation (RACE) score.65 This study might provide real-world evidence 
for the use of a prehospital stroke scale, but the results will only be applicable to regions 
with similar population density, geographic distribution of hospitals and in-hospital workflow 
times. Modeling studies will therefore always be required to translate trial results to regions 
with other geographic and organizational characteristics.
Prehospital stroke scales
Because the likelihood of LVO is one of the main drivers of triage decisions, early prehospital 
identification of patients at risk of having an LVO in the ambulance is of utmost importance. 
Numerous prehospital stroke scales have been proposed, but none of these scales predict 
LVO with both a high sensitivity and a high specificity.66,67 Most validation studies used 
retrospective reconstruction of the scores with data from the in-hospital assessment by 
experienced physicians, which is not representative of clinical practice. The RACE score was 
prospectively validated in a prehospital setting and showed a sensitivity of 84% and a 
specificity of 60% at a cutoff at ≥5 points.68 The prevalence of LVO among suspected stroke 
patients was 20%, resulting in a positive predictive value of 34%. When transporting all 
patients with a positive RACE score to an intervention center, there will be two non-LVO 
patients (false positives) for every patient with LVO stroke (true positives). 
Further prospective, prehospital validation of prehospital stroke scales is needed to compare 
their accuracy. Choosing the optimal prehospital stroke scale for triage of suspected stroke 
patients depends on the false positives (ie, patients without LVO that are transported to an 
intervention center) and false negatives (ie, patients with LVO that are transported to the 
primary stroke center). These numbers are based on the sensitivity and specificity of a scale, 
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but also on the prevalence of LVO in the local population. Previous studies reported a 
prevalence among ischemic stroke patients ranging from 7% to 60%.69 Most physicians will 
prefer a scale with a high sensitivity to increase the number of patients with LVO stroke 
directly transported to an intervention center. However, the specificity of a score reflects 
the number of false positives, which is a very relevant measure when financial resources 
or the capacity of intervention centers are limited. 
We designed the PRESTO study to prospectively evaluate and compare several prehospital 
stroke scales used by emergency medical services in a broad population of suspected stroke 
patients (Chapter 11). The simultaneous in-field validation of several prehospital stroke 
scales allows for direct comparison of their accuracy in an unselected population. Patient 
inclusion was finished in September 2019 and the final results of this study, including core 
lab assessed imaging data, are expected soon. 
Strengths and limitations
The main analyses in this thesis were performed with data from the MR CLEAN trial, which 
is considered to have the broadest inclusion criteria of the recent trials, and the MR CLEAN 
Registry, one of the largest cohorts of consecutive patients treated with EVT. Both cohorts 
are representative of patients treated in routine clinical practice without mandatory clinical 
or imaging-based selection criteria, which makes them especially suitable for the 
development of clinical prediction models. Patient outcomes in MR CLEAN and the Registry 
were less favorable than in the HERMES cohort, but this might be explained by the strict 
selection criteria, the inclusion of high-quality centers with ample experience, and the fast 
workflow times of the studies included in HERMES, which may not correspond to real-life 
clinical practice. On the other hand, the relatively small sample size of the MR CLEAN trial 
(n=500) limits generalizability, especially for small subgroups (eg, patients with M2 occlusions 
or low ASPECTS). The Registry, although larger in sample size, is limited by the lack of a 
control group and the high number of missing values, including missing outcomes.
Experienced clinicians are able to consider multiple factors when predicting outcome of 
individual patients with ischemic stroke, but several cognitive biases may occur and 
physicians’ predictive accuracy showed to be suboptimal compared to prediction models 
that combine the information of large datasets.70-73 Well developed and externally validated 
models can be used to aid the clinician when making treatment decisions or rehabilitation 
plans. MR PREDICTS showed modest predictive ability, especially in the clinical trial 
population, but the main predictor effects were comparable in the different cohorts, and 
the model was updated using data from daily clinical practice. The effect of MR PREDICTS 
on patient selection will be limited, due to the substantial treatment effect and small 
potential harm of EVT. More difficult treatment decision arise when patients present after 
6 hours of symptom onset, but there is currently insufficient data to develop an accurate 
model for late window patients.
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The analyses of treatment delay and prehospital transportation times were performed with 
data from the Netherlands, which is a small, densely populated country compared to other 
Western regions. The average transfer time in our study was less than 30 minutes, which 
limits the generalizability of our results to other regions. It is likely that the negative effect 
of inter-hospital transfer is even larger in countries with large between-center distances. 
Therefore, we used the wide variety of geographical areas in the United States to further 
evaluate triage strategies. 
The driving force of our prehospital model was to optimize patient outcomes, but the effect 
of triage strategies extends far beyond functional outcome alone. Unnecessary 
transportations to a more distant intervention center are inconvenient for patients and their 
relatives, and may lead to problems with resources and crowding at the intervention centers. 
This can be reduced by choosing a higher cut point or a more specific prehospital stroke 
scale. The shift of patient volume will also have economic consequences for the primary 
stroke centers that will receive and treat less stroke patients. This will create a substantial 
incentive for these centers to improve their workflow times, which makes transportation 
to a primary stroke center less harmful. 
Comparison with acute myocardial infarction
The current developments in the field of vascular neurology have many similarities with 
previous developments in cardiology due to the large similarity between ischemic stroke 
and myocardial infarction (MI). During MI, the blood flow in a coronary artery is suddenly 
blocked, causing ischemia of the heart muscle. An electrocardiogram, which records the 
electrical activity of the heart, is used to identify patients with an ST elevation MI, which 
indicates salvageable tissue in distress. These patients benefit from direct restoration of 
the blood flow by a percutaneous coronary intervention (PCI), while patients without ST 
elevation are initially treated with medication. 
Treatment of MI is time-critical, just like ischemic stroke treatment, and delayed initiation 
of PCI is associated with increased mortality.74 In 1999, the American Heart Association 
recommended a door-to-balloon time of <90 minutes to increase the chance of good 
outcome.75,76 This target time was achieved in only half of the American patients in 2005, 
which increased to 76% of the patients in 2008 due to the efforts of a national quality 
campaign implementing several workflow interventions.77 A study on specific strategies 
showed a significant effect of rapid activation and availability of the catheterization 
laboratory, 24/7 availability of an attending cardiologist, and the provision of real-time 
feedback to the entire team.78 Early emergency department activation of the catheterization 
team can reduce door-to-balloon times with >30 minutes.79,80 
As in ischemic stroke, the transfer of patients from a non-intervention center to an 
intervention center is associated with significant delay. Several strategies to improve 
workflow of the emergency medical services, emergency department and in-hospital care 
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Table 12.3 Potential interventions to reduce delay between symptom onset and start of treatment.
Time metric Prehospital targets In-hospital targets
Symptom onset to EMS 
notification
•	 Increasing public awareness
•	 Training family doctors
Scene to first hospital •	 Improving stroke recognition  
of EMS staff
Scene to intervention 
center
•	 Bypassing the primary stroke 
center when the likelihood of LVO 
is high
•	 Use of mobile stroke unit to 
identify patients with LVO
Door-to-imaging •	 Prehospital notification
•	 Direct EMS transfer to CT scanner
•	 Direct activation of the stroke 
team 
Door-in-door-out •	 Enlisting EMS crew to remain at 
primary stroke center until the 
definitive treatment decision is 
made
•	 Rapid imaging acquisition
•	 Parallel treatment with IV alteplase
•	 Direct contact with intervention 
center
•	 Initiation of transfers without 
awaiting approval of the 
intervention center in patients 
clearly meeting well-defined 
criteria
•	 Providing time targets with 
frequent feedback to the entire 
team
Transfer time •	 Air transportation
Door-to-groin puncture 
(general)
•	 Rapid imaging acquisition
•	 Parallel treatment with IV alteplase
•	 Extending the on-site presence of 
stroke team members during 
off-hours
•	 Early activation of the 
interventional team
•	 More experienced teams
•	 Providing time targets with 
frequent feedback to the entire 
team
Door-to-groin puncture 
(transferred patients)
•	 Direct EMS transfer to the 
angiosuite
•	 Electronic transmission of CT 
images
•	 Early activation of the 
interventional team
Angiosuite to groin 
puncture
•	 Protocols to preselect devices
•	 Ready-to-use equipment tray
•	 Early consultation of the 
anesthetist
•	 Avoiding general anesthesia if 
possible
CT, computed tomography; EMS, emergency medical services; IV, intravenous; LVO, large vessel occlusion.
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were independently associated with decreased door-in-door-out times, but the prehospital 
processes were the most important factor.81 Despite the similarities between the treatment 
of MI and stroke, the prehospital triage of MI patients is less complex. MI patients that should 
receive rapid treatment with PCI are easily identified in the ambulance using an 
electrocardiogram. This enables direct transportation of these patients to a PCI center, while 
the triage of suspected stroke patients is complicated by the fact that the diagnosis can only 
be confirmed with a CT angiography in the hospital. Our efforts should therefore be aimed 
on identifying eligible EVT patients in the prehospital setting, for example using prehospital 
stroke scales or a mobile stroke unit. 
Recommendations for clinical practice
The MR PREDICTS decision tool and MR PREDICTS@24H are online available for use in clinical 
practice (www.mrpredicts.com), and emphasize the importance of taking various factors 
into account when making treatment decisions. EVT should never be withheld based on a 
single characteristic, and patients directly presenting at the intervention center within 6 
hours after symptom onset should be treated as soon as possible, considering the large 
treatment effect and the small potential harm. I suggest that the decision tool may be 
particularly relevant when patients have to be transferred to an intervention center and 
there is doubt whether EVT will be beneficial. Transferring patients with low expected benefit 
causes unnecessary health care costs and inconvenience for patients and their families. 
Clinical judgement remains important, especially when there are rare, but strongly predictive 
characteristics not captured by the model, for example an abnormal anatomy of the circle 
of Willis or fluctuations in the course of symptoms.
Further reorganization of acute stroke care should be aimed on structuring workflow 
processes to ensure rapid treatment independent of the time or day of presentation. 
Multiple interventions can be combined to maximize the potential effect (Table 12.3). 
Ambitious but feasible time targets should be determined to motivate hospital staff and 
policy makers to improve in-hospital workflow. These time metrics should be monitored in 
every hospital and reported back to the stroke team regularly. At this moment, I would 
suggest that primary stroke centers in the Netherlands aim for a median door-in-door-out 
time of <45 minutes, which will only be possible when the ambulance waits at the emergency 
department until the result of CT angiography. Intervention centers should strive for a door-
to-groin time of <60 minutes for directly admitted patients and <25 minutes for transferred 
patients. 
Prehospital triage of suspected stroke patients is essential to reduce the number of inter-
hospital transfers. I would recommend to extend the current AHA triage algorithm for 
prehospital triage in the US and allow more delay when bypassing a primary stroke center. 
No universal time threshold can be given, because this strongly depends on geographic 
circumstances and organization of stroke care, but it seems beneficial to allow at least 30-45 
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minutes additional driving time for suspected LVO patients. Regional protocols should be 
further optimized based on local driving times, financial resources, and capacity of the 
intervention centers. The online tool, based on the decision model described in Chapter 9, 
can be used to inform these decisions. 
Currently, there is insufficient evidence to recommend one prehospital stroke scale over 
another, but one should at least use a scale that was prospectively validated in the 
prehospital setting (eg, RACE or the Cincinnati Prehospital Stroke Severity Scale (CPSSS)), 
and that is easy to use for emergency medical services.68,82 The choice for a prehospital 
stroke scale should not depend on sensitivity alone, because adequate specificity is required 
to limit the number of patients unnecessarily transported to an intervention center. 
Assessment of the individual likelihood of LVO based on a continuous scale instead of one 
fixed threshold, may further improve the effectiveness of prehospital triage. 
Recommendations for future research
Despite the huge impact of EVT on clinical outcome, still more than half of the treated 
patients are deceased or disabled at 3 months after stroke.1 This emphasizes the devastating 
effect of the disease and warrants innovations for further improvement of the current 
treatment options. 
Patient selection is especially important for patients presenting more than 6 hours after 
onset of symptoms or last seen well, because EVT might be futile or even harmful in many 
of these patients. However, the currently available trial data only includes a strictly selected 
patient population and is therefore insufficient to use for predictive modeling. Large 
databases of patients treated in the late time window are required to develop a robust 
model that can aid patient selection. Results of the ongoing MR CLEAN LATE trial 
(ISRCTN19922220), which assesses the use of more liberal selection criteria without 
restrictions on infarct core size, might be useful in identifying which late window patients 
benefit from treatment.
Machine learning methods, or artificial intelligence, are increasingly popular in the medical 
field and are suggested to improve personalized predictions by discovering data patterns 
and associations through automated algorithms.83,84 However, these algorithms require very 
large datasets for which clinical data sources are often not sufficient.85 The relatively small 
number of variables available might explain why machine learning methods did not 
outperform conventional logistic regression in the MR CLEAN Registry.86 Also, machine 
learning models do not provide further insight in the underlying pathophysiological 
mechanisms and cannot be adjusted for the use in different settings or populations. 
Therefore, I believe that machine learning is mostly valuable for pattern recognition tasks, 
for example for the automatic interpretation of neuroimaging. Prediction modeling should 
focus on the development of simple, robust models and adequate external validation of 
existing models. 
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It is important to acknowledge that patients with a poor prognosis might still benefit from 
treatment, and therefore MR PREDICTS estimates outcome with and without EVT. However, 
evaluation of treatment benefit brings a number of challenges. In Chapter 4, I used the 
c-for-benefit to evaluate the discriminative performance of the predicted treatment benefit. 
While the traditional c-statistic assesses whether a model can discriminate between patients 
with a low risk versus high risk of the outcome, this novel measure focuses on the whether 
the model can separate patients who are very likely to benefit from treatment and those 
who are not.87 Because the real treatment benefit of a patient cannot be observed, the 
c-for-benefit uses the outcomes of patient pairs that were matched on predicted benefit 
but discordant for treatment assignment. This method needs further evaluation and new 
benchmark values should to be defined to guide the interpretation of this promising 
measure.
A large number of prehospital stroke scales have been developed, and researchers should 
now focus on thorough validation of these scales in the prehospital setting, rather than the 
development of new scales. The future results of the PRESTO study will allow direct 
comparison of several prehospital stroke scales to improve triage decisions. Further decision 
modeling combined with geographic information systems can provide guidance for triage 
decisions in different settings. It can also be used to determine in which regions the 
implementation of a mobile stroke unit could be beneficial. Integration of a decision model 
with a GPS-controlled navigation application will facilitate personalized triage based on 
real-time information about driving times and in-hospital workflow times.
Final remarks
Although the overall effect of EVT is overwhelming, there are many targets to further improve 
outcome of individual patients. In this thesis, I developed and validated prediction models 
to predict outcome and treatment benefit; identified determinants of treatment delay and 
interventions to improve workflow; and applied decision-analyses to evaluate and optimize 
prehospital triage strategies.
The MR PREDICTS decision tool is the only model that estimates individual benefit of EVT 
and thereby improves patient selection. It performed reasonably well in a an international 
trial population and a large cohort of patients treated in daily clinical practice. Treatment 
benefit is substantial in the vast majority of patients, but absence of treatment effect is 
suggested in a small number of patients with multiple unfavorable characteristics. Rapid 
initiation of EVT is essential to improve patient outcomes, and requires the implementation 
of various prehospital and in-hospital workflow interventions. Inter-hospital transfer is the 
main determinant of treatment delay and should be avoided by transporting suspected 
stroke patients directly to an intervention center, but the optimal triage strategy varies based 
on regional characteristics. The future results of the PRESTO study will provide more 
information on the real-world performance of prehospital stroke scales, allowing further 
improvement of prehospital decision-making. 
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Treat the right patient
Endovascular treatment should never be withheld from an individual patient based 
on a single characteristic. The MR PREDICTS decision tool can be used to evaluate 
the effect of multiple patient and imaging characteristics simultaneously, when there 
is uncertainty about the treatment indication or when patients need to be transferred 
to an intervention center. Patient selection is particularly important for patients 
presenting more than 6 hours after symptom onset, but large databases of not 
strictly selected patients are required to develop a robust model for the late time 
window.
Treat at the right time
Rapid initiation of endovascular treatment is essential to improve patient outcomes, 
and requires the implementation of various prehospital and in-hospital workflow 
interventions. Acute stroke care should be reorganized to reduce any delay between 
stroke onset and start of treatment. Every effort is needed to streamline workflow 
processes, improve team work and communication, and reduce the number of inter-
hospital transfers. Door-in-door-out times and door-to-groin times should be 
monitored and reported back to the stroke team regularly.
Treat in the right place
A validated prehospital stroke scale should be used to identify patients that benefit 
from direct transportation to an intervention center. The choice of a specific 
prehospital stroke scale and the maximum allowed delay when bypassing the 
primary stroke center depends on local geographic characteristics, resources and 
preferences. Decision modeling will therefore be needed to translate results of 
clinical studies on prehospital triage to different settings and regions.
Box 12.2 Overview of the main recommendations.
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Summary
The effect of endovascular treatment (EVT) for ischemic stroke due to a proximal, intracranial 
large vessel occlusion (LVO) varies between individual patients. Treatment benefit, defined 
as the difference between the chance of a good outcome with and without treatment, is 
affected by differences in clinical characteristics at baseline. For example, the treatment 
effect strongly declines over time because a larger part of the brain tissue is already 
irreversibly damaged. Early initiation of EVT is therefore associated with better functional 
outcome, and time to treatment should be reduced to improve chances of good recovery. 
A possibility to reduce delay is to directly transport patients with suspected LVO to an 
intervention center capable of performing EVT, instead of bringing them to a primary stroke 
center for the first evaluation. However, this strategy might be harmful for stroke patients 
without LVO, who only benefit from rapid treatment with intravenous thrombolytics in the 
nearest hospital. The likelihood of LVO in suspected stroke patients can be assessed in the 
ambulance using a prehospital stroke scale, but the optimal triage strategy requires a trade-
off between the harm of delaying intravenous thrombolytics versus the potential benefit of 
rapid EVT.
The overall aim of this thesis was to increase the benefit of EVT by optimizing prediction of 
outcome and treatment effect (Part I), reducing treatment delay (Part II), and improving 
prehospital triage strategies (Part III). 
The specific research questions were:
1. Which are the right patients to treat?
a.  Can we reliably and accurately predict outcome and treatment benefit of EVT for
individual patients?
2. How can we treat patients at the right time?
a. What are the main causes of prehospital and in-hospital delay of EVT?
b. How do workflow improvements effect treatment delay and outcome?
3. How to direct patients to the right place?
a.  Which factors should influence the decision to transport individual patients directly
to an intervention center?
b. What is the optimal prehospital triage strategy for suspected stroke patients?
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Part I  – Treat the right patient
The first part of this thesis concerns the development and external validation of a prediction 
model for functional outcome and treatment benefit of individual patients (MR PREDICTS), 
and a post-procedural model to improve outcome prediction for patients treated with EVT 
at one day after the intervention (MR PREDICTS@24H). 
Chapters 2 and 3 describe the development of the MR PREDICTS decision tool with data 
from the MR CLEAN trial. Eleven baseline patient and imaging characteristics were included 
in the model, together with three interaction terms to account for differential relative 
treatment effects. An external validation with data from the IMS III trial showed a moderate 
ability of the model to distinguish between patients with low and high likelihood of a good 
outcome. Predicted treatment benefit varied substantially between individual patients, and 
clinically relevant benefit was predicted for some patients from subgroups in which no effect 
of EVT was expected, such as those with no or poor collaterals.
In Chapter 4, we performed external validation of MR PREDICTS with data from multiple 
international trials within the HERMES collaboration, including patients from different 
healthcare systems and countries. Based on these results, the model was updated and 
validated again in the MR CLEAN Registry, representing daily clinical practice in the 
Netherlands. The model performed reasonably well in both cohorts. Median predicted 
treatment benefit of routinely treated patients in the Registry was 10.6% (IQR 6.4% to 14.5%). 
A small group of patients in the Registry with low predicted treatment benefit had poor 
outcomes irrespective of reperfusion status, suggesting potential absence of treatment 
benefit.
MR PREDICTS@24H was developed with data from the HERMES collaboration, as described 
in Chapter 5. This prognostic model includes nine pre- and post-procedural characteristics, 
of which the National Institute of Health Stroke Severity scale at 24 hours after EVT was the 
most predictive of functional outcome at 3 months. External validation with data from the 
MR CLEAN Registry showed excellent discriminative performance, although the observed 
probability of survival was lower than predicted. This was resolved by providing separate 
intercepts that reflect the differences in outcome between the trial population and the broad 
group of routinely treated patients.
Part II  – Treat at the right time
Chapter 6 describes the effect of workflow characteristics on the time intervals in the MR 
CLEAN trial. Patients admitted during off-hours had an average delay of 23 minutes before 
the start of EVT, and patients treated under general anesthesia were treated 19 minutes 
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later from arrival at the emergency department. Prior administration of intravenous 
thrombolytics was not related with any significant treatment delay. Most importantly, almost 
half of the patients (44%) were transferred from a primary stroke center, and those patients 
received EVT on average 65 minutes later than patients directly admitted to an intervention 
center. 
To further explore the effect of inter-hospital transfer on time to treatment and functional 
outcome after EVT in daily clinical practice, we performed an analysis with data from the 
MR CLEAN Registry (Chapter 6). More than half of the routinely treated patients (54%) were 
transferred from a primary stroke center and these patients had an average delay of 57 
minutes between first presentation and start of EVT. The negative impact of this delay on 
functional outcome of transferred patients was reflected in an absolute decrease of 8.5% 
in the probability of achieving functional independence after 3 months.
Chapter 7 consists of a systematic review and meta-analysis on the effect of workflow 
improvements for EVT, including 51 studies on different types of workflow interventions. 
The most frequently reported interventions were aimed at using local anesthesia or 
conscious sedation instead of general anesthesia, reducing in-hospital patient transfers, 
and optimizing the prehospital workflow. The mean time to treatment was 26 minutes 
shorter for patients in the intervention group, and simultaneous implementation of multiple 
interventions even reduced treatment delay with 50 minutes.
Part III  – Treat in the right place
Because inter-hospital transfer is the most important factor of modifiable treatment delay, 
we constructed a decision tree model to determine the optimal prehospital transportation 
strategy of suspected stroke patients (Chapter 8). This model combines the likelihood of 
LVO in an individual patient with local driving times and in-hospital workflow times. Direct 
transportation to an intervention center was beneficial for patients with a high risk of having 
an LVO, especially in scenarios with short between-center distances. The optimal triage 
decision was also affected by the in-hospital workflow characteristics of both the primary 
stroke center (door-to-needle time and door-in-door-out time) and the intervention center 
(door-to-groin time).
In Chapter 9, our decision model was integrated in a geographic information system analysis 
to assess the effect of prehospital triage strategies for the United States. Evaluation of the 
current triage algorithm of the American Heart Association showed that this strategy is 
suboptimal for most states and counties. Modified versions of this algorithm, allowing for 
more time delay when bypassing a primary stroke center, showed large improvement of 
outcomes of the ischemic stroke population. 
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These triage strategies rely on prehospital stroke scales to assess the likelihood of LVO in 
suspected stroke patients, but prospective, prehospital validation of these scales is lacking. 
Therefore, I present the study protocol of PRESTO (prehospital triage of patients with 
suspected stroke symptoms) in Chapter 10. This prospective, multicenter, observational 
cohort study will evaluate the performance of several prehospital stroke scales based on 
the initial assessment in the ambulance. The results of this study will provide a unique 
insight in the characteristics of an unselected group of patients with suspected stroke in 
the prehospital setting.
Discussion
Although the overall effect of EVT is overwhelming, there are many targets to further improve 
outcome of individual patients. In this thesis, I developed and validated prediction models 
to predict outcome and treatment benefit; identified determinants of treatment delay and 
interventions to improve workflow; and applied decision-analyses to evaluate and optimize 
prehospital triage strategies.
Based on my findings, I recommend to never withheld EVT from an individual patient based 
on a single characteristic. The vast majority of patients will benefit when treated within 6 
hours after stroke onset, but the MR PREDICTS decision tool can be used to evaluate the 
effect of multiple patient and imaging characteristics when there is uncertainty about the 
treatment indication or when patients need to be transferred to an intervention center. 
Patient selection is particularly important for patients presenting more than 6 hours after 
symptom onset, but large databases of not strictly selected patients are required to develop 
a robust model for the late time window. 
Rapid initiation of EVT is essential to improve patient outcomes, and requires the 
implementation of various prehospital and in-hospital workflow interventions. Acute stroke 
care should be reorganized to reduce any delay between stroke onset and start of EVT. 
Every effort is needed to streamline workflow processes, improve team work and 
communication, and reduce the number of inter-hospital transfers. Ambitious target times 
should be set for the door-in-door-out time in the primary stroke center and the door-to-
groin time in the intervention center. These time metrics should be monitored and reported 
back to the stroke team regularly.
To improve prehospital triage, a validated prehospital stroke scale should be used to identify 
patients that benefit from direct transportation to an intervention center. The choice of a 
specific prehospital stroke scale and the maximum allowed delay when bypassing the 
primary stroke center depends on local geographic characteristics, resources and 
preferences. The future results of the PRESTO study will provide more information on the 
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real-world performance of prehospital stroke scales, allowing further improvement of 
prehospital decision-making. However, decision modeling will always be needed to translate 
results of clinical studies to different settings and regions.
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Samenvatting
Patiënten met een herseninfarct op basis van een proximale intracraniële occlusie in de 
voorste circulatie kunnen baat hebben bij intra-arteriële therapie waarbij het stolsel wordt 
verwijderd (trombectomie). De winst van deze behandeling, gedefinieerd als het verschil 
tussen de kans op een goed resultaat met en zonder behandeling, varieert tussen individuele 
patiënten en wordt beïnvloed door verschillen in klinische factoren. Zo neemt het effect van 
intra-arteriële therapie sterk af in de eerste uren na het ontstaan van de symptomen, 
doordat met het verstrijken van de tijd een groter deel van het hersenweefsel onomkeerbaar 
beschadigd raakt. Een snelle start van de behandeling wordt geassocieerd met een betere 
functionele uitkomst. De tijd tussen het ontstaan van de symptomen en het starten van 
intra-arteriële therapie moet daarom zoveel mogelijk worden gereduceerd om de kans op 
goed herstel te vergroten. 
Een mogelijkheid om vertraging te voorkomen is om patiënten rechtstreeks naar een 
interventiecentrum te brengen waar intra-arteriële therapie kan worden uitgevoerd, in 
plaats van naar een primair stroke centrum voor de initiële opvang. Deze triage strategie 
kan echter schadelijk zijn voor patiënten met een herseninfarct zonder intracraniële occlusie, 
aangezien die patiënten alleen profiteren van snelle intraveneuze trombolyse in het 
dichtstbijzijnde ziekenhuis. Bij patiënten met de verdenking op een herseninfarct moet 
daarom worden ingeschat hoe waarschijnlijk het is dat zij een intracraniële occlusie hebben. 
Dit kan in de ambulance worden gedaan met behulp van een prehospitale stroke score. 
Optimale prehospitale triage vereist echter een afweging tussen de schade die kan ontstaan 
door het uitstellen van intraveneuze trombolyse versus het potentiële voordeel van snelle 
intra-arteriële therapie.
Het algemene doel van dit proefschrift was om de winst van intra-arteriële therapie voor 
patiënten met een herseninfarct te vergroten door voorspellingen van uitkomst en 
behandeleffect te optimaliseren (Deel I), vertraging van de behandeling te verminderen 
(Deel II) en prehospitale triage strategieën te verbeteren (Deel III).
De specifieke onderzoeksvragen waren:
1. Welke patiënten moeten worden behandeld?
 a.  Kunnen we uitkomsten en de winst van intra-arteriële therapie voor individuele 
patiënten betrouwbaar en nauwkeurig voorspellen?
2. Hoe kunnen we patiënten op het juiste moment behandelen?
 a.  Wat zijn de belangrijkste oorzaken van vertraging in de prehospitale setting en in het 
ziekenhuis?
 b.  Hoe beïnvloeden workflow interventies de tijd tot behandeling en de uitkomsten van 
behandelde patiënten?
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3. Hoe kunnen we patiënten naar de juiste plaats leiden?
 a.  Welke factoren zouden van invloed moeten zijn op de beslissing om individuele 
patiënten rechtstreeks naar een interventiecentrum te vervoeren?
 b.  Wat is de optimale prehospitale triage strategie voor patiënten met de verdenking op 
een herseninfarct?
Deel I  - Behandel de juiste patiënt
Het eerste deel van dit proefschrift betreft de ontwikkeling en externe validatie van een 
predictiemodel voor functionele uitkomst en behandelwinst voor individuele patiënten (MR 
PREDICTS), en een post-procedureel model om de voorspelling van uitkomsten te verbeteren 
één dag na de interventie (MR PREDICTS@24H).
Hoofdstukken 2 en 3 beschrijven de ontwikkeling van het MR PREDICTS model met 
gegevens van de MR CLEAN studie. Elf patiëntkarakteristieken en radiologische kenmerken 
werden in het model opgenomen, samen met drie interactietermen om rekening te houden 
met differentiële relatieve behandeleffecten. Een externe validatie met gegevens van de 
IMS III studie toonde een redelijk voorspellend vermogen van het model in het onderscheiden 
van patiënten met een lage en een hoge kans op een goede uitkomst. De voorspelde winst 
van de behandeling varieerde aanzienlijk tussen individuele patiënten. Er werd ook baat 
van de behandeling voorspeld voor sommige patiënten uit subgroepen waarin eerder geen 
effect van intra-arteriële therapie werd verwacht, zoals patiënten met een zeer slechte 
collaterale bloedvoorziening.
In Hoofdstuk 4 heb ik een externe validatie van MR PREDICTS uitgevoerd met behulp van 
zes internationale, gerandomiseerde studies die zijn aangesloten bij de HERMES 
collaboration. Op basis van deze resultaten is het model geactualiseerd en opnieuw 
gevalideerd in de MR CLEAN Registry, een database waarin alle patiënten zijn opgenomen 
die in de dagelijkse praktijk in Nederland worden behandeld. Het model presteerde redelijk 
goed in beide cohorten. Voor de routinematig behandelde patiënten in de Registry werd 
een absolute toename van 10.6% voorspeld in de kans op goed functioneel herstel 
(interkwartiel range 6.4% tot 14.5%). Bij een kleine groep patiënten in de Registry werd geen 
baat van de behandeling voorspeld en een slechte uitkomst waargenomen ongeacht de 
reperfusiestatus, wat duidt op een mogelijk afwezig behandeleffect.
MR PREDICTS@24H is ontwikkeld met gegevens van de HERMES collaboration, zoals 
beschreven in Hoofdstuk 5. Dit prognostische model omvat 9 pre- en post-procedurele 
kenmerken, waarvan de National Institute of Health Stroke Severity score afgenomen 24 
uur na de interventie de belangrijkste voorspellende factor was van de functionele uitkomst 
na 3 maanden. Externe validatie met data van de MR CLEAN Registry toonde een uitstekend 
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discriminerend vermogen, maar de waargenomen overlevingskans in dit cohort was lager 
dan voorspeld. Dit werd opgelost door twee afzonderlijke intercepts te presenteren die het 
verschil in uitkomst weerspiegelen tussen de studiepopulatie en de brede groep van 
patiënten die in de dagelijkse praktijk behandeld wordt. 
Deel II  - Behandel op het juiste moment
Hoofdstuk 6 beschrijft het effect van workflow factoren op de tijd tot behandeling in de 
MR CLEAN studie. Patiënten die buiten kantooruren werden opgenomen zijn gemiddeld 23 
minuten later behandeld dan patiënten binnen kantooruren, en patiënten onder algehele 
narcose zijn gemiddeld 19 minuten later behandeld. Het toedienen van intraveneuze 
trombolyse was niet gerelateerd aan enige significante vertraging van de behandeling. De 
belangrijkste bevinding was dat bijna de helft van de patiënten (44%) werd overgeplaatst 
vanuit een primair stroke centrum. Deze overgeplaatste patiënten werden gemiddeld 65 
minuten later behandeld dan patiënten die rechtstreeks werden opgenomen in een 
interventiecentrum.
Om het effect van overplaatsingen tussen ziekenhuizen op de tijd tot behandeling en 
functionele uitkomst na intra-arteriële therapie in de dagelijkse klinische praktijk te 
onderzoeken, heb ik ook een analyse uitgevoerd met data van de MR CLEAN Registry 
(Hoofdstuk 6). Meer dan de helft van de routinematig behandelde patiënten in Nederland 
(54%) werd overgebracht vanuit een primair stroke centrum en deze patiënten hadden een 
gemiddelde vertraging van 57 minuten tussen de eerste presentatie en het starten van de 
intra-arteriële therapie. Het negatieve effect hiervan kwam tot uiting in een absolute afname 
van 8.5% in de kans op goed functioneel herstel na 3 maanden.
Hoofdstuk 7 bestaat uit een systematische review en meta-analyse naar het effect van 
workflow interventies, waarin 51 studies van verschillende type interventies geïncludeerd 
werden. De meest frequent gerapporteerde interventies waren gericht op het gebruik van 
lokale anesthesie of sedatie in plaats van algehele narcose, het verminderen van 
overplaatsingen van patiënten en het optimaliseren van de prehospitale workflow. De 
gemiddelde tijd tot de behandeling was 26 minuten korter voor patiënten in de 
interventiegroep en gelijktijdige implementatie van meerdere interventies verkortte de tijd 
tot behandeling zelfs met 50 minuten.
Deel III  - Behandel op de juiste plaats
Omdat overplaatsingen tussen ziekenhuizen de belangrijkste factor zijn in de vertraging 
van intra-arteriële therapie, heb ik een besliskundig model opgesteld om de optimale 
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prehospitale strategie te bepalen voor patiënten waarbij een herseninfarct vermoed wordt 
(Hoofdstuk 8). Dit model combineert de waarschijnlijkheid van een intracraniële occlusie 
bij een individuele patiënt met lokale reistijden en doorlooptijden in de regionale 
ziekenhuizen. Direct vervoer naar een interventiecentrum was gunstig voor patiënten 
waarbij een intracraniële occlusie waarschijnlijk is, vooral in scenario’s met korte afstanden 
tussen de verschillende centra. De optimale triage strategie werd ook beïnvloed door de 
doorlooptijden in het primaire stroke centrum (deur-tot-naald tijd en deur-in-deur-uit tijd) 
en het interventiecentrum (deur-tot-lies tijd).
In Hoofdstuk 9 werd dit besliskundige model geïntegreerd in een geografisch 
informatiesysteem om het effect van prehospitale triage strategieën in de Verenigde Staten 
te beoordelen. Het huidige triage algoritme van de American Heart Association bleek 
onvoldoende effectief te zijn in de meerderheid van de staten en provincies. Aangepaste 
versies van dit algoritme, die meer vertraging toestaan bij het vervoer naar een 
interventiecentrum, hadden een groot positief effect op de uitkomsten van de Amerikaanse 
patiëntenpopulatie.
Prehospitale stroke scores worden gebruikt om de waarschijnlijkheid van een intracraniële 
occlusie te beoordelen in de ambulance, maar prospectieve, prehospitale validatie van deze 
scores ontbreekt. Daarom presenteer ik in Hoofdstuk 10 het studieprotocol van PRESTO 
(prehospitale triage van patiënten met de verdenking op een herseninfarct). Deze 
prospectieve, multicenter, observationele cohortstudie zal het voorspellend vermogen van 
verschillende prehospitale stroke scores evalueren op basis van de initiële beoordeling in 
de ambulance. De resultaten van deze studie zullen tevens inzicht bieden in de 
ongeselecteerde groep van patiënten met de verdenking op een herseninfarct.
Discussie
Hoewel het algehele effect van intra-arteriële therapie overweldigend is, zijn er veel 
mogelijkheden om de uitkomsten van individuele patiënten met een herseninfarct verder 
te verbeteren. In dit proefschrift heb ik predictiemodellen ontwikkeld en gevalideerd om 
functionele uitkomst en behandelwinst te voorspellen; determinanten die leiden tot 
vertraging van de behandeling en interventies om de workflow te verbeteren geïdentificeerd; 
en besliskundige analyses toegepast om prehospitale triage strategieën te evalueren en te 
optimaliseren.
Op basis van mijn bevindingen raad ik aan om nooit een individuele patiënt intra-arteriële 
therapie te onthouden op basis van één enkele eigenschap. Het MR PREDICTS model kan 
worden gebruikt om het effect van meerdere patiëntkarakteristieken en radiologische 
kenmerken tegelijkertijd te evalueren, wanneer er onzekerheid bestaat over de 
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behandelindicatie of wanneer patiënten moeten worden overgeplaatst naar een 
interventiecentrum. Patiëntselectie is vooral belangrijk voor patiënten die zich meer dan 6 
uur na het begin van de symptomen presenteren, maar er zijn grote databases met niet 
strikt geselecteerde patiënten nodig om een  robuust model voor het late tijdvenster te 
ontwikkelen.
Een snelle start van intra-arteriële therapie is essentieel om de uitkomsten van patiënten 
te verbeteren en vereist implementatie van verschillende workflow interventies in de 
prehospitale setting en in het ziekenhuis. De acute beroertezorg moet worden 
gereorganiseerd om de vertraging tussen het begin van een herseninfarct en de start van 
de behandeling te verminderen. Er moet alles aan gedaan worden om de logistieke 
processen te stroomlijnen, samenwerking en communicatie te verbeteren en het aantal 
overplaatsingen tussen ziekenhuizen te verminderen. Het is raadzaam om de 
doorstroomtijden te monitoren en regelmatig aan het stroke team te rapporteren.
Om de prehospitale triage te verbeteren, moet een gevalideerde prehospitale stroke score 
worden gebruikt om patiënten te identificeren die baat hebben bij direct transport naar 
een interventiecentrum. De keuze voor een specifieke prehospitale stroke score en de 
maximaal toegestane vertraging wanneer wordt omgereden naar een interventiecentrum 
hangt af van geografische kenmerken, beschikbare capaciteit van de ziekenhuizen en lokale 
voorkeuren. De toekomstige resultaten van de PRESTO studie zullen naar verwachting meer 
informatie verschaffen over de werkelijke prestaties van prehospitale stroke scores, zodat 
de besluitvorming kan worden geoptimaliseerd. Besliskundige modellen zullen echter altijd 
nodig zijn om de resultaten van klinische studies te vertalen naar verschillende regionale 
omstandigheden.
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In life, it’s not where you go, it’s who you travel with
Charles M. Schulz
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Dankwoord
Het is eindelijk zover, mijn boekje is af! Er is hiermee een einde gekomen aan een mooie en 
bijzondere periode in mijn leven. Een promotieonderzoek doe je niet alleen en ik ben blij 
dat ik nu iedereen kan bedanken die mij de afgelopen jaren geholpen heeft. Ik heb het geluk 
gehad om met een groep geweldige mensen samen te mogen werken en daarnaast veel 
lieve mensen om me heen te hebben die het leven zo mooi maken.
Allereerst wil ik natuurlijk mijn promotoren, professor Ewout Steyerberg en professor 
Diederik Dippel, bedanken.
Beste Ewout, ik kan me onze eerste meeting nog goed herinneren. Nadat we eerst gezellig 
over hardlopen en familiezaken spraken, ging je plotseling in de tweede versnelling en had 
je in een mum van tijd alle pijnpunten van onze studieopzet blootgelegd. Ik kwam terug met 
een lijstje vol nieuwe ideeën en analyses waar ik nog nooit van gehoord had. In de loop van 
de tijd leerde ik je gelukkig steeds iets beter bijhouden en anders had ik altijd nog je boek 
om het terug te zoeken. Dank voor je kritische blik, waardevolle commentaar en 
indrukwekkende snelheid van reageren op mijn manuscripten.
Beste Diederik, het begon eigenlijk allemaal toen ik onder jouw begeleiding tijdens mijn 
keuze-onderzoek aan de MR CLEAN pre-trial mocht werken. Later gaf je me de mogelijkheid 
om dit promotieonderzoek te doen waarvoor ik je nog steeds erg dankbaar ben. Je bent 
een ontzettend fijne supervisor: enthousiast, gedreven en makkelijk benaderbaar. Ik heb 
veel van je geleerd, niet alleen medisch-inhoudelijk, maar ook over samenwerken, 
grammatica en het opzetten van studies en beslisbomen. Je bent een voorbeeld voor 
iedereen die gedegen methodologisch onderzoek wil combineren met de klinische praktijk. 
Naast twee promotoren heb ik ook twee fantastische copromotoren. Hester, ontzettend 
bedankt voor alle kansen en de ruimte die je me hebt geboden om mezelf te ontwikkelen. 
Onze meetings zijn altijd gezellig maar ook heel productief. Ik heb met veel plezier met je 
kunnen sparren, zowel over lopende projecten als over mijn toekomstplannen. Ik hoop dat 
we onze samenwerking nog lang mogen voortzetten. Bob, je bent betrokken en ambitieus 
met een goed gevoel voor humor. Tijdens de langdurige procedures in het kader van de 
nieuwe AVG gaf ik de moed soms bijna op, maar jij wist altijd overal weer een oplossing 
voor. Bedankt voor je scherpe blik en nuttige suggesties bij het beoordelen van mijn 
manuscripten. 
Beste leden van de promotiecommissie, bedankt voor het doornemen van mijn proefschrift 
en het deelnemen aan de verdediging. Ik hoop op een interessante gedachtewisseling. 
Professor Fiona Lecky and professor David Kent, thank you for your willingness to travel to 
Rotterdam to take place in the committee if the situation regarding COVID-19 allows. 
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Dear David, thanks for your guidance during my time in Boston and afterwards. You taught 
me a lot about research (and good food!) and I still enjoy working together. 
De artikelen in dit proefschrift zouden er niet zijn gekomen zonder de waardevolle inbreng 
van alle coauteurs. Ik wil jullie allen bedanken voor de prettige samenwerking de afgelopen 
jaren. Speciale dank gaat uit naar Maxim, Vicky, Paula, Nikki en Adrien voor de papers die 
ik heb mogen gebruiken in mijn proefschrift. I would like to thank professor Joseph Broderick, 
professor Mayank Goyal, and the HERMES investigators for their cooperation on the MR 
PREDICTS project. Dank ook aan alle onderzoekers van de MR CLEAN trial en MR CLEAN 
Registry (pagina 259) voor het beschikbaar stellen van de door hen met veel toewijding 
verzamelde data. 
Maxim, ooit werkten we al met veel plezier samen aan de MR CLEAN pre-trial en ik ben blij 
dat we dat tijdens onze promotietijd konden voortzetten. Het was heerlijk om samen te 
sleutelen aan MR PREDICTS en voor het eerst onze helden tegen te komen op congres. Je 
enthousiasme en doortastendheid heb ik wel eens gemist tijdens het afronden van dit 
boekje! Vicky, we hebben de afgelopen jaren lief en leed gedeeld. Urenlang bijpraten op de 
gang of lekker samen R’en, waarbij we meestal alleen maar nieuwe problemen tegenkomen 
(en weer oplossen!). Wat hebben we veel gelachen, zeker tijdens alle tripjes en de ESO 
summerschool. Bedankt dat je mijn paranimf wilt zijn!
Martijne, aan jou kon ik PRESTO met een gerust hart overdragen en daar ben ik je heel 
dankbaar voor! Je hebt een enorme hoeveelheid werk verricht en hopelijk kunnen we snel 
de eerste resultaten publiceren. Daarnaast natuurlijk dank aan alle PRESTO onderzoekers 
(pagina 261), met name Henk Kerkhoff, Anouk Rozeboom, Walid Moudrous, Frederique 
Vermeij, Ad van Es en professor Aad van der Lugt. Ook veel dank aan alle deelnemende 
ambulanceverpleegkundigen van regio Rotterdam-Rijnmond en Zuid-Holland Zuid.
Charlie, Eveline en Benjamin, waar moet ik beginnen? Jullie brachten een hoop leven, muziek 
en nieuwe ideeën in de toren. Daarnaast hebben jullie me te vaak uit de brand geholpen 
als mijn planning weer eens faalde (valet parking in Leiden of een visum halen in Brussel, 
ga zo maar door), waarvoor eeuwig dank. Met jullie enthousiasme en daadkracht hebben 
jullie veel bereikt in korte tijd!
De afgelopen jaren heb ik veel meer mensen leren kennen binnen en buiten het Erasmus 
MC. José en Veerle, kamergenootjes van het eerste uur. Collega’s op MGZ en binnen de sectie 
Medische Besliskunde (onder andere Jilske, Ernest, Daphne, Nikki, Daan, David, Arvind, Isabel, 
Marzyeh, Ana). Commissieleden van Promeras en het JVO. De MR CLEAN predictie groep 
(Noor, Rob, Kars, Femke, Nikki, Sanne, Nadinda, Jim) en promovendi van de MR CLEAN Registry. 
Allen bedankt voor de gezellige tijd op de afdeling, de congressen, de borrels en de etentjes!
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Many thanks to George Ntaios for organizing the fantastic ESO summerschool. I’ve made 
many friends within Europe and really enjoyed the trip with the Lisbon group (Vicky, 
Sebastian, Alex, and Mariana). All colleagues at the PACE center, especially Chrissy, Jinny, 
and Jenn, thanks for your hospitality in Boston and the pleasant collaboration.
SEH-artsen en verpleegkundigen uit Bergen op Zoom, jullie hebben me laten zien wat een 
mooi vak de spoedeisende geneeskunde is. Collega’s en oud-collega’s van de SEH, zowel in 
het Erasmus MC als het Albert Schweitzer ziekenhuis, ik ben blij om met jullie samen te 
kunnen werken.
Wat het leven buiten het werk om zo leuk maakt, zijn natuurlijk alle vrienden en familie 
waarmee ik mezelf gelukkig kan prijzen. Ik kan jullie niet genoeg bedanken voor alle steun 
en gezelligheid!
Van den Bergjes, al zo lang als ik me kan herinneren zijn jullie mijn tweede familie. Van 
horrornights, tuinhuisparty’s en de Yellow tot aan Radewijk en de Dominicaanse republiek, 
de Tokkies hebben overal de boel op stelten gezet (vooral die paaltjes waar water uit komt!). 
Rox, Mies en Eef, hoelang we elkaar ook niet gezien hebben, het is altijd weer als vanouds! 
In de loop van de tijd is de groep langzaam uitgebreid en het wordt er alleen maar gezelliger 
op (zolang we maar niet gaan midgetgolfen!).  
Meiden van de doc groep, het is alweer 14 jaar geleden dat we aan de geneeskundestudie 
begonnen. Hoe had ik het ooit zonder jullie kunnen volhouden? Lonneke, ik bewonder je 
gedrevenheid en hoop later samen met jou op een SEH te kunnen werken. Simone, we zijn 
al vriendinnen vanaf de basisschool, hoe bijzonder is dat! Natas, mijn huisgenootje tijdens 
de Eurekaweek, bij de nonnen in Mtinko en later op de Boezemlaan. We hebben zoveel 
gelachen en zoveel mooie herinneringen samen! Sher, je bent altijd vrolijk en deelt mijn 
enthousiasme voor fanatiek zingen/meeblèren in de auto. Samen met Ro en Will zijn we 
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